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Abstract 
Medication errors account for a significant number of medical errors. Giving 
medications to patients is an activity that carries a high risk of error. In an effort to 
improve patient safety in this area several approaches have been employed. Many of 
these have taken a systems approach in that they consider how organisational factors 
such as medicines management, staffing levels, ward layout, shift patterns and staff 
training have contributed to the errors. None of these studies describe errors in 
detailed form at task level. This Thesis addresses the gap in knowledge by presenting 
a systematic analysis of the component tasks of hospital drug administration where 
none exists and goes on to describe novel design artefacts that assist the identification 
of drugs. 
The thesis highlights how hierarchical task analysis, a human factors technique, can be 
applied to the hospital drug administration task. Task analysis techniques have been 
used in many high-risk domains in industry as a means of analysing human activity in 
complex systems but remains an underused technique in health care. Used with the 
Systematic Human Error Reduction and Prediction Approach (SHERPA), hierarchical 
task analysis provides an effective way of predicting where errors in the drug 
administration task are likely to occur. SHERPA uses a taxonomy of human error 
modes to highlight types of error and makes suggestions to reduce these errors. 
Medication errors take many forms however it was decided to focus on the immediate 
interaction between the nurse and the patient. The measures considered to potentially 
have a significant influence were adding conspicuous labelling to medication 
packages. These were enhanced by icons intended to represent categories of drugs. 
Constructing a three dimensional representation of the icon design was considered to 
provide nurses with an additional channel of information. 
Technological solutions were proposed and a patient identity bracelet that uses a 
programmable chip to link the patient to their prescribed medication was viewed as 
having a huge potential to simplify the checking aspect of administering medications 
in which the nurse compares a medication order which is often badly written with 
available drug stock. The device prevents nurses giving medications to the wrong 
patient. It also prevents them administering an overdose. 
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Chapter I 
Medical and Medication Errors 
1.1 INTRODUCTION 
Errors in health care have increasingly become the focus of media attention during 
the past few years. Many of these errors involve the use of drugs both within 
hospitals and in the wider community. As drugs become more powerful and 
prolific there is a need to examine the issues surrounding their distribution and use. 
A summary of this Thesis is presented in figure 1.1. This work begins with a 
literature review of the wider context of medical errors of which medication errors 
are a subset. The review highlights the prevalence of medication errors in the UK 
and the rest of the world and considers some of the underlying factors influencing 
medication errors and the effect of these errors on nurses. Consideration is also 
given to techniques used in high-risk industries that have been employed to address 
the issue of medication errors. 
Lane, R 
Literature review and 
data on drug errors 
Figure 1.1: Thesis Summary 
Chapter 1: Introduction 
Conclusions 
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Chapter two describes how two human reliability assessment techniques, 
hierarchical task analysis and the Systematic Human Error Reliability and 
Prediction Approach (SHERPA), that have been successfully used in other safety 
critical domains, can be applied to the hospital drug administration task in a bid to 
reduce the number of errors. The SHERPA analysis highlights several drug 
administration errors that can be resolved by design solutions such as increasing the 
conspicuity of packaging, labelling and employing technology. The literature 
review of warnings presented in Chapter three was carried out to inform the next 
stage of work which involved considering how colour, the use of icons could be 
used to increase conspicuity in order to enhance perception of the infon-nation 
contained on packaging and labelling. Chapter four demonstrates the execution of 
these principles in that colour coding and iconography are employed to help 
distinguish between classes of drugs. This chapter also demonstrates how adding 
tactile coding features to packaging has the potential to increase recognition types 
of drugs. Chapter five is concerned with designing icons for use on drug packages 
and testing for appropriateness and recognition. 
The SHERPA analysis described in chapter 2 recommends the use of technology to 
address several medication errors such as giving the wrong drugs to patients, failure 
to check patients' charts or failure to check patients' identities. Chapter six 
describes the design of an intelligent patient identity bracelet that uses ibutton 
technology that can be programmed to make a direct link between the patient and 
their medications, whilst chapter seven provides a summary of the thesis. 
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This Thesis contributes to knowledge by presenting a study of medication error at 
task level. Many studies have focussed on describing and categorising error types 
first and have considered causal factors such as the nature of nurses' tasks as a 
secondary issue. In presenting a task analysis of the hospital drug administration 
task this study is offering something that has not been done before. In 
systematically analysing medication errors using the SHERPA technique the study 
applies a well-established human error identification technique to a novel domain. 
The Thesis goes on to develop and test novel design products developed to address 
aspects of the medication error problem. 
1.2 LITERATURE REVIEW 
Medical Error 
Medical errors affect up to 850,000 people in the UK each year (Department of 
Health, 2000). These errors cost the NHS up to E2 billion in additional treatment, 
extended time spent in hospital and in community care. The cost of clinical 
negligence settlements is about E400 million. These figures are based on a study 
by Vincent et al (2001) which indicated that 10.8% of 1014 patients admitted to two 
London hospitals suffered adverse events. Of these 66% (63) suffered minimal 
impairment or recovered within one month. Twenty-one patients (19%) suffered 
moderate impairment and 7 (6%) were permanently harmed whilst 9 (8%) died. In 
48% of cases these adverse events were judged preventable. 
Medical error is also a significant cause of death in the US. The Harvard Medical 
Practice Study (Brennan et al, 1991) using data obtained from 30,121 randomly 
selected patient record charts taken from 51 acute non-psychiatric hospitals for the 
4 
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year 1984 identified a total of 1278 adverse events. An adverse event is an 
unintended injury resulting from any form of medical treatment rather than the 
disease process (Leape et al, 1995). From this figure it was estimated that in New 
York State, adverse events occurred in 3.7% of hospitalisations and 27.5% of these 
were due to negligence. For 70% of patients the adverse event led to slight 
temporary disability. Seven percent of patients suffered permanent disability and 
in 13.6% of cases the outcome was fatal. 
Similar findings were noted in a study by Gawande et al (1999) of the states of 
Colorado and Utah. The charts of a random sample of 1500 discharged patients 
were reviewed. Adverse events occurred in 2.9% of cases, half of which were 
considered preventable. Of these, 6.6% lead to the death of the patient and 19.3% 
related to the use of medication. 
More than 33.6 million people were admitted to US hospitals in during the year 
1997. Extrapolating the results of these two studies imply that between 44,000 and 
98,000 Americans die in hospitals each year as a result of medical errors. These 
figures exceed the number of deaths resulting from vehicle accidents (43,458), 
breast cancer (42,297) or AIDS (16,516). Total national costs in terms of lost 
income, disability and health care costs are estimated to be between $37.6 billion 
and $50 billion for adverse events and between $17 billion and $ 29billion for 
preventable adverse events (Kohn et al, 1999). 
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1.2.2 Medical errors in Australia, New Zealand and Canada 
The Quality in Australian Health Care Study (Wilson, 1995), was modelled on the 
Harvard Study in that it was also a retrospective chart review study, this time using 
14,179 medical record charts of admissions to 28 hospitals in New South Wales and 
South Australia. Adverse events occurred in 16.6% of admissions and half of these 
were considered preventable. In a review of various data sources Runciman (2003) 
revealed that between 2 and 4 percent of all hospital admissions involved 
medication related incidents and up to 75% of these were preventable. The drugs 
most often implicated are: anticoagulants, anti-inflammatories, opiods, 
antihypertensives, antibiotics, cardiac glycosides, diuretics, hypnotics, anti- 
convulsants, and antipsychotics. 
Davis (2002) reviewed 6579 medical records drawn from patients admitted to 13 
general hospitals in 1998. The sample was highly representative of admissions to 
all of New Zealand's generalist hospitals with 100 or more acute beds. The sample 
figures for age, gender, ethnic group, discharge status and mortality were 
comparable to national data. Adverse events occurred in 12.9% of admissions and 
most of these had a minor impact. 
Baker et al (2004) randomly selected one teaching and three community hospitals in 
each of 5 provinces of Canada. A total of 4164 patient charts were sampled and 
3776 were included in the initial screening. Full screening was carried out on 3745 
charts. Of these, 1527 (40.8%) were assessed as positive for one or more screening 
criteria and were reviewed by physicians. A total of 1133 adverse events were 
6 
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identified in 858 charts and of these 401 (46.7%) patients suffered harm that 
resulted in an extended stay in hospital, disability or death. 
1.3 MEDICATION ERRORS 
Ferner and Aronson (2000) define a medication error as "a failure in a drug 
treatment process that leads to or has the potential to lead to harrn to the patient. " 
The definition most commonly used is that given by the National Co-ordinating 
Council for Medication Error Reporting and Prevention (NCCMERP) in the USA: 
11 ... any preventable event that may cause or lead to inappropriate 
medication use or patient harm, while the medication is in the control of 
the healthcare professional, patient or consumer. Such events may be 
related to professional practice, healthcare products, procedures, and 
systems including: prescribing; order communication; product labelling, 
packaging and nomenclature; compounding,, dispensing; distribution; 
administration; education; monitoring and use. " 
American systems for monitoring medication errors are more advanced than those 
in the UK. For instance the United States Pharmacopeia (USP) in association with 
the Institute for Safe Medication Practices (ISMP) has monitored medication errors 
since 1991. It also works with the Food and Drug Administration (FDA) to provide 
information and implement working practices in an effort to reduce errors. Since 
1998 the USP has collected information about medication error through 
MedMARx, an internet-based reporting system. A report of its findings is 
published annually and during the year 1999,184 healthcare facilities sent a total of 
7 
Lane, R Chapter 1: Introduction 
41,296 error reports of which 42% were due to administration errors (Figure 1). 
The other errors that occurred were: prescribing (13%), transcribing (27%), 
dispensing (17%) and monitoring (1%). Sixty three percent of the errors were not 
intercepted before they reached the patient and 3% of errors caused harm or a 
fatality. 
2500 
2000 
1500 
1000 
500 
0 
Prescribing Docun*nbng Dlspenshg Adrrýmstarlng Momtoring 
LO-C. 
-. 655 1281 1039 2491 61 
Figure 1.2: Node where most errors have been reported (USP, 2002) 
It is only recently that medication error reporting systems have been set up in the 
UK on a similar scale to the MedMARx system. This has largely happened as the 
result of Governnient concern about the number of errors occurring in hospitals. 
The National Patient Safety Agency (NPSA) was set up in 2001 by the Department 
of Health to improve the quality of patient care at a national level. Its remit is to 
gather and analyse safety-related infon-nation from the existing reporting healthcare 
systems and to implement a learning and feedback system ensuring that lessons are 
learned from errors, risk areas are identified and addressed and solutions put into 
place to prevent harm. 
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1.4 MEDICATION ERRORS IN THE UK 
The Audit Commission Report, A Spoonful of Sugar (2001), indicates that about 
1200 deaths occur in the LJK each year due to medication related problems. Of 
these, 200 are the result of medication errors. The flgures given by the Department 
of Health (2004) range from eight to 24 percent; whilst approximately a quarter of 
all claims to the medical defence union relate to drugs. However it should be 
pointed out that some of these claims might also be due to adverse drug events 
(ADEs). An ADE is an injury caused by a medication (Leape et al, 1995). It may or 
may not be the result of an error. 
Much of the quoted literature is of North American origin (Bates et al, 1995; Leape 
et al, 1995; Lesar et al, 1997; Classen et al, 1997, Cowley et al, 2001, Kaushal et al 
2001) however large medication error studies have been conducted in the UK (Dean 
et al, 1995; Ross et a], 2000; Bruce and Wong, 2001; Taxis and Barber, 2003). 
Dean et al (1995) compared medication errors in a hospital in the United States and 
a hospital in the United Kingdom. The study was conducted in wards with a high 
oral-drug-related workload in two large university hospitals. Medication errors 
were identified retrospectively in the US hospital by comparing the observer's notes 
with the original drug orders made in the patient's chart by the physician. In the UK 
hospital, identification of errors took place concurrently; as doses were 
administered, they were compared with the orders on the medication chart. In the 
US hospital 919 opportunities for error were observed and the medication error rate 
was 6.9%. Incorrect doses and unordered doses were the most common types of 
9 
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error. In the UK hospital, 2756 opportunities for error were observed and the error 
rate was 3.0%. The most common types of errors were omitted doses and incorrect 
doses. 
Ross et al (2000) carried out a study to determine the incidence and type of 
medication errors in large paediatric hospital. Their results indicated that over a 
five-year period from April 1994 to August 1999 the incidence of medication errors 
was 0.15% (one error in 662 admissions); the neonatal intensive care unit 
experienced the highest rate at 0.98%, nevertheless most errors occurred in the 
medical wards. Nurses reported most errors and at the time of reporting most errors 
were considered to be minor. In this study the age of the children involved in 
medication errors was not a strongly associated factor except in the case of younger 
children. Forty four percent of errors occurred in children under two years of age. 
Incorrect infusion rate was the commonest error followed by incorrect dose (14.8%) 
whilst the third most common error was giving the patient an extra dose. Fifty six 
percent of errors involved drugs given by the intravenous route and oral medication 
errors accounted for 34% of cases. The most frequent drugs involved in these 
errors were antibiotics. Intervention measures included instruction of junior doctors 
in good prescribing practice by a senior paediatric pharmacist and the provision of 
paediatric formularies. Training in the use of intravenous systems was provided for 
junior medical staff when they started work at the hospital. 
Taxis et al (1999) compared the incidence of medication errors in a UK hospital 
that used the ward pharmacy system and two German hospitals - one using the unit 
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dose system and the other using the traditional German system. The ward 
pharmacy system entailed keeping the most frequently dispensed drugs on the ward 
as stock. Nurses administered medication by pushing a wheeled trolley from bed to 
bed during each of the four daily drug rounds and recorded the doses given. In the 
traditional German system each ward kept a large floor stock of formulary drugs 
that were ordered from the pharmacy twice each week by nursing staff. Doctors 
prescribed medication in a section of the of the patient's medical notes which was 
then transcribed by the nurse onto a drug administration chart for each patient. 
Each patient's drug administration card was placed under a plastic cover of their 
section of the drug administration tray. Nurses prepared medication using the 
charts in the drug preparation room for each of the four daily drug rounds. Patients' 
drugs were prescribed on an admission sheet. Any further changes made were 
written on sheets and added to the patients' notes. In the case of the unit dose 
system nurses and phannacists could enter prescriptions into the computer and 
medication was dispensed in the pharmacy in single packages each with the 
patient's name, room number, drug details and time of administration. The doses 
were placed in individual patient drawers in a drug trolley. 
Medication errors were identified by observing the preparation and administration 
of regularly scheduled solid oral medications. The medication error rate was 8.0% 
in the UK hospital, with most errors occurring during medication administration. In 
the German hospitals the error rates were lower. The hospital using the traditional 
system recorded an error rate of 5.1 % mainly due to omission, wrong dose or extra 
dose errors, whilst in the hospital using the unit dose system the error rate was 2.4% 
II 
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largely due to omissions, which originated at the transcription stage. These 
omissions also resulted in wrong drug and wrong dose errors. In both the German ID t> 
systems the errors were largely due to transcription of the original prescription. 
Suggestions to overcome these problems were to use the original prescription for 
medication administration and to use cabinets with the patients' own drugs. 
1.5 MEDICATION ERRORS WORLWIDE 
A study by Philips et al (2001) examined 5366 medication error reports from across 
the world submitted betweenl993 and 1998. Fifty-nine reports were excluded as 
duplicates or intentional overdoses. Patients suffered serious outcomes in 68.2% of 
cases and 469 (9.8%) people died. The most common types of error resulting in 
patient deaths were: 
Improper dose 40.9% 
Wrong druc, 16% 0 
Wrong administration route 9.5% 
Wrong strength 5.7% 
The most common causes of error were deficits in performance and knowledge 
(44%) and errors in communication (15.8%). A summary of further studies is 
presented in table 1.1. 
1.6 CAUSES OF ERROR 
Medication use is complex and is dependent on the successful interaction of health 
professionals functioning within different disciplines. Errors can occur at any one of 
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Step Action 
Prescribing Evaluate patient 
Establish need for medication 
Select right medicine 
Determine interaction and allergies 
Prescribe medicine 
Documenting Transcribe prescription 
Pass to pharmacy 
Dispensing Review prescription 
Review warnings 
Confirm transcription if necessary 
Contact prescribe about discrepancy if 
necessary 
Prepare medicine 
Pass medicine to patient 
Administration Review prescription 
Confirm transcription 
Review warnings, interactions and allergies 
Evaluate patient 
Administer medicine 
Monitoring Assess patient's response to medicine 
Report and document results 
Table 1.2: Opportunities for medication error 
(adapted from Clarkson et al, 2004, p 76) 
the five main stages of prescribing, documenting, dispensing or preparation, 
administering and monitoring (table 1.2). Wolf (1993) has pointed out that nurses 
make medication errors regardless of their speciality and that errors occurred on 
medical and surgical floors, postpartum units, emergency units and medical and 
surgical intensive care units. 
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In a US study Leape et al (1995) identified several causes of medication error. These 
were: lack of the knowledge of the drug; lack of information about the patient; rule 
violations (failure to follow accepted and well established procedures); slips and 
memory lapses in which the individual "knew better" and could not explain why the 
error occurred; faulty drug identity checking; faulty interaction with other services C, 
(problems in communicating with physicians or other services when patients are in 
transition between units); faulty dose checking; infusion pump and parenteral 
delivery problems; inadequate monitoring (failure to adjust the dose of medication in 
accordance with blood levels, vital signs or lab values); drug stocking and delivery t> 
problems; preparation errors in either calculating and n-dxin,,,, drugs and lack of 
standardisation in drug concentrations, dosing schedules or infusion rates. 
Philips et al (2001) identified 583 causes of error each of which were classified 
according to the NCCMERP Taxonomy of Medication Errors (1998) into one of the 
five major categories. 
The categories are: 
o communication - oral and written 
* name confusion - look- or sound-alike proprietary names 
* labelling - similar or misleading container labels 
* human factors - perfonnance or knowledge deficits 
* packaging and design - inappropriate package or device design. 
Sixty five percent (380) of the causes were due to human factors followed by 
communication, which accounted for 15.8% (92) causes. 
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Figure 1.3: Model of how defence barriers and safeguards can 
be penetrated by an accident trajectory (Reason, 1990) 
Responsibility for the error is often placed on the nurse as she or he is the last person 
in the drug administration chain. A parallel can be drawn with aviation. Pilots used 
to be held responsible for aviation accidents until analysis revealed other factors 
were highly significant. The reality is that there are many different causes of errors 
and they often combine to cause the incident (Vincent et al, 2000). The model in 
figure 1.2 illustrates how the course of an accident can by-pass a system's defences. 
Factors such as good design, effective safety devices, and tolerance limits and 
recommended operating procedures can all function as system defences against 
accident or failure (Reason, 1990). 
1.7 THE EFFECT OF ERROR ON NURSES 
In a study of nurses' attitudes and beliefs about what causes medication 
administration error, Hand and Barber (2000) identified three different categories: 
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personal factors, contextual factors and knowledge based factors. Examples of CP 
personal factors were tiredness, stress, lack of confidence to challenge doctors about 
incorrect prescriptions, lapses in individual performance, lack of concentration or 
attention to detail lack of care, complacency. Contextual factors included lack of 
trained staff, general shortness of staff in the hospital, heavy workloads and long 
drug rounds, long working days, busy wards. Also cited were interruptions by other tý' C> 
heath care professionals, relatives, telephone calls, checking drugs for colleagues and 00 
buzzers. 
Medical staff are responsible for writing new drug charts on admission, rewriting full Cý 0 
charts and writing discharge prescriptions. However, it is often the case that doctors 
do not perceive transcription as prescribing and consequently did not perform these 
tasks with the same care as when prescribing a new drug (Dean et al, 2002). This 
attitude leads to instances of omitted or badly written orders which then become part 
of the error chain. 
Meurier et al (1997) report that nurses commonly become emotionally distressed as 
the result of error. They may become angry and feel guilty or inadequate, responses 
that may be associated with taking responsibility for the error. 
1.8 LABELLING AND PACKAGING 
Drug packaging and labelling are often poorly designed such that it is difficult to 
discriminate between different categories of drugs, different strengths and routes of 
administration. The main criterion for manufacturers is that the packaging looks 
18 
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good and that the product is recognised as an identifiable brand (Kenagy and Stein, 
2001). The lettering on labels is often small and in some cases difficult to read 
(Ferner, 1995). 
According to Kenagy and Stein (2001) many packages contain visually confusing 
information and are more likely to be designed for the marketplace than for practice 
conditions. This often means that the name of the manufacturer is more prominent 
than the drug name. It is often difficult to distinguish between two or more 
strengths of the same preparation and when the manufacturer changes the packaging 
or the brand name the drug is unrecognisable, and practitioners become confused. 
Confusing drug names are also a significant source of medication errors. Drug 
names often look similar when written down and sound alike when referred to 
verbally. Examples of this are Tolbutamine and Terfenadine (Kenagy and Stein, 
2001), Flomax and Vlomax (Phillips et al, 2002) and prochlorperazine and 
procyclidine. The Audit Commission (2001) cites the case of a cancer patient being 
prescribed the sedative temazepam instead of the anti-cancer drug tamoxifen. 
Further examples are shown in figure 1.4. 
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Figure 1A An illustration of similarities between generic drug names (FDA, 2003) 
Michaeli (2002) describes how a name confiision error caused a fatality in the 
treatment of a neonate. The child had been born suffering the effects of pethidine 
given to the mother during labour for pain relief. Whilst attempting to resuscitate the 
infant the doctor requested the drug naloxone which reverses the effects of opiod 
overdose. The nurse gave him lanoxine which is commonly used for heart failure. 
The infant died from ventricular flutter. In this case, the similarity of the drug names 
and the labels on the injection vials contributed significantly to the error. With the 
increased numbers of generic drugs, this kind of mistake is a common one that 
might be preventable if generic names were printed in letters that are more 
conspicuous than brand names. 
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1.9 ADDRESSING THE PROBLEM 
1.9.1 Reporting systems 
In the past accident investigation has been people-centred and this has often resulted 
in punitive measures. This approach does not remove the potential for recurrence of 
the incident as the underlying causes are not addressed. Anonymous incident 
reporting systems are likely to be more successful at reducing errors because 
potential problems are more likely to be reported as well as actual errors (Anderson 
and Webster, 200 1). 
Galletly and Mushet (1991) describe a data gathering and analysis system that 
identified the factors that aided and hindered the process of error detection, diagnosis 
and management. An average of 8.1 factors were reported as contributors to each 
reported error. The authors go on to describe a systems oriented approach to 
identifying and resolving problems occurring in anaesthesia by devising a schema to 
organise systematic data collection. Attention was also given to recovery pathways 
and factors that helped or hindered the effects of error. 
1.9.2 Failure mode and effects analysis (FMEA) 
High-fisk industries (aerospace, defence, -nuclear power generation) accept human 
error as an artefact of human fUnctloning and have taken steps to address it 
systematically by a variety of means. Failure mode and effects analysis (FMEA) is 
one such method and was originally developed for use in the field of reliability 
engineering. The approach is based on the assumption that there are always 
circumstances in which errors will occur regardless of how knowledgeable or careU 
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the individual is. At its initial stage FMEA sets out to desciibe a system and all its 
functional aspects in detail. It allows the analyst to examine critical aspects of a 
0. 
given process in order to identify all possible or likely errors and to indicate what 
their effects will be. The steps to follow are: 
* Describe the system in detail and its functional blocks 
* Identify all possible failure modes and their associated effects 
* Develop a critical items list 
& Document the analysis 
FMEA has been applied to drug administration as a process of continuous quality 
improvement and is usually carried out by- an interdisciplinary group of healthcare 0 
professionals (Cohen et al, 1994). A FMEA anticipates what errors can be made and 
what the results will be. Thus for each medication the analyst will ask what will 
happen when someone mistakes a drug package for something else; uses the wrong 
amount of drug, gives the drug to the wrong patient, gives the drug by the wrong 
route, gives the wrong rate of a drug and so on. The analyst then goes on to consider 
how best to prevent incorrect iction being completed or to minimise their ability to 
cause an adverse event if they are completed. 
1.9.3 Root cause analysis 
Root cause analysis (RCA) works backwards in time from the adverse incident to 
identify and record each salient event (Dhillon, 2003). In collecting the relevant C) 
information it is important that the focus of inquiry remains firn-dy on the facts of 
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what occurred and why rather than seeking out individuals and apportioning blame. 
In the US the Joint Commission on the Accreditation of Healthcare Organisations 
(JCAHO) recommends that health care facilities respond to events in an effective 
manner within 45 days using RCA. In the UK, the NPSA has developed a web 
based toolkit that can be accessed by healthcare professionals and used in their 
workplace. 
The benefits of using RCA are that it is a well-structured approach that focuses on 
processes and is therefore an effective tool to address organisational and systems 
issues. Its strength lies in the fact that it can uncover underlying root causes of 
apparently separate incidents. On the downside, it can be a labour intensive, time- 
consuming technique and it is possible that the analyst might be influenced by the 
effects of hindsight. One other important factor is that it is impossible to deten-nine 
if the root cause identified is the one that actually caused the accident. 
1.9.4 Technological solutions 
There are 100 steps from the time a prescription is written to the time a patient 
receives the medication. Technology has the potential to reduce medication errors by 
reducing complexity, avoiding over-reliance on memory, simplifying key processes, 
and, if designed and implemented properly, increasing efficiency. It can also be a 
cost-effective tool for improving quality (Hospitals and Health Networks, 2001). 
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In recent years technological solutions have been employed in an effort to reduce 
errors in prescribing. These systems alert the physician to inappropriate dosages 
which in turn contribute to potentially fewer administration errors. Johnson et al 
(2002) describe how a bar code medication administration (BCMA) system could be 
used to reduce drug administration errors. This is an automated system using 
wireless, point of care technology with an integrated bar code scanner. In the UK 
GPs also use prescription writing software however this technology is only used in a 
few hospitals. 
Other interventions involving information systems that have considerably reduced 
medication errors particularly those occurring during the prescription stage are: 
computerised physician order entry, computerised physician decision support, 
prescription filling robots, bar coding, automated dispensing devices and 
computerisation of the medication administration record (Bates, 2000 and Ragan, 
2005). 
1.9.5 Potential for other human factors solutions 
The success with which human factors solutions have been applied to this problem in 
the past suggests that other human factors strategies could be utilised successfully 
within the present context and these are discussed in the next chapter. 
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Chapter 2 
Applying HTA and SHERPA 
To Drug Administration 
2.1 BACKGROUND TO MEDICATION ADMINISTRATION 
2.1.1 General background 
Many of the above studies have systematically analysed the context of drug 
administration. Some of these, as pointed out in Chapter 1, have used a human 
factors approach, the benefits of which have been highlighted by Schneider (2002) 
within the context of medication errors. He makes the point that health care 
providers need to be more aware of the limits of human performance and that 
system changes need to be made to accommodate these limits. There is still an 
expectation of perfection among medical professionals at a time when risk is an 
accepted part of daily life in other fields of activity. This is in part due to training 
and a number of other factors such as the culture of blame and the punitive 
measures that still exists within the health care domain. The added pressure of 
increasing media coverage of errors in recent years has placed the medical 
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profession under intense public scrutiny which in turn has lead to a certain degree 
of defensiveness. 
There are no studies that have applied task analysis to the hospital drug 
administration task. Task analysis is a method of describing and analysing how 
people interact with systems and with other people within that system. It describes 
what an operator or person is required to do in terrns of actions or cognitive 
processes or both in order to achieve the goal of the system (Kirwan, 1994). 
Giving medications to patients is a fundamental nursing role. It is also an activity 
that carries a high risk of error, as the involvement of different health care 
professionals means that errors may occur at any stage of the process (Hand and 
Barber, 2000). According to Anderson and Webster (2001) drug administering 
medication is probably the highest risk task a nurse can perform, occupying up to 
one third of their time in hospitals. Nurses seek to give medications correctly or 
perfectly. However their efforts are often confounded by poorly written 
prescriptions, constant interruptions, conflicting demands and high workloads. 
2.1.2 The ward pharmacy system 
In the UK many hospitals have used the ward pharmacy system in which about 
80% of medications administered are held as ward stock. These drugs are the most 
frequently used and are stocked in bottles of 50 or 100 tablets or capsules. 
Physicians use the patient's chart to indicate to the nurse which medications the 
patient is to receive. This is kept with the patient and used to record drug 
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administration. The order includes the drug name, the dose and the drug 
administration round when it is to be administered. Nurses make a drug 
administration round with a trolley four to six times daily depending on the ward. 
Each dose is recorded on the medication chart, which usually allows 14 days of 
documentation. This allows the patient's most recent drug history to be seen. 
Pharmacists visit their designated wards daily to review all patient charts 
perfon-ning a clinical and supply function. If a drug that is ordered that is not held 
as ward stock, the pharmacist makes a note on the medication chart and a supply 
sufficient for several days is dispensed with the patient's name on the container 
(Dean et al, 1995). 
Type of Error No of Errors (%of 
Total) 
Omission 49(58) 
Incorrect drug 6(7) 
Unordered dose 3(4) 
Incorrect dose 12(14) 
Incorrect route 0(0) 
Incorrect formulation 8(10) 
Other 6(7) 
Table 2.1: Types of medication administration 
errors in a UK hospital 
The errors identified from the above study by Dean (bid) are shown in the table 
2.1. The causes behind these errors were reported as: incorrect selection by nurse 
(40%), unavailability of medication on unit (39%), unclear prescription or incorrect 
medication administration record (13%), drug chart unavailable (5%). The 
methodology used in this study was disguised observation - the investigator's 
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presence was explained to the nursing staff as being part of a medication 
administration and work-sampling study. The study did not look at the individual 
tasks associated with medication administration. 
2.1.3 Using patients' own drugs 
Patients are often required to take their medication into hospital so that a full 
medication record can be taken. The Audit Commission (2001) recommended that 
patients should use their own drugs whilst in hospital rather than have them thrown 
away. This recommendation has led to the current transitional state of the in- 
patient drug distribution system in which some hospitals use the ward pharmacy 
system as described above and others use the patients' own drug system. It is not 
unusual to find the two systems operating on different wards within the same 
hospital. 
Dean and Barber (2000) carried out an observational study to examine the effects 
of using patients' own drugs on the incidence and severity of medication 
administration errors when compared to the more traditional ward pharmacy 
system. In this study a medication error was defined as any dose of medication 
administered or omitted that deviated from the written medication order. A total of 
257 medication administration errors were noted from 6,067 opportunities for 
error. Error rates were 4.3 per cent for the traditional system and 4.2 percent for 
the patients' own drug system. The difference was not significant and contrary to 
expectations using patients' own drugs did not reduce administration errors. The 
reason for this was due partly to factors relating to the drugs such as the nurse 
28 
Lane, R Chapter 2: Applying HTA and SHERPA 
to drug administration 
selecting the wrong number of tablets for administration. Similarly, unavailability 
of a particular brand or formulation of a drug led to it being omitted altogether. 
Additionally labelling on patients' medication was more varied compared to the 
standard format of medications dispensed from the hospital pharmacy. 
2.1.4 Equipment 
*- - 
". 4. Vkýj Ado". 0-4 Dý -i 
A. =.;; - 
KWA, ctq '521tal F-CWl& K, 9s 
l 
1; 4, W Co l - 
4m, twr- 
3-m 
- IW54*TI at ItA1(t 
V ___ 
Figure 2.1 Part of a patient medication administration record 
(Source: Audit Commission Report -A Spoonful of Sugar, 200 1) 
Figure 2.1 manifestly illustrates how confusion arises when attempting to interpret 
the doctors' orders. The drug names are badly written and the deletions, though 
noticeable create difficulty in making out the doctor's intention. 
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The problem of badly written drug orders has potentially been overcome by the 
introduction of physician order entry systems (Bates, 2000) however this will be 
discussed in more detail in the chapters that follow. Medications are often stored in 
cupboards in roughly alphabetical order or in trolleys in an arbitrary manner as 
illustrated by figures 2.2 and 2.3. 
 . 
i. 
4 
Figure 2.2: Drug Storage in a trolley 
I 
30 
Lane, R Chapter 2: Applying HTA and SHERPA 
to drug administration 
Figure 2.3: Patient's own drugs in bedside medicines locker 
2.2 OVERVIEW OF TASK ANALYSIS 
2.2.1 Defining task analysis 
The term task analysis refers to a range of techniques used by ergonormsts, 
designers, operators and assessors to describe or evaluate human machine and 
human-human interactions in systems. Task analysis can be defined as the study of 
what an operator (or team of operators) is required to do in terms of observable 
physical actions or cognitive processes to achieve the system goal. It is a 
methodology that can also document the information and control facilities used to 
carry out a task. A task analysis enables the analyst to collect information and 
organise it in a systematic way in order to gain a detailed understanding of human 
involvement within a system. It enables infon-nation to be collected and organised 
in a way that will usefully inform judgements and decisions (Kirwan and 
Ainsworth, 1992). 
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Although the concept of the task is the focus of task analysis there is little 
consensus about what constitutes a task (Starnmers and Shepherd, 1995). Miller et 
al (1953) described the task as "a group of discriminations, decisions and effector 
activities related to each other by temporal proximity, immediate purpose and a 
common man-machine output. " This description implies that a consistent set of 
behaviours are employed in achieving a system's goals. In reality, humans are 
adaptive in their behaviour, a prerequisite when dealing with controlled systems as 
these are complex and unpredictable. Behaviour is determined by higher processes 
and is often less influenced by the immediacy of the purpose. Use of the tenn 
'temporal proximity' is unclear as it could refer to any period of time from one 
second to one day. Generally such definitions are not precise and the tenns are 
used interchangeably. 
The main commonly held assumptions are shown in Figure 2.4. 
" The term 'task'generally applies to a unit of activity within work situations 
"A task may be given to or imposed upon an individual or alternatively 
carried out on the individual's own initiative and volition 
" It is a unit of activity, requiring more than one simple physical or mental 
operation for its completion 
" It is often used with the connotation of an activity which is non-trivial, or 
even in some cases onerous in nature 
a It has a defined objective. 
Figure 2.4: The main elements that comprise a task (Stammers and Shepherd, 
1995) 
32 
Lane, R Chapter 2: Applying HTA and SHERPA 
to drug administration 
Many task analyses deal with large-scale complex activities, with the overall 
activity of the user defined in terms of an overall objective. This is decomposed 
into constituent tasks, which may themselves have subordinate tasks. The 
definition of the task is not simply a matter of saying 'it's what a person does'. 
Within this context it is more complex and encapsulates the three interacting 
components of task requirements (the objectives or goals carried out by the 
individual); task environment (the factors in the work situation that limit and 
determine how well the individual perfonns) and task behaviour (the actions that 
are perfon-ned to complete the task within the previous two constraints). 
The first two elements - task requirements and task environment are determined by 
the systems context and are influenced by such factors as the organisational 
framework, operating requirements and procedures, capability of technology, 
design of interfaces and enviroru-nental conditions. These are features that can be 
observed recorded and predicted. The third element, task behaviour can vary as a 
function of individual factors and experience (Starnmers and Shepherd, 1995). 
2.3 HIERARCHICAL TASK ANALYSIS 
2.3.1 Background to hierarchical task analysis 
The task analysis most frequently used is the Hierarchical Task Analysis (HTA) 
technique as it is straightforward to use and can be used to address a large range of 
problems. Developed by Annett et al (1971), the technique allows large amounts 
of information to be assimilated relatively quickly unlike many of the other task 
analysis techniques which require extensive scrutiny. It is best to think of HTA as 
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a model of a system's goals "developed in sufficient detail to enable an analyst to 
identify each of the features pertinent to making design decisions. In this fashion, 
the analyst re-describes a goal in progressive detail until each aspect of the task is 
understood sufficiently to offer an appropriate design hypothesis. As re-description 
of the task develops, the analyst is able to: 
* express the system's goals more explicitly 
a identify appropriate features of the context with more precision 
e establish methods for accomplishing the task 
HTA has been applied to problems associated with issues of task design, training 
documentation and human reliability analysis. It has been used in many contexts 
such as managerial, supervisory and operating tasks in the process industries. It 
has also been used in office environments, warehousing and maintenance and 
whilst it has been employed in the para-medical professions it is still an underused 
technique in this area (Stammers and Shepherd, 1995). 
The HTA describes a task from its top-level goals down to individual operations, 
although in reality the task would probably be part of a larger goal. If further 
description of the task is justified the HTA progresses by adding subordinate 
operations and a plan. Each of the tasks must completely define how to achieve the 
top level goal. There should not be any additional but necessary tasks missing from 
the analysis (Kirwan, 1994). 
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The three structural components of the HTA are: the plan, the stopping rule and the 
numbering system. The plan defines the way in which the subordinate tasks are 
carried out. Very often the plan is simply 'do in order', which means tasks must be 
carried out sequentially. Some plans however are complex and certain conditions 
have to be met before the next task can be carried out. The important aspect of the 
plan is that it deten-nines when to move from one task or operation to the next. 
The stopping rule is point at which the analyst stops re-describing the task in terms 
of subordinate tasks or operations. The point at which to stop is when further 
description would not add further useful information for analysis purposes. The 
level of re-description necessary depends on the purpose of the HTA and the level 
of detail required. However, the analyst usually makes the decision about when to 
stop. 
All but the smallest of HTAs use a hierarchical numbering system. This is done to 
aid identification of the various parts of the HTA and is a very useful feature when 
several levels are present. 
2.3.2 Lack of protocols 
Prior to drawing up the drug administration HTA that follows in this chapter a 
search was made on the Internet using the Google search engine intemet for 
guidelines related to medication administration by nurses. The guidelines produced 
by the Nursing and Midwifery Council (2002) are very generalised and do not give 
specific information partly because hospitals have their own formularies. Different 
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specialities have drugs specific to various treatment regimes. However Leape et al 
(1994) recommended standardisation in medication usage and this has been echoed 
by Cohen (1999). Dougherty and Lister (2004, p203) give useful guidance. 
2.3.3 The Drug administration HTA 
The HTA (shown in figure 2.5) was drawn up by the author who trained as a 
hospital pharmacy technician and was reviewed by two nurses, a hospital risk 
manager and two patient safety experts. The top-level goal of the HTA is to deliver 
drugs to the patient at Level 0 (Figure. 2.5) and is indicated by the phrase 
'administer drug to patient'. The assumption is that the order for the drug has been 
written on a prescription order or medication administration chart and that the 
drugs are available in the hospital ward. This goal can be broken down to a lower 
level of 4 sub-goals labelled I to 4 in the HTA. These are: 1) checking the 
patient's chart for the relevant details; 2) acquiring the medication; 3) 
administering the drug to the patient; 4) recording the dosage given. Plan 0 
indicates the order in which the activities or sub-goals that should be carried out in 
order to achieve the goal. 
The two actions required to achieve the sub-goal 'check patient chart' (step 1)' are 
'find patient chart' (step 1.1) and 'read chart' (step 1.2). Step 1.1 encourages the 
analyst to think where the chart might be if not located in the most obvious place 
on or near the patient's bed by considering alternative locations that may need to be 
searched. The actions for searching these locations are entered into the HTA at a 
lower level as operations 1.1.1 - 1.1.5 and the sequence for carrying out these 
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operations is determined by Plan I. I. I. Having found the chart it is important to 
read it in order to gather the relevant infonnation. The pertinent pieces of 
information are 'drug name', drug dose', 'drug form', 'drug strength', 'drug route' 
and 'start date' (steps 1.2.1 - 1.2.6) and these are executed according to plan 1.2. 
2.4 THE SHERPA ANALYSIS 
2.4.1 Background of SHERPA 
Having constructed a task analysis to identifying the process of drug administration 
at a systemic level it is possible to consider what can go wrong in terms of human 
errors. This is the basis of human error identification which in essence is 
concerned with the actions or activities people might do in a given situation rather 
than what they are supposed to do. Analysis of errors in this way leads not only to 
identification of the errors themselves but also highlights other factors such as: 
opportunities for error recovery, examination of the consequences of errors and 
identification of error reduction strategies. In order to do this a classification 
system of error modes (taxonomy) is devised and it is the taxonomy that underpins 
the framework of any human error identification technique. The advantages of 
using taxonomy are that it provides: 
37 
Lane, R Chapter 2. - Applying HTA and SHERPA 
to Drug Administration 
0 
M 
d Ee Z0 
0 A 
0 
g0 
c: Z u 
Nu8 
tm 
r 
E 
E 
21? 
h 
--; fý ZA to cý 
E -6 
.e _Uc 
m a 2 . -. r= i 2 0 ý5 - Di c - -Z - -  *: t -Z 
f2 
E cL Z 
mo 
L- ei -5 - lý 
,Z x ic "' 
V) , 
e 
CL 
'0 
i 
L r- i X 
eE 
o 
12 c 
m 
A 
m 
0 
0 
0) 
0 
tu 
9 
Co 
m 
CL 
, 0-2 
cr 
'2 
20 
ým ýi ýi --: c4 ý 
E, 
gr, 0 Z 
Ic 
12. 
E- 
38 
Lane, R Chapter 2: Applying HTA and SHERPA 
to Drug Administration 
39 
Lane, R 
cm 0 «ä fa Lq .U (U (14 a (ý «ö 0 _O V Co :ý CL (1) 
co 
Cý 
6i 
Lfi 
c 
C14 
LO 
" t;. 2 
u) E 
N 
ki 
C4 
r 
(D 
cc 0 
C'i LD 
C., 
0) 
IT 
9 
. C14 Lri 
oi U) 
Ci 
C-4 
Chapter 2: Applying HTA and SHERPA 
to Drug A dm in istration 
0. 
m 
J-E 
c, i .1 
c, i E 'Zah 
. ei 
cli 
0.5 
CD 
CL 
N 
In 
V 
q .2o C4 
ui 
a 
r 'all 
1 
04 1. ui 
04 
0 N I; 
-[M " cc 1ý -S (1) a m C-4 
C%i Ui 
cli C%i wi 
tc) :3 
Vi csi a C-4 
00 
Ir4o 
vI 
cli ui Cý 
Cli 
tri 
-Y c1d 
' 
cli I , S tm gI " N cl 
'1 .8a 
ý CD 2 04 
li c 
C%i 
CZ) E i 
Cl 
: %2 
r= c2. 
EE 
-2 ry (ý 2Z 
.a wi .0*. 
- 
vi 
c2. -i c2. 
cli ', 
40 
Lane, R Chapter 2: Applying HTA and 
SHERPA to Drug Administration 
ma structure for the assessor 
0 robustness 
0 meaning to the assessment - defining underlying causes and reasons 
Many of the tools used to model human error are descriptive. However some like 
the Systematic Human Error Reduction and Prediction Approach (SHERPA) are, 
as the name implies, predictive of error occurrence. It is a good method to use in 
the present study because it allows the assessor to carry out a finely detailed 
analysis and a thorough set of error modes (Kirwan, 1994). Within the present 
context using a predictive approach like SHERPA has the obvious advantage that 
medication errors can be analysed without actually observing them, to the benefit 
of both nurses and patients. 
SHERPA was developed by Embrey (1986) for use in the process industries 
(conventional and nuclear power generation, petrochemical processing and oil and 
gas extraction). It is a human error prediction technique that analyses a task and 
identifies potential solutions to errors in a structured manner. The technique is 
based on a taxonomy of human error (table 2.2) that in its original form specified 
the psychological mechanisms underlying the error. On-going development of 
the technique has removed this reference to the underlying psychological 
mechanism. This human identification error technique allows the analyst to 
define the infonnation that is useful for error reduction strategies. Kirwan (1994) 
demonstrates how SHERPA can be applied to the procedure for filling a road 
tanker with liquid chlorine. The technique has been applied to consumer products 
such as ticket machines (Baber and Stanton, 1996), vending machines (Stanton 
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Error type Code Error Mode 
Action Errors Al Operation too long/short 
A2 Operation mistimed. 
A3 Operation in wrong direction 
A4 Operation too little/much 
A5 Misalign 
A6 Right operation on wrong object 
A7 Wrong operation on right object 
A8 Operation ornitted. 
A9 Operation incomplete 
A10 Wrong operation on wrong object 
Checking Errors C1 
C2 
C3 
C4 
C5 
C6 
Retrieval E. rrors RI 
R2 
R3 
Check omitted 
Check incomplete 
Right check on wrong object 
Wrong check on right object 
Check niistimed 
Wrong check on wrong object 
Information not obtained 
Wrong information obtained 
Information retrieval incomplete 
Communication Errors Il Information not communicated 
12 Wrong information communicated 
13 Information communication incomplete 
Selection Errors S1 Selection oinitted 
S2 Wrong selection made 
Table 2.2: SHERPA Error Modes (Stanton and Stevenage, 1998) 
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and Stevenage, 1998), in-car audio systems (Stanton and Young, 1999) and 
aviation (Stanton et al, 2003). In the medical domain, Joice et al (1998) used 
SHERPA to analyse the nature and incidence of errors enacted during 
laparoscopic (keyhole) surgery as a means of identifying training needs and 
informing prospective research areas. 
2.4.2 Validity of SHERPA 
In a study to determine if the incidents predicted by several human error 
identification techniques matched those that had actually occurred, Kirwan (1992) 
compared SHERPA with 5 other identification techniques on the criteria of 
comprehensiveness, accuracy, consistency, theoretical validity, usefulness, 
resource usage and auditability/acceptability with the result that SHERPA was the 
most highly rated by expert users. Stanton and Stevenage (1998) report 
concurrent validity and reliability statistics of 0.74 and 0.65 respectively for the 
application of SHERPA by 25 novice users to the prediction of errors on a 
confectionery vending machine. Stanton and Young (1999) observed eight 
novice users predict errors on a radio-cassette machine report a concurrent 
validity statistic of 0.2. and a reliability statistic of 0.4. 
2.4.3 Applying SHERPA to drug administration errors 
The task steps from the lower levels of the HTA fon-n the inputs for the SHERPA 
analysis. These are examined in turn and classified into one of the error types 
using the human error taxonomy shown in table 2.2 and recorded in tabular form. 
The most likely error modes associated with a task step or operation are 
considered. For example, the task step 1.1.1 in the HTA "check patient bed" is 
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classified as a checking activity. Looking at the associated checking error modes 
(table 2.2), only the most credible errors for the task step are taken into account. 
It is possible that whilst searching for a patient chart a nurse may fail to check the 
area around a patient's bed or may be called away to attend to another patient and 
so not complete the search. In nursing terms these are not strictly errors but 
within the SHERPA system these actions would prevent the goal of finding 
patient chart being achieved and thus fall short of the top level goal of ensuring 
that the correct patient receives the drug prescribed by the doctor in the correct 
dosage and form, at the correct time. 
A table is drawn up (table 2.3) and in the first column the number of the task step 
is listed (1.1.1). In the second column the error mode Cl is entered. This denotes 
that a check has been missed. In the third column of the SHERPA table a 
description of the error is entered. In this case the description would be "Fail to 
check patient bed area". At this stage of the analysis it is possible to make a 
prediction of what the consequence of that error might be. The chart would 
remain mislaid and because the nurse had no record of what drugs were due to be 
taken or when, drug doses would be missed. Thus, in the fourth column under the 
heading "consequences" a description of the potential consequence of the activity 
is entered. The fifth column of the table (recovery) indicates whether or not the 
error can be recovered. It may be that by completing further task steps, the nurse 
will be able to go back and correct the original error or omission. If this is the 
case then the task step at which the original error may be recovered is entered in 
column 5 under the heading "Recovery". If it is not possible to recover the error 
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then the "Recovery" column is left blank. The probability of the error occurring 
is denoted in the table by P and is categorised as low (hardly ever occurs), 
medium (has occurred once or twice) or high (occurs frequently). The final 
column shows the remedial measures that could be taken to reduce that particular 
error. These are mainly in the form of design solutions however it is recognised 
that in order to be effectively implemented any design solution would need to 
regulated by the appropriate organisational controls. 
2.4.4 Remedial design solutions 
2.4.4.1 Technology 
In the SERPA analysis tagging was suggested as a solution to the problem of 
missing medication administration records. It is also a useful system for the 
location of equipment. Medication errors are made in prescribing because of slips 
in attention or because prescribers do not apply the relevant rules (Dean et al, 
2002). Computerised order entry might be a better solution to resolve the problem 
of missing charts since the drug information is held in a data bank. This system 
solves the problems related to prescribing (bad handwriting, non-standard 
abbreviations, incomplete drug orders) and in particular errors related to 
compatibility of combined drugs or patient allergies. Cornputerised order entry 
coupled with bar coding would solve the problem of reading the wrong drug name 
or not reading it at all. 
Although technology has great potential to reduce a high number of errors care 
needs to be exercised when employing such a costly solution. Potts et al (2004) 
reporting a prospective trial of computerised physician order entry in a paediatric 
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unit noted that whilst medication prescribing errors were reduced by 99.4% and 
rule violation errors by 97.9%, potential adverse drug events were only reduced 
by 40.9%. Whilst the total error reduction was significant but the overall level of 
error reduction suggests other factors associated with drug administration and 
patient monitoring needed to be addressed. 
Nurses have said they feel they don't have time to read the labels. So using a 
scanner to read a barcode on a package goes a long way to overcoming this 
problem. Barcoding solution can be extended to patient identification 
infori-nation. Bar coded labels would overcome the problem of reading wrong 
drug names from packaging. Patient identity problems could be resolved by this 
methodology. It is still important, however, to maintain standard patient 
identification systems and to attach standard labels on packaging to act as a 
double check or as a back-up in the event of equipment failure. 
2.4.4.2 Labelling 
Medical personnel often complain about the similarity of drug labels which makes 
it difficult to discriminate between products. Pharmacy products dispensed for 
named patients have a small white label printed with the patient's name, the drug 
name, administrations instructions and any warnings in a small black or grey font. 
The result is that very often the bottles and labels all look similar. Adding 
colourful or eye-catching features to the packaging or labelling would increase the 
nurse's capability to distinguish products. For instance, highlighting salient 
information such as drug name and strength would enable these features to be 
readily picked out and might be a useful solution. Increasing the conspicuity of 
53 
Lane, R Chapter 2: Chapter 2: Applying HTA and 
SHERPA to Drug Administration 
product labels should help to improve search strategies. This concept could also 
be extended to storage areas so that one class of drugs is not mistaken for another. 
Using colour labels to distinguish categories of drugs is a common practice is 
anaesthesia. 
2.4.4.3 Equipment 
Selecting the wrong needle for a syringe assembly or the wrong tube for an IV set 
might be due to genuine lack of knowledge or because of the large availability of 
items from which to select. Limiting the variety of equipment from which 
selections are made is a good way to force individuals to make the right choice. 
This could be achieved by purchasing from a small number suppliers and then 
making accessible only the minimum variety of equipment. This would help 
agency nurses and those who work on several units. Writing formal protocols for 
setting up and checking IV systems as well as attaching simplified instructions to 
the device itself which could be seen when programming is in progress would be 
useful. 
Errors frequently occur because both doctors and nurses do not have sufficient 
training in the use of medication. Dean et al (2002) recommend training junior 
doctors in the principles of drug dosing before they start prescribing and more 
training about the effects of drugs is advocated by Kohn et al (1999). 
2.4.5 Discussion 
The SHERPA table (table 2.3) highlighted the errors of-. drug omission, incorrect 
drug, incorrect dose, incorrect formulation, giving extra doses and giving drugs by 
the incorrect route. These matched the errors cited in the studies of Philips et a] 
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(2001) and Ross et at (200) in chapter I and Dean et at (1995) at the beginning of 
this chapter. Table 2.4 gives a summary of the recommended design solutions. 
From the summary it can be seen that barcoding, tagging and computerised 
prescription order entry have the greatest potential to resolve errors with the most 
critical consequences. 
Criticality 
Solution LM H Total 
Barcoding 35 5 13 
Computer order entry -5 2 7 
Increase label/package -4 5 9 
conspicuity 
Smart labelling -- 2 2 
Tagging 54 1 10 
Table 2.4: Summary of SHERPA findings 
The main purpose for carrying out this analysis was to highlight areas where 
design solutions would have the greatest impact. The overall aim is to protect 
patients from error or in the event an error does occur to allow the nurse the 
opportunity to recover. The analysis predicts what steps can be taken to achieve 
resolution and highlights those aspects of the drug administration process where 
design solutions would have the greatest impact. These were identified as drug 
inforination systems, labelling, drug storage and patient information systems. 
Technological solutions including electronic tagging, bar coding and 
computerised order entry have been suggested as error reducing strategies for a 
number of errors. 
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Many of the tasks presented in the HTA could be subdivided into further levels of 
component tasks and operations thus revealing a highly detailed description of the 
drug administration task. The SHERPA error mode taxonomy prompts the 
analyst to consider potentially unforeseen errors and the error reduction strategies 
are readily identified. The strength of the SHERPA technique is that it can be 
used to analyse tasks or processes at many different levels. The technique could 
be adapted to different ward settings and could also be applied to a range of 
different health care procedures. For instance, the method could be used to 
analyse equipment usage in order to highlight training requirements or to re-draft 
protocols as part of the quality review process. 
One disadvantage of using SHERPA as an error prediction tool is that a task 
analysis has to be drawn up before error predictions can be made. In order to gain 
a full description of every step of the drug administration task, several long HTAs 
would be required. Thus it could prove time-consuming to obtain a high level of 
detail particularly in cases where no formal protocols exist. Another weakness of 
SHERPA is that actions considered highly unlikely are excluded from the 
analysis. An example of such exclusion occurs at step 3.3.2 of the HTA C'hang 
an infusion bag") as part of setting up an IV infusion. Failing to hang an IV bag 
would be considered by most nurses as an impossible error to make. But if the 
situation arose where there was a shortage of infusion stands or the infusion bag 
had been removed from the stand whilst the patient was being moved, then this 
situation would not be so improbable. However, failing to hang the IV bag due to 
a shortage of stands would constitute a systems error and thus this error mode 
should be included in the SHERPA analysis. 
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Medication administration errors occur due to a number of varying and often 
interacting factors that may originate from organisational practices, the working 
environment or personal and professional practices. There is an underlying 
assumption that the SHERPA taxonomy is able to capture the full range of error 
producing activity whereas this is not the case. Communication with patients and 
their relatives, colleagues and various departments all impinge on the process of 
drug administration. These factors cannot be analysed effectively using the 
taxonomy and would require other techniques. 
The task analysis could be extended to take account of the activities occurring 
during the administration of controlled drugs, injections that have to be 
reconstituted or diluted and those that are calculated according to the patient's 
weight. The overall technique could be used to compare different systems of 
administering medication. The errors highlighted refer to the ward based 
pharmacy system. Further work could be carried out to predict errors that might 
occur within the patient's own drug system. Validation of the errors predicted in 
the model need to be compared with data gathered by observation of actual drug 
administration in ward settings in order to analyse both opportunity for error and 
the types of error that actually occur. This simplified model excludes the 
condition of the patient and the routine checks (blood pressure, temperature, 
kidney function) that are carried out on a regular basis. The model would benefit 
from inclusion of patient states, as these have direct bearing on how nurses 
respond. 
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This chapter illustrates how two human error identification techniques can be 
applied to the process of administering drugs to hospitalised patients as a means 
of preventing error or reducing the effects of error. Whilst this chapter considers 
the actions of an individual nurse in the process of administering drugs, it is 
recognised that, as noted above drug administration errors are rarely entirely due 
to the actions of a single individual. There is still an expectation of perfection 
among medical professionals at a time when risk is an accepted part of daily life 
in other fields of activity. This is due to training and a number of other factors 
such as the culture of blame and the punitive measures that still exists within the 
NHS. The blame culture is slowly changing largely due to several patient safety 
initiatives set up by the Department of Health and through the activities of the 
National Patient Safety Agency. 
Having considered what can go wrong during drug administration the next phase 
of the research was to design products that would reduce these errors or at the 
very least highlight the errors before they reached the patient. Technological 
products were suggested in the SHERPA analysis as solutions to the largest 
number of errors and this issue is the focus of chapter six. Increasing conspicuity 
on packaging addressed 9 errors (table 2.4) and this is the subject of chapter 4. 
However, prior to that, consideration was given to the design and development of 
warning signs and labels as it was felt that the research previously carried out in 
this field would inform the development of products with eye-catching features. 
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Chapter 3 
A Literature Review on Warnings 
3.1 INTRODUCTION 
One of the design solutions suggested in the SHERPA analysis in chapter 2 to 
address the problem of failing to read product labels was to increase their 
conspicuity in an effort make them more eye-catching. Catching people's attention 
in order to influence their behaviour has been achieved with a high degree of success 
in the design and production of warning signs and labels primarily through the use of 
colour and pictures. Extensive research in this area has lead to a wealth of literature, 
therefore reviewing this should provide useful principles that could be applied to the 
design of medication labels. 
Warnings operate in several ways but most ostensibly their purpose is to decrease the 
risk of accidents or serious injury and thereby promote safety. Warnings are 
intended to influence or modify people's behaviour such that they act in a safe 
manner. Another aspect of a warning is to provide information that enables people 
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to understand the hazard, thus enabling them to make informed decisions (Laughrey 
and Wogalter, 1997). 
An effective visual warning has four message components according to Adams et al 
(1998) and Wogalter et al (2002). The first, the signal word, attracts attention; the 
second component identifies the hazard; the third describes the consequences of 
exposure if the individual is exposed to the hazard; whilst the fourth provides 
directives for avoiding the hazard. Signal words such as DANGER, POISON AND 
DEATH are often used on warnings as they have been found to connote high levels 
of hazard (Wogalter et al, 1989: Young, 1998), whereas warnings containing the 
words WARNING and CAUTION tend to convey lower levels of hazard. 
Despite the importance of the words used to convey the presence of a hazard the 
effectiveness of a warning is influenced by other factors. For instance Trommelen 
(1997) has pointed out that when people are presented with new information they are 
more likely to read and remember it. Conversely, the more often a warning is 
encountered the less likely the person will be to notice it on subsequent encounters 
(Wogalter et al, 2002). Edworthy and Adams (1996) suggest the ultimate 
effectiveness criterion of a good warning sign is the extent to which the warning 
leads users to comply. This is in comparison to the level of compliance in the 
absence of the sign. They contend that because well-designed signs do not produce 
100% compliance, other deten-ninants such as social and individual factors may 
influence users (figure 3.1 ). 
60 
Lane, R Chapter 3: Literature review 
on warnings 
The referent The warning 
Product or situation 
Iconic Informational I 
aspects aspects 
Objective risk ýMýpp! inýý 
Mapping) Perceiveo urgency 
Subjective assessment of risk 
Decision 
Figure 3.1: Components of warning compliance (Edworthy and Adams, 1996) 
Warnings are often presented on labels attached to products and whilst it has been 
demonstrated by Adams and Edworthy (1995) that using larger print increases the 
hazardousness ratings of warning by users, the limited size of labels, particularly 
those attached to small packages restricts the size and the amount of information that 
can be presented. This has the effect of reducing conspicuity, legibility and 
sometimes comprehensibility (Wogalter and Young, 1994). A warning sign must 
first be legible before it can be comprehended and is of significance to those whose 
vision might be compromised, a concern not only of elderly or partially sighted 
people but also in environments of poor visibility (smoke, fog, poor illumination, 
darkness). Legibility can be augmented by incorporating redundant features into the 
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waming message such as shape, borders, colours, pictorials (Riley et al, 1982; 
Young, 1998) or combinations of these as demonstrated by Riley et al (1982), 
Chapanis (1984), Rodriguez (199 1), Cochran et al (198 1) and Serig (2003). 
This literature review looks at some of the various methods that have been devised to 
test the effectiveness of warnings, or the degree to which the warning accomplishes 
its intended effect. Many of the studies outlined in the following sections examine 
non-verbal aspects of the warning such as the use of colour, shape or pictorials. 
Consideration will also be given to aspects of users' attitudes, beliefs and 
expectations when they encounter warnings. 
3.2 CONSPICUITY 
In order to be effective, a written warning must be noticed, read, understood and 
heeded. Although the ability of a warning to influence behaviour is subject to 
several factors, noticing it in the first place is of prime importance. Conspicuity 
relates to how prominent or eye-catching warnings are and several elements have 
been added to warning notices and labels to increase their ability to capture the 
attention. These include the use of large size text (Adams and Edworthy, 1995), 
colour (Kline et al, 1993), graphics (Kalsher et al, 1996) and shape (Riley et al, 
1982; Wogalter and Young, 1994). Barlow and Wogalter, (1991), and Wogalter and 
Young (1994) increased the overall size of the product label was to enable more 
information be printed. Laughrey and Brelsford (1991) made signs larger to enable 
them to be seen by the elderly. 
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Young (1991) orthogonally manipulated colour, pictorial signal icon and border 
features to detennine their effect on the noticeability of warning information. 
Seventy-two participants were asked to view 96 simulated alcohol labels presented 
singly on a computer screen. For each label subjects pressed buttons labelled 'yes' 
or 'no' to indicate respectively the presence or absence of warnings. The computer 
measured the time taken to respond. Where pictorials were present on warnings, 
faster response times were noted than when they were absent. Warnings printed in 
red were located more quickly than those printed in black and warnings paired with 
an icon were located more quickly than those without. Using a border did not 
produce a significant reduction in response latencies compared to warnings without a 
border. The results demonstrated that using pictorials, colour and icons increased 
noticeability of warning information. 
Safety messages or warnings occurring in familiar situations or on familiar products 
are less likely to be noticed (Otsubo, 1988). In a study designed to assess the 
effectiveness of different types of label on two consumer products incorporating two 
levels of perceived hazard Otsubo presented 131 participants with four label types. 
These were: words only, pictograph only, words and pictographs and no warning. 
The consumer products representing low and high hazard respectively were a jigsaw 
and a circular saw. Effectiveness was assessed by which of the participants noticed, 
read, complied with and recalled the warning message. The notices were more 
effective on the product perceived to be more dangerous than the one perceived as 
less hazardous. The data gathered suggested that people more familiar with the use 
of the product would tend to read, comply with and recall the warning less than those 
less familiar. Furthennore, (Wogalter et al, 2002) contend that people who have had 
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an accident or know someone who has been injured using a product are more likely 
to exercise caution when using that product. This behaviour is related to perception 
of risk which will be discussed in greater detail below. 
3.3 TEXT 
3.3.1 Signal Words 
Warnings often contain words intended to attract the attention of the user or to alert 
them to the hazardousness of the situation or action in which they are engaged. The 
most commonly used signal words are DANGER, WARNING, and CAUTION 
(Wogalter et al, 1989; Chapanis, 1994 and Laughrey and Wogalter, 1997). The 
signal words DEADLY, LETHAL and DANGER were found by Young (1998) to 
significantly differ from CAUTION and NOTICE. In this study the word 
WARNING did not differ from DANGER or CAUTION. Wogalter and Silver 
(1995) identified the additional words of ATTENTION, NOTICE, CAREFUL, 
DEADLY, NOTE as having high carefulness ratings. Rated from the greatest to the 
least. Their results indicated a significant main effect of signal words in the 
following order: DEADLY, DANGER, WARNING, CAUTION, CAREFUL, 
NOTICE, ATTENTION, NOTE. 
Wogalter et al (1994) report higher hazardousness ratings for LETHAL than 
DANGER when the two words were combined with a signal icon. Whilst in a study 
by Young (1998) subjects compiled signs for 30 different scenarios. DEADLY was 
considered the most hazardous, followed by LETHAL, DANGER, WARNING, 
CAUTION and NOTICE. DEADLY and LETHAL were considered as conveying 
significantly more hazard than CAUTION and NOTICE but less than WARNING. 
64 
Lane, R Chapter 3: Literature review 
on warnings 
WARNING was considered to convey more hazard than NOTICE but less than 
CAUTION. 
Presenting the text in different colours or with colour backgrounds also has an effect 
on hazardous ratings as demonstrated by Chapanis (1994), Braun and Silver (1995) 
and Young (1998). The effects of colour will be discussed further in section 3.4. 
3.3.2 Size 
The physical size of the signal word characters are likely to be more easily read 
(Laughrey and Wogalter, 1997). Work by Silver and Braun (1993) has indicated that 
varying the font used affects perceived readability with 10-point print considered 
more readable than 8-point print and that a2 point contrast between the signal word 
and text size is more effective than a difference of 4 points. 
Adams and Edworthy (1995) studied the effects of text point size by examining the 
relative changes in perceived urgency produced by manipulating font size (8-32 
points), border width (I to 8 points), white space around the signal word (2 to 32 
points) and colour. The signal word warning was emphasised by presenting it in red, 
surrounded by a border. Increasing the text size by 4 points produced the same 
degree of perceived urgency as increasing border width by 2.3 points. Adams and 
Edworthy (ibid) indicated that when the signal word was printed in black it needed to 
be twice as large as when printed in red to produce the same urgency rating. The 
effect of white space on perceived urgency was found to be very small compared to 
the other variables. It was considered not worthwhile for label designers to 
emphasise the signal word by providing additional space around it. 
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Using bold type text is preferable as it has good contrast with most backgrounds, 
however the stroke width should not be so wide that the features of individual letters 
are obscured (Sanders and McCormick, 1993). 
3.4 COLOUR 
According to Ryan (1991) using colour in warnings serves as a redundant coding 
dimension and the effects of using colour in coding for visual displays has been 
examined by Christ (1984). It is particularly useful to draw attention to a signal in 
crowded displays such as control panels and enhances the communication of hazard. 
Kline et al (1993) demonstrated that coloured warning labels were perceived as more 
readable and connoting more hazard than achromatic labels. Red conveyed 
significantly more hazard than the other colours. This finding has been replicated in 
the studies of Braun et al (1994), Braun and Silver (1995) and Wogalter et al (1995). 
The other colours in descending order of hazardousness are orange, black, green and 
blue. Higher rates of compliance were recorded when the warning label was printed 
in red rather than in green or black. 
Whilst red is often perceived as connoting the highest level of hazardousness, 
Wogalter et al (1995) point out that with the exception of this colour, people do not 
make fine hazard level distinctions between colours. This view accords with Young 
(1998) who found that the surround colour of signal words did not cause subjects to 
perceive colours in the hierarchy suggested by the American National Standards 
Institute, ANSI Z535 (1998). There were three tiers of hazard with red as the highest, 
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orange and yellow representing the mid level and blue signifying the lowest level of 
hazard. Young's findings indicated that people tend to connote hazard as high 
(signified by red) or low (denoted by blue). 
Chapanis (1994) evaluated the level of hazard conveyed by safety signs displaying 
the signal words DANGER, CAUTION and WARNING printed in red, orange, 
yellow and white. These were assessed by combining them with the background 
colours of red, orange, yellow and white. The colours rated in descending order of 
perceived hazard were given as red, orange, yellow and white however trade-offs 
between signal words and colours were noted. Combining the elements produced 
various hazardousness ratings with DANGER printed in black on a red background 
considered to convey the greatest level of hazardousness. There was little 
consistency among participants of the best colours associated with CAUTION and 
WARNING. Trade-offs have also been demonstrated by Braun et al (1994) and 
Braun and Silver (1995). Using 21 signal words presented in red, orange, green and 
black, rated on a9 point Lickert scale ranging from 'not at all hazardous' to 
'extremely hazardous'. Braun and Silver (ibid) demonstrated that the word 
DEADLY presented in black was rated as conveying the same level of hazard as 
CAREFUL presented in red. Thus communication of hazards is a function of both 
the signal word and the colour in which it is printed. 
The use of colour panels can be a useftil way to build redundancy into warnings, 
however Young (1998) has pointed out that standard recommendations tend not to 
specify panel formats in a way that enables panel components to be used optimally. 
67 
Lane, R Chapter 3: Literature review 
on ivarnings 
Moreover, using panels can make the signal word more difficult to read (Wogalter et 
al, 1999). 
3.5 WARNING SHAPE 
As pointed out in the previous section warning signs have often incorporated colour 
and shape as redundant features to improve detection, legibility and comprehension. 
Riley et al (1982) examined 19 different geometric shapes of warning labels by pair 
comparisons. When shape alone was the determining factor for describing a 
warning, an equilateral triangle pointing downwards was the most preferred warning 
shape of the 19 shapes compared. The results suggest shapes that appear unstable 
are preferred as warning shape indicators. Other preferred shapes are shown in 
figure 3.2. 
Research by Serig et al (2000) examined the extent to which container shape and 
colour of consumer packaging influenced hazard perception of the product. Pre- 
existing schemas and scripts about the products derived from past experience 
appeared to deten-nine how to safely transport, store and use them. The study 
findings indicated that colour type selection appeared to be influenced by the 
described levels of hazard, red being associated with high hazard and white with low 
hazard. As the perceived hazard increased so did the participants' intention to 
engage in precautionary measures. 
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Rank Shape Shape number 
Iv4 
2.5 0 10 
2.5 
0 
15 
4.5 A5 
4.5 
>3 
60 17 
7 <2ý 18 
8.5 
<2 
8.5 13 
10 12 
Figure 3.2: Ranking of preferred shape (Source - Riley, 1991) Identical rank values indicate that shapes had the same preference 
scores and the appropriate consecutive ranks were averaged. 
The experiment demonstrated that participants were able to design product packages 
that signalled the identity and potential hazard of the contents, implying that they 
were able to use package shapes to identify levels of hazard that might be present in 
consumer products. People were familiar with types of product being presented in 
certain types of packaging, for example milk, in a cardboard carton. They were able 
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to consistently identify from line drawings the package shapes that were more likely 
to contain hazardous products such as pesticides compared with more non-hazardous 
packaging likely to contain food products. These results indicated that people use 
shape as cues to inform them about the hazardousness of materials in combinations 
of colours and shapes that are relatively independent of each other as coding 
variables. 
Wogalter and Young (1994) compared tag and wing designs with a conventional 
design, to see what effect there would be on behavioural compliance with a warning 
on a small container of glue. Forty-four student participants were asked to construct 
a model using the glue without being infonned of the real purpose of the study. 
After completing the task participants were asked: whether or not they noticed the 
instructions on the glue bottle, whether they read the instructions, to recall (or guess) 
what the instructions said; whether they noticed the warning, whether they had read 
the warning, to recall (or guess what the warning said); if they had any experience of 
constructing models and approximately how many models they had previously 
constructed. 
In this study the participants complied more often with the tag warning than with the 
wings or the control warnings (Figure 3.3). This was attributed to the noticeable way 
in which the warning was presented on the tag. Participants were readily able to see 
the warning as it faced upwards and was continuously visible throughout the 
duration of the task. With the control and the wing design the bottle had to be picked 
up from the table in order to see the warning which could be covered by the 
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participant's hand whilst holding the container. Thus increasing the size of the label 
can have the effect of increasing its conspicuity and inducing greater compliance. 
3.6 GRAPHICS 
3.6.1 General Points 
There are differences in graphics, icons, pictogram, pictorials and symbols. 
However the tenns will be used interchangeably. Pictorials have been increasingly 
used across a wide range of consumer products and information during the past few 
years (BS 8501: 2002). Pictorial symbols increase the salience of warnings and the 
likelihood of them being noticed (Wogalter et al, 2002), memorised (Young and 
Wogalter, 1990) and comprehended (Young and Wogalter, 1990; Dewar, 1999). 
They are generally 'readable' at a greater distance than words (Dewar et al (1976) 
and appear in health contexts (Kalsher et al, 1996; Morrow et al, 1996) and 
industrial settings (Lehto, 1998). Well designed pictorials can communicate large 
amounts of infon-nation quickly and can be useful for those who cannot read printed 
verbal messages. 
InsuvaiOns 
I Waniiiig 
Control 
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Tag 
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Figure 3.3: Alternative designs for warning information 
Poorly designed pictorials may communicate nothing other than that a warning is 
present (Kalsher et al, 1996). They are most effective when communicating simple 
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concrete concepts (Wogalter et al, 2002) and are less effective at representing 
complex or abstract ideas (Bruyas et al, 1997). Kalsher et al (1996) suggest that 
labels with pictorials were preferred by college students to those without. When 
designing pictorials there needs to be enough detail to convey meaning without 
providing so much that legibility and comprehensibility are reduced. 
Arthur et al (1997) tested a system of signs to warn visitors to Canada's national 
parks of natural hazards by presenting participants with black and white pictographic 
representations of 36 warning messages in a questionnaire booklet. Each message 
comprised either one or two pictographs but no words. The first picture indicated 
the hazard and the second picture, when present informed the user how to avoid the 
hazard. Context was given by indicating above each pictorial the location where it 
would be seen, for instance, on a beach or at the beginning of a trail. Participants 
were required to comment on several aspects of the signs: how well the pictographs 
conveyed the message, what was confusing about it, how it might be improved and if 
the second pictograph aided understanding. Most messages were well understood 
and of the 27 signs tested only 7 received wrong responses of greater than 20%. 
In a study by Mayer and Laux (1989) 139 participants identified 16 pictograms from 
the Westinghaus Product Safety Label Handbook. The results ranged from 100% 
identification of pictograms to completely unrecognisable. Generally pictograms 
representing simple clearly identifiable hazards of protective equipment were more 
identifiable than symbols. 
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Use of symbols or pictorial representations to convey warnings is not without 
problems as demonstrated by Bruyas et al (1997) and some pictorials currently in use 
are not always well understood (Wolf and Wogalter, 1998 and Davies et al, 1998). 
In the Mayer and Laux (1989) study pictograms depicting injury occurring to a hand 
were more recognisable compared to those showing the entire body. Pictograms 
developed for concrete concepts are often well understood but conveying ideas or 
abstract principles using pictorials has proved notoriously difficult. Processing 
pictures and images is a complex perceptive and cognitive activity as viewers have 
to call upon their diversified knowledge of the items being represented. Being able 
to recognize an object does not necessarily mean the message associated with it will 
be understood. In order to convey complex information it is sometimes necessary to 
combine several codes or elements which requires the user to make inferences to link 
them. Waming messages associated with water hazards caused problems with 
understanding in the studies of Arthur et al (1997) and Dewar and Arthur (1999). 
Similarly conveying abstract notions such as the passage of time, the presence of 
radiation, or the pharmaceutical concept 'take until gone' pose great challenges for 
designers. Dewar and Arthur (ibid) used sequential pictograms to convey the 
complex warning: 'Fishing here is dangerous. Waters can rise rapidly anytime. You 
may lose your balance and be swept away in the current' (Figure 3.4. ). 
Young and Wogalter (1990) demonstrated that conspicuous print warning messages 
presented with icons in an instrument manual facilitated comprehension and memory 
for warning messages and enabled users to better identify the semantic meaning of 
the icons. 
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Figure 3A Sequential pictographs Original and redesigned 
versions of 'No fishing, rising water' 
Bruyas et al (1997) devised a study to examine how users attribute meaning to 
complex messages by analysing how meaningful links were built between complex 
pictogram components. Two groups of participants (young and old) were shown 
road safety signs on a computer screen in one of 6 display times ranging from 100 
milliseconds to 5 seconds. The findings indicated that whilst participants recognised 
familiar symbols they did not always understand their meaning if the representation 
was unexpected such as in the instance of a damaged or crashed car. Furthermore, 
using the same symbol in various contexts also impaired recognition. An example of 
this is the use of the arrow symbol, which is used in the Highway Code in various 
differing contexts. This research demonstrated the pitfalls of using rules unknown to 
users in warning of potential hazards. 
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3.6.2 Training 
Brelsford et al (1994) conducted a study to determine whether or not the level of 
comprehension and retention of heterogeneous pharmaceutical pictorials could be 
enhanced. A training paradigm was used in which sixty participants were asked to 
identify and explain the significance of concepts represented by 40 pictorials. Half 
the participants viewed the pictorials with a defining label printed below each 
pictorial. The other half viewed the pictorials with a verbal label and an 
accompanying short explanation of the concept or hazard. Participants were given a 
brief training session after which they performed a filler task before half were tested 
again. All participants completed a final comprehension test 7 to 10 days later. The 
results indicated that training increased comprehension scores. Increased 
comprehension was maintained one week after the final test. Very brief instruction 
with only the associated verbal labels substantially increased comprehension of 
difficult pictorials. This was a significant finding bearing in mind that pictorials are 
used in a variety of contexts in which their meanings are not readily apparent and 
suggests that very brief training of poorly understood pictorials can improve 
comprehensibility. 
3.6.3 Consumer Products 
Davies et al (1998) investigated the role of pictograms in conveying consumer safety 
information, since a large amount of infon-nation is provided to consumers in 
pictorial form. Data collected from 325 subjects in 4 LJK cities indicated that 
comprehension of the pictograms used on consumer products was poor. Only 3 of 
the 13 pictograms investigated were correctly understood by more than 66% of the 
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sample. Three of the 5 pictograms with the lowest comprehension scores were 
represented by an abstract graphic. However Davies et al (ibid) point out that as 
many symbol comprehension studies lack contextual information comprehension 
levels may be lower than might be expected in real-world situations. This issue was 
addressed by Wolf and Wogalter (1998) who suggested that adding contextual 
features to pictorial symbols helps viewers to recognise them. 
3.6.4 Controls 
In the case of controls which tend to be universally labelled, Woodson et al (1992) 
suggest that it is not always possible to represent all information pictorially as the 
resulting image would be unrecognisable to those unfamiliar with an object or 
situation. They elaborate this point by taking an example from the field of 
engineering. The symbol used for the choke system used on some vehicles is highly 
significant to engineers who are familiar with the system. However the symbol may 
have little meaning to many drivers who believe the symbol represents something 
else. Their recommendation for producing pictorials is to give just enough detail to 
make the symbol recognizable and no more. This is because fine detail cannot be 
seen in certain lighting conditions or from far away and can lead to confusion. Over- 
stylisation should be avoided as this may render the symbol indescriminable from the 
others. Using a border is useful to prevent blending in with background images. 
3.6.5 Prohibitive Pictorials 
A pictorial inside a red circle overlaid with left to right slash at a 40' angle is often 
used to denote a prohibited activity. Murray et al (1998) devised a study to test 
perception of 4 different variations of prohibitive notice: a slash over the symbol, a 
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slash under the symbol, a partial slash and a translucent slash (figure 3.5). Sixteen 
pictorials with different semantic message content were used. The results were that 
over- and under- slashes were preferred to the translucent or partial slashes. In the 
case of the asymmetrical symbols, orientation and slash type influenced preference. 
Some pictorials with the over-slash received lower evaluations when critical features 
were occluded. Murray et al (ibid) suggest that participants' preference for the over- 
and under-slash may be due to familiarity to concordance with gestalt principles of 
good figures. That is, the tendency to organise perceptual inforination into coherent 
pattems. 
(S(S(S(S 
0 
(S(S(8(3 
Figure 3.5: Example 'No trucks' pictorial in the 8 slash type variations and 
illustrating both the left and right orientation (source Murrary et al, 1998) 
Whilst investigating the effects of pictorial size and thickness of the red circle on 
glance legibility Sheih and Huang (2004) discovered that when luminance contrast is 
high and exposure time is long (50ms) participants were sufficiently able to process 
the symbols and the effects of pictorial size and slash thickness were not significant. 
However in conditions when luminance contrast is degraded and glance time short, a 
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large pictorial size benefits glance legibility. Additionally in conditions of low 
luminance contrast, a small slash thickness benefits glance legibility. 
3.7 COMPREHENSION 
Wogalter and Sojourner (1999) point out that experts sometimes have 
misconceptions about how warning information will be interpreted. They assume 
receivers of the message will understand it as it was intended. The knowledge held 
by experts is often ingrained and they may not appreciate the difficulty others have 
in understanding their position. It is important to understand that people bring their 
own knowledge and experience to situations. Designers of warnings need to 
understand that members of the target audience may not understand hazards, 
consequences and instructions as well as they do and may not possess what is 
considered common knowledge (McCarthy et al 1995, Laughrey and Wogalter, 
1997). 
When conveying a message to readers who may have lower reading skills or limited 
understanding, the label or warning should be targeted to the lowest practical level of 
readers. Wogalter and Sojoumer (1999) give the example of the waming carried by 
cigarette packets of 'low birth weight' intended to wam prospective mothers that 
smoking is harmful to the baby. However this has been interpreted as a beneficial 
effect of smoking leading some women to believe that smoking during pregnancy 
would make labour easier due to the smaller size of the baby. Other women 
interpreted the phrase as a way to keep their weight down. Wogalter and Sojourner 
(ibid) argue that the wording should have been tested to rule out unintentional 
ambiguities. 
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Explicitness of the warning is also an important factor in comprehension. Explicit 
messages contain specific information about the nature of the hazard. They give 
definitive instructions on how to avoid the hazard as well as give information about 
the consequences of non-compliance. For example, 'may be hazardous to health' is 
vague and gives little information. An explicit warning would be, 'can cause lung 
cancer which almost always leads to death'. The latter explains what the problem is 
and the likely outcome (Wogalter 1999). 
3.8 COMPLIANCE 
3.8.1 General Points 
Recommendations have been made that effective warning signs should have a 
number of components such as alerting word, statement of the hazard, of it's 
seriousness and probable consequences and how to avoid the hazard (Adams et al, 
1994). It might be tempting to think that displaying a conspicuous warning adhering 
to some of the findings highlighted in previous research would guarantee 
compliance. Wogalter et al (1994b) demonstrated improved rates of compliance in 
response to lift signs that had been enhanced by the use of colour, a signal word 
panel, pictograms and explicit wording of the required behaviour. Many warnings 
are designed to be seen though other modes of presentation are often more effective. 
Verbal warnings have been investigated by Edworthy (1994), Barzegar and 
Wogalter, (1998), Hellieretal (2000) and Edworthyetal (2000). Selconetal(1995) 
demonstrated that using four sources of warning infon-nation produced significantly 
better compliance among participants than either three or two sources. 
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Braun and Silver (1995) examined the effect of colour on compliance assessed by 
subjects putting on protective gloves as directed by the warnings printed in red. A 
higher level of compliance was noted than for the green and black notices. 
If people noticed the warning, they were very likely to read, recall and comply with 
it (Wogalter and Young, 1994). In their study where 100% of participants noticed a 
warning 80% of them complied with it. However in a previous study Friedman 
(1988) demonstrated a lower rate of compliance. In a 3x2x2 between subjects design 
the effects of three independent variables were examined: the conspicuity of the 
warning, compliance with the warning and recall of the warning infon-nation on 
either a bottle of liquid drain opener or wood cleaner. The dependent variables were 
the manner of presenting the warning information, product familiarity and 
compliance requirements. Measures were taken of subjects noticing, reading, 
remembering and complying with the warning 
Across all conditions subjects did notice the warning in 88% of cases. Despite this, 
they did not always read the warning. In fact, 46% read the entire warning but only 
27% followed it. Forty nine percent correctly recalled the danger associated with the 
product and 42% recalled the precautionary action correctly. In those experimental 
conditions where a symbol was presented on the back panel, 30% of subjects noticed 
it. However it was correctly identified by only 23% of them. People were more 
concerned to learn about what the product did rather than the dangers associated with 
its use. Once people had read the warning, several factors influenced their 
compliance. The more hazardous the product was perceived to be, the more likely 
users were to comply with the warning. 
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This accords with the findings of Davies et al, (1998) and Ursic (1984). Moreover, in 
the Friedmann (1988) study some users felt that if they used the product in what they 
considered to be a safe manner they would not be hurt. This belief may have been a 
consequence of the type of warning presented on the product or due to the personal 
attributes of the person using the product. Placing a symbol on the label of the 
product increased the perceived hazardousness but had no effect on levels of 
compliance. 
3.8.2 Cost of compliance 
The strong association between noticing a warning and compliance accords with the 
findings of other studies: Wogalter et al (1987), Dingus et al (1991) and Rodriguez 
(1991). However noticeability is not the only factor promoting compliance. 
Wogalter et al (1989) discuss the effects of effort involved in complying with the 
warning. In the cases where users were required to put on protective gloves that had 
been conveniently placed, compliance with the warning was high. 
In instances where personal protective equipment (PPE) is not convenient to locate 
and use, compliance is likely to be fairly low (Otsubo, 1988). Otsubo also 
demonstrated that less confident users to tended to read and comply with warnings 
and the type of warning label had no effect. However in all conditions with a 
warning label there was an average compliance of 25.5%. Where no warning label 
was present no precautions were taken by the participants The findings support the 
view that conspicuous placement of warning labels on products will influence people 
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to behave cautiously, but it is questionable whether this alters their perception of 
risk, a point that will be taken up later in this chapter. 
3.8.3 Stress 
Complex behaviour has been observed between reading labels and compliance. 
Wogalter et al (1998) demonstrated that external factors such as stress influences rate 
of compliance. Participants complied more frequently with the warning by wearing 
protective equipment when they were under low stress conditions (no time pressure) 
than those who were not. Participants in the high time stress conditions reported not 
reading the warning, not noticing the PPE and being less careful in performing the 
task. 
3.8.4 Task Performance 
Lehto and Salvendy (1995) argue that people often fail to read warning labels 
because they are focused on the task related goals and objectives and only look for 
information needed to successfully complete the task element they are currently 
performing. In other words, their attention is highly focused on a specific subtask. 
If the person is interrupted they may notice, read and comply with warning signs or 
labels. This was demonstrated by Frantz and Rhoades (1993) and Franz et al (1999) 
who observed that warnings which temporarily interfered with task performance 
were significantly more effective than those that did not. 
3.8.5 Product Familiarity 
Product familiarity and perception of hazardousness can also influence the level of 
compliance. In cases where opinions have been fon-ned of product hazard and 
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appropriate use by experiences instructions or warnings are often discarded (Pollack- 
Nelson, 1995). This is especially true if the warning contradicts the individual's own 
experience. For instance, prior injury can mitigate poor effects of compliance 
particularly in the case of people who have been injured or those who know of 
someone who has been injured whilst using a product. They are more likely to be 
cautious and to take the precautions they judge necessary regardless of the 
manufacturer's warning. 
Prior knowledge of a product and its associated hazards dictates behaviour with that 
product (Davies et al, 1998). The familiarity a person has with products or in certain 
situations makes them more confident of their probabilistic assessment of the 
situation (Papastavrou and Lehto, 1996). Their assessments are unlikely to change 
as familiarity increases. The warning becomes less likely to change the expected 
cost of intervening or the expected cost of a miss. Therefore, on familiar products 
warnings are less likely to change decisions and people learn to disregard them. 
Presenting warnings on a rotating basis could ensure that individuals are exposed to 
a specific warning less frequently, thus reducing the negative effects of habituation 
(Wogalter and Brelsford, 1994). 
Pollack Nelson (1995) examined the effect of labels on the behaviour of people 
using paint stripper, non-automotive spray paint and adhesive remover, products all 
containing the hazardous chemical methylene chloride. Participants were asked if 
they changed their behaviour as a result of what they had read on the label. About 
one tenth of respondents indicated they changed the way they intended to use or 
dispose of the product in consequence of what they had read. Users were aware of 
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potential hazards - health concerns were expressed by 25% of the participants 
working with paint strippers and adhesive removers. Seventeen percent of 
participants working with spray paint expressed health concerns. There was no 
direct relationship between label reading and precautionary behaviour such as taking 
fresh air breaks. 
3.8.6 Perception of Risk 
Adams et al (1994) suggest that without attention being drawn to them in normal 
use, warnings are frequently not seen or complied with. Part of the reason for this 
may be that most people are able to assess levels of risk associated with consumer 
products quickly and accurately (Wogalter et al , 1993; Davies et al, 1998). If they 
perceive use of the product to present a high level of hazard they are more likely to 
look for the warning (Friedmann, 1988; Wogalter et al, 1991). Another reason may 
be that on many consumer products warnings are presented in a long list of safety 
and use information. Product-specific hazard information is embedded in other 
product information appearing on packages amid manufacturers' fears that 
customers will not buy the item if the warning is placed more prominently (Pollack 
Nelson, 1995). Trommelen (1997) maintains that consumer product warnings should 
inform the user of what to avoid, what the product-related hazards might be and the 
consequences of unsafe behaviour in terms of injuries. But this approach may have 
the opposite effect. 
If the attention of the user is captured warnings can positively affect a person's 
perception of the safety effectiveness of product. (Ursic, 1984). In a study that 
attempted to examine the impact of safety warnings on perceptions of safety 
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effectiveness of brands and memory of product information, Ursic (ibid) found that 
products with warnings were perceived as being more powerful than similar 
products. Warnings positively influenced the user's perception of risk perhaps 
because the manufacturer was deemed to have taken more care in producing and 
marketing the product. The type of safety warnings had little impact on the 
perception of the brand or on the memory of the warning. Similarly, Trommelen 
(1997) demonstrated that people thought products with explicit warnings were more 
dangerous and injuries incurred whilst using these products would be more serious 
than products with no warning. They also thought injuries arising from products 
provided with explicit warnings would be more severe than products provided with a 
non-explicit warning. 
Papastavrou and Lehto (1996) make the point that warnings have little or no effect 
because they provide limited information due to their 'all or nothing' nature. 
Papastavrou and Lehto suggest that either the warning is present or it is not. 
Experiencing repeated warnings in the absence of the associated hazard often results 
in "cry wolf' effects such as when medical staff ignore auditory warnings on 
equipment. People tend to weight frequent but minor inconvenience dispro- 
portionately compared to inconvenience that is infrequent but has devastating 
consequences. However, if the warnings are not given frequently, they could result 
in costly misses. Using the examples of seat-belt wearing and smoking, the authors 
point out that compliance is likely if drivers are told to buckle their seatbelts when 
they are undone or if smokers are informed of the risk factors of lung cancer or heart 
attack associated with smoking were provided on the cigarette packet. Giving 
intelligent warnings would convey the desired sensitivity of the warning message 
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and shape people's attitude towards the message. it is suggested that conservative 
warnings should be given if the cost for a miss is high and the cost for a false alann 
is small as frequent false alarms will result in people ignoring the warning. 
A second approach is to use confirming information such as that provided by Dingus 
et al (1993) who increased the use of protective eyewear when they posted a sign on 
the door of a racket ball court. Stating that eye Injuries related to the sport were very 
common (for example possessed odds of 1 in 4). Protective eyeglasses were 
provided in a box by the door. The low cost of compliance coupled with information 
about the probability of injury induced players to put on the glasses when the notice 
was present as compared to its absence. 
3.8.7 Training 
Power plant operators are trained to respond to the warnings that indicate abnormal 
operation. Training is important when a complex response is called for as based on 
the limited information given by warnings, it might be impossible for the individual 
to understand what actions are necessary (Wogalter et al, 2002). 
3.9 DEMOGRAPHY 
3.9.1 Age 
Dewar and Arthur (1999) have shown that using sequential pictographs is useful to 
convey hazard to young people or those with low reading ability. However, older 
adults tend to be better at processing text than symbolic instructions compared to 
younger adults. This may be due to age-related differences in exposure to the two 
kinds of media (Dejoy, 1999; Leonard et al, 1999). Silver and Wogalter (1991) 
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compared the ratings of 43 signal words on a carefulness scale between college 
students, elementary school students and middle school students. A follow-up study 
with elderly subjects indicated that rank ordering did not differ significantly between 
the groups, although it was noted that younger students assigned higher carefulness 
ratings to the signal words than the college students. When given various hazard 
scenarios older subjects assigned words connoting higher levels of hazard (Leonard 
et al, 1989). This may have been related to their actual or perceived experience of 
injury. 
Edworthy and Warren (1997) investigated the effect of colour and signal word in 
eight year old children. The results indicated that from an early age (about 8 years) 
children have already learned that the word DANGER signifies a greater hazard than 
either WARNING or CAREFUL. They are also aware that red is intended to convey 
the highest level of hazard followed by orange, green, yellow, blue then white. 
These findings are similar to those for adults in the cases of red, orange, yellow and 
white. The effects of blue and green were generally less pronounced for adults. 
I 
In the assessment of road safety signs older subjects needed a longer time to identify 
the drawings in order to understand them and were less confident in their responses. 
However they gave more descriptive responses than the younger participants. This 
was mainly due to the fact that they focused on different elements of the symbols 
I than their younger counterparts, ignoring those that were unexpected and focusing 
more on more easily recognised features. The younger participants, on the other 
hand, gave less detailed descriptions these were more spontaneously integrated in the 
whole meaning of the message (Bruyas et al, 1997). 
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Lesch (2003) demonstrated that many warning symbols are poorly understood 
particularly by the elderly. Whilst both young and older participants had difficulty 
understanding symbols, older adults (50-67 years) recorded lower correct scores than 
did younger adults (18-35 years). With training, the scores for correctly identifying 
the symbols improved from 37% for older adults and 52% for younger participants 
i 
to 68% and 88% respectively. Older participants also experienced difficulty in 
rejecting incorrect meanings. 
3.9.2 Gender 
Very few studies report gender differences in relation to warnings. However Larue 
and Cohen (1987) have demonstrated that women are more likely to read and 
comply with warning information than men. Gender differences have been noted on 
measures of the perceived hazardousness of products (Young et al, 1989; Friedmann, 
1989). Products considered relatively hazardous by both males and females were 
assigned lower hazard ratings by males. Males were also more confident about 
? 'knowing all the hazards' than females. Females believed that accidents were more 
t 
likely if protective equipment was not worn when using the products (Friedmann, 
1989). 
3.9.3 Cultural differences 
Wogalter and Silver (1995) carried out a study to detennine whether signal words 
are interpreted by school children, the elderly and non-native English speakers in the 
same way as college students with the intention to construct a list of words that 
might be used for special populations. They used comprehensibility ratings for the 
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signal words that would provide suitable assessment criteria for a broad range of 
populations. These included filling in blanks and ranking the words. The rank 
ordering of the words was consistent across all groups. The younger students gave Zý 
higher carefulness ratings than the undergraduates. The words that the younger 
children and the non-native English speakers frequently left blank were given lower 
understandability ratings. The rank ordering of the words was found to be consistent 
% 
between the non-native English speakers and elderly participant groups. A shortlist 
of terms was drawn up that was understood by at least 95% of the youngest students 
and by 80% of the non-native English speakers. 
In assessing the level of perception among non-native English speakers of hazard, 
Leung and Hellier (1998) carried out a questionnaire study designed to test perceived 
hazard and understandability of signal words and warning pictorials by the Chinese 
community in Britain as compared to English subjects. They used a point rating 
scale with the anchors: (0) not at all understandable, (2) somewhat understandable, 
(4) understandable (6) very understandable, (8) extremely understandable. Forty- 
three signal words used by Wogalter and Silver (1995) including: NOTE, 
I 
ATTENTION, NOTICE, CAREFUL, DANGER, CAUTION, WARNING, 
DEADLY were assessed. There were no significant differences in the 
understandability ratings between Chinese and English subjects. Wogalter and 
Silver (1995) suggest the reason for this is the possibility that the Chinese received 
training on the intended meanings of these commonly used words. Further testing 
revealed that understandability ratings of the Chinese subjects were significantly 
lower than those of the English subjects. 
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Smith-Jackson and Wogalter (2000) compared ratings of perceived hazard of 10 
ANSI colours; and six symbols among English and Spanish language users. Red 
followed by yellow, black and orange were awarded the highest hazard ratings. The 
symbols rated highest were the skull, prohibition (circle with slash), and the electric 
shock symbols. These findings were similar to those of Wogalter et al (1994) and 
Wogalter et al (1998). In descending order Spanish language users specified red, 
orange, black and yellow as representing the highest level of hazardousness in 
accordance with the findings of Chapanis (1994). This research provides some 
support for the significance of culture in the perception of colours and symbols as 
well as suggesting that this factor is an important consideration when designing 
labels or use by other cultures. 
Several trait and environmental factors that vary by culture have been shown to 
influence risk-perception, risk taking behaviour and compliance as well as other 
processes (Wogalter et al, 1997, Wogalter et al, 1998). Cultural differences may 
influence variables such as risk perception, risk tolerance, stress vulnerability and 
decisions to report injuries/accidents. Signal words used in warnings and other safety 
related communication have attempted to incorporate a cultural components (Smith- 
Jackson and Wogalter, 2000). However Wogalter et al (1997) demonstrated that 
Spanish language users do not communicate levels of hazard using the same words. 
PELIGRO the word used in the United States to communicate the highest level of 
hazard was rated 5th among Spanish language users. Four other words: 
EXPLOSIVO, MORTA, VENENO and PELIGROSO conveyed higher levels of 
hazardousness to them. 
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Smith-Jackson et al (2003) demonstrated cultural differences in the interpretation of 
symbols among Ghanaian students compared to US students at college level. The 
Ghanaian students recorded more incorrect responses than American students. The 
differences are likely to be due to culture-based trait variables which influence risk 
taking behaviour or compliance (Ajzen and Fishbein, 1980). Trait variables such as 
fatalism and religious belief vary among cultures and have a significant effect on 
attitude to and perceptions of risk (Neff and Hoppe, 1993). The culture based 
processing of related risk is known as the culture based risk mental model (CRMM). 
The CRMM is the culture-dependent knowledge, representations and decision- 
making patterns associated with personal risk assessment and behavioural intent 
Smith-Jackson et al (2003). 
3.10 EVALUATION 
In many of the studies outlined in this review subjective methods have been used to 
assess the effectiveness of warnings with participants rating warnings along several 
dimensions using Likert-type scales. Measures of noticeability (Friedmann, 1988), 
reaction time (Young, 1991 and Bruyas, 1997), comprehension, recall and 
knowledge (Lelito, 1998; Dewar and Arthur, 1999; Leonard, et al, 1999; Lesch, 
2003) and ratings of hazardousness (Chapanis, 1994) have been assessed. 
The selection criteria used to evaluate warnings must be carefully selected (Wogalter 
et al, 2002). Ideally all warnings should be developed and tested by measuring the 
criterion of behavioural compliance. However it not always possible to measure this 
due to the costs and risks that may be incurred. Some researchers have used 
behavioural intent as a substitute for behavioural compliance based on the findings 
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of Doll and Orth (1993). This has been measured by asking participants to rate their 
likelihood of acting or behaving in a particular manner. 
In situations where it is not possible or desirable to measure compliance then various 
measures may be used in a process of triangulation. It is also best to consider the 
context of evaluation which is of particular importance when assessing pictorials on 
a computer or in a laboratory setting for which there are no environmental cues. 
3.11 PHARMACEUTICAL LABELLING 
One problem identified by Kalsher et al (1996) with prescription drug labels is that 
they lack formal specification in the order the information is displayed and the 
amount and type of information presented is not standard. European Directive 
92/27/EEC has laid down guidelines of what should be included but not how it 
should be laid out. Various label characteristics affect readability of prescription 
drug labels. These include line space, letter contrast, print and label background 
colour, type and style. Prescription product inserts (PPI) are increasingly used to 
provide information about drugs. These contain information that patients might need 
to know such as any relevant warning and any necessary instructions to ensure 
correct drug usage. However, these can become lost. Increasing the label size by 
using fold out labels and tag designs as described in section 3.6 enables pictorials to 
be added to facilitate understanding. Pharmaceutical pictorials need to be tested for 
comprehension and legibility as well as recall of information contained on the label. 
The tag designs also enable larger print sizes to be used (Kalsher et al, 1996). 
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Wogalter and Sojourner (1999) make several recommendations for the design of 
phannaceutical labels: 
9 Labels should be designed in a way that captures attention. This can be 
achieved increasing the overall surface area of the package. 
9 Pharmaceutical information should be iterated by simplified wording and 
organising the material using headings and pictorials. 
9 Pharmaceutical information should contain persuasive, assertive statements 
to ensure that readers form the correct belief or attitudes. 
* Information printed on the label should motivate people to cOmPlY. The cost 
of compliance needs to be low and die consequences of non-compliance 
should be stated explicitly. 
Whilst these recommendations have been suggested, Wogalter and Sojourner (ibid) 
acknowledge that trade-offs have to be made in order to accommodate the 
appropriate combination of desirable features. For instance, the recommended 
explicit warnings require more space than less explicit warnings. There is also a 
I need to test the labels using various methods which might include subjective ratings, 
legibility assessments, comprehension tests and behavioural compliance. Whilst this 
discussion applies to over the counter medications (OTC) and outpatients, the basic 
principles can be applied to medication for use by hospital professionals. 
The SHERPA table (table 2.3) highlighted the need for conspicuity of 
label ling/packagi ng to address the problems of errors caused by failure to read drug 
labels. The recommendations in this chapter can be used to develop some form of 
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novel packaging that incorporates the systematic use of colour. Other features such 
as the addition of icons should also increase conspicuity of labelling and help in the 
identification. of drugs. This is the focus of the next chapter. 
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Chapter 4 
Design Solutions 
4.1 BACKGROUND 
The summary SHERPA table (table 2.4 on page 55) indicated that the greatest 
number of errors (13) could be solved by employing some form of barcoding system. 
This will be considered in more detail in Chapter 6. The next most prevalent number 
of errors that were highlighted (9) in the summary table could be addressed by 
conspicuous packaging and it is this solution that forms the subject of this chapter. 
IA designer was consulted in order to discuss the issue of presenting relevant 
information on packaging in a way that would capture the attention of nurses. In 
light of the recommendations of Sojourner and Wogalter (1990) that pharmaceutical 
labels should capture the attention, it was felt that a combination of colours, 
iconography and drug imagery would all be useful eye-catching features as nurses 
are often presented with a collection of bottles or packages with uniform white labels 
on which information is printed in small black or grey font sizes as outlined in 
chapter 2. 
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The model by Roozenburg and Eekels (1995, p5) in figure 4.1 highlights the 
importance of analysis of the initial design problem and emphasises the development 
of criteria for judging the success of the resulting design. The functioning of a 
potential solution is assessed in a simulation. The observed properties of this 
solution are used to deduce the properties that might be expected from the actual 
product still to be manufactured. The match between the expected properties derived 
from the simulation and those required from the product (the design criteria) 
determines the quality of the potential solution (Adams, 1999). The analysis used to 
address the original problem was carried out by the task analysis and SHERPA 
outlined in chapter 4. The main criteria for any designs were that they could be 
achieved within the scope of this project. The other criteria were that prospective 
designs should address the pressing issues of information management and drug 
labelling and packaging. 
4.2 DRUG PACKAGING 
The problems of drug packaging were highlighted in Chapter 1. A substantial body 
of work has been carried out on pharmaceutical labels and information by Morris and 
Kanouse, (1980); Wogalter et al (1993); Morrell et al (1990), Magurno et al (1994); 
Kalsher et al (1996); Morrow et al (1996); Ringseis et al (1995); Sojourner and 
Wogalter (1997); Vigilante and Wogalter (1997); Wogalter and Sojourner (1999). 
These studies were carried out to address problems encountered by members of the 
public and many apply to over the counter (OTC) preparations. Nonetheless the 
same fundamental principles apply in the context of professional users. Wogalter 
and Sojourner (1999) make the point that pharmaceutical labels are used to 
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Prorem 
Analysis < 
Criteria 
Synthesis 
Preliminary Design 
Simulation 
Expected p perties 
Evaluation F 
Value of Te design 
Decision 
Acceptable Design 
Figure 4.1: The Roozenburg and Eekels (1995) model of the design process 
disseminate information about medication uses, indications, benefits and potential 
hazards and that they are used as a method to influence behaviour. Although 
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registered nurses are trained in the knowledge of drugs, this should be no less true 
for hospital staff than members of the public. 
4.2.1 Colour 
Colour has been used systematically in safety warnings, with red signalling the 
highest level of hazard, yellow - general hazard, green and blue - instructional 
warnings to wear goggles or the direction of the nearest fire exits. The European 
Commission's Safety Signs Directive (92/58/EEC) has examples of these. 
4.2.2 Font size 
The Medicine and Healthcare Regulatory Authority (MHRA, 2001) recommends 
that text on medicine labels should be in sans serif fonts at the largest type size 
possible. The report advises that on smaller packages all the available space should 
not be used to impart information as this could lead to difficulty in quickly locating 
and interpreting relevant inforination. 
4.2.3 Original packs 
Original pack dispensing has led to the presence of increasingly greater numbers of 
brightly coloured packages in hospitals with the associated problems of a lack of 
differentiation between competing colours. As a result of this some manufacturers 
are reviewing their long-term packaging strategy. Dispensing medicines to patients 
in original packs which can be taken home when the patient is discharged (combined 
with storing medication at the patient's beside) has some important cost-saving 
benefits and is in compliance with the European Commission regulations (EC 
Directive 92.227). 
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In hospitals generic drugs are used in 75% of cases because they are cheaper than 
branded drugs (Audit Commission, 2001). These are often supplied as patient packs 
which can sometimes cause more problems than the branded drugs due to the 
similarity of the packaging. Figure 4.2 shows examples of three drugs representing 
two different types of drugs. Allopurinol is used to treat gout whilst bendrofluazide 
and furosemide are both diuretics. 
Branded drugs are also used because they are in a form that may work better for 
some patient conditions. For instance, some drugs might only be available in a 
sustained release (thereby having a longer therapeutic effect) in the branded fann. In 
such cases it might be important to label the drug by the branded name as well as its 
generic name (its chief active ingredient). 
Allopurinol 
Tablets SP 
100mg 
PATIFNI PACK 
bl,, t,, p,, k, NCMTqNX 
endrofluaxide 
rablets SP 
Frusemide Tablets RIP Q, 
40mg 
Figure 4.2 Generic drugs in similar packaging 
4.2.4 Label information 
One of the issues of using branded drugs is that vital information on proprietary drug 
packaging can often be confusing (Cohen, 1999; Kalsher et al, 1999). Relevant 
information is sometimes obscured by the dispensing label. This label is necessary 
because it contains the drug name (generic), patient's name, number of tablets in the 
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pack and dosing instructions and the address of the pharmacy. It also contains a 
warning to keep medications out of the reach of children. However it is often printed 
in small text and is difficult to read. The package might also contain additional 
warnings. For example, Atorvastatin should have a warning for patients not to drink 
grapefruit juice whilst taking the medication. 
The MHRA (2001) advises that medication packaging should carry a "number plate" 
of standardised information and that more work should be done on making medicine 
labels easier to understand. There is also a recommendation to show information in 
a standard format on both prescription and non-prescription medicines. The key 
information should be: 
o Brand name and generic name in the same font size 
o Pharmaceutical form 
o Strength 
* Dosage (applied by dispenser) 
o Warnings (applied by dispenser) 
The report calls for manufacturers to leave a clear space on the package, with no text 
or markings for a standard 70 x 35mm dispensing label. 
Label usability research indicates that the most easily readable labels are those that 
have the minimum required information. Too much information on the label is 
counter-productive and this applies across all medicine categories as noted by 
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Australia's Therapeutic Goods Administration (TGA, 2002). Guidance for label 
design can be found in Rogers et al (1995), Sless (200 1) and BS 8501: 2002. 
4.2.5 Colour Coding 
According to Cohen (1999, p13.6) colour coding is the systematic application of a 
colour system to identify specific products. This is in contrast to colour 
differentiation in which colour is used to distinguish a single product. Colour codin., 
may be used to help to distinguish drug classes. However as Cohen (ibid) points out 
the system has not been scientifically tested. Colour coding, along with distinctive 
background patterns or borders, has been proposed as a way to reduce drug 
administration errors in anaesthesia (Parr, 1986). In a study of 687 
anaesthesiologists, Orser et al (2001), report that only 47% of respondents admitted 
to always reading the drug labels of the medication they administered. Many 
responders identified colour as the single most important feature used to identify 
drugs. When asked to rate the importance of certain features of the package and 
label they used for identification, colour was the most frequent response, The colour 
of the ampoule and its label were considered extremely important for drug 
recognition. Similarly the colour of a vial and cap were considered extremely 
important. In the case of pre-filled syringes the text colour and external packaging 
were considered "extremely important". 
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Figure 4.3: Branded drug showing how colour has been used to differentiate between 
different strengths 
Class Colour Pantone Number 
Anti-infectives Tan 467 
Anti-inflanmiatories/steroids Pink 197,212 
Mydriatics and cycloplegics Red 485C 
Nonsteroidal and anti-inflamnudones Grey 4C 
Motics Green 374,362,348 
Beta-blockers Yellow, or blue, yellow 290,281 
Adrenergic Agents Purple 2582813 
Prostaglandin analogs Turqoise 326C 
Table 4.1 Colour codes for topical eye preparations (Source Cohen, 1999) 
The American Academy of Ophthalmology has endorsed the use of colour-coded 
caps and labels on ophthalmic products (table 4.1). The American Society for 
Testing and Materials (ASTM) has developed a standard for user-applied labels in 
anaesthesiology. The ASTM standard calls for each colour and border or 
background to represent a different class of drugs. Under this system induction 
agents are signified by yellow labels, benzodiazepines are denoted by orange labels 
and narcotics are represented by blue labels. A similar system is in use in Canada, 
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Australia and New Zealand (Radhakrishna, 1999). A national survey of anaesthetists 
by Christie and Hill (2002) has revealed extensive use of colour labels in the UK but 
these differ from those used internationally. Moreover the drug company Alpharma 
has taken the decision to colour code all of its products with one of seven colours 
(pink, blue, tan, violet, red, green or turquoise). Warfarin is the exception with the 
colour of the boxes matching the colour of the tablets (Pharmaceutical Journal, 
2002). 
Colour can also be used to differentiate between different concentrations or strengths 
of the sarne drug (figure 4.3). However it should be acknowledged that there are 
disadvantages of using colour coded labels as they may fade over time when exposed 
to light (Cohen, 1999) and it can be difficult for manufacturers to reproduce 
standardized Pantone colours from one batch to the next however with modem inks 
and contemporary printing techniques this is becoming less problematic. Whilst 
some official bodies endorse the use of colour there is opposition. The American 
Society of Health System Pharmacists (ASHP) and the MHRA, do not recommend 
the use of colour coding as a specific way to identify medicines on the grounds that 
its use may tempt users not to read the label. This, they argue, is because colour can 
become a short cut to identifying medicines causing people to neglect reading the 
label text, thereby increasing the potential for error. 
4.3 DESIGNING THE NEW PACKAGING 
A cursory look at the layout and features of existing drug packaging, reveals that 
many original packages use colour arbitrarily. The primary fimction of colour is to 
emphasise the brand name or to accentuate the name of the manufacturer in an 
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attempt to make it distinguishable from other drugs. (Kenagy and Stein, 2001). This 
is demonstrated very well by Nurofen (figure 4.4). This over the counter preparation 
is the branded form of anti-inflammatory and pain relieving drug ibuprofen. It is 
marketed and sold by Crookes Healthcare, a subsidiary of Boots Healthcare 
International. However in this case, unlike many branded drugs, the manufacturer's 
name is not located in a prominent place on the fi7ont of the package. The packaging 
of Nurofen is now a highly recognised analgesic largely because of its distinctive 
silver and orange packaging and the heavy marketing it receives. The branding 
design has become so widely recognised that Nurofen has been acknowledged as an 
official superbrand by the independent arbiter on branding the UK Superbrands 
Council. The definition of a superbrand described by the UK Superbrands Council is 
a brand that offers significant emotional and/or physical advantage over its 
competitors" (Www. nurofen. co. uk/default. asp? nid=15, accessed 16/l/2004). 
Figure 4A Nurofen package displays made distinguishable 
from other analgesics by dominant use of colour 
The process of redesigning the drug packages was to consider what were the salient 
features used to identify drugs. These are usually colour, positioning and salience of 
drug name. Using the principles of branding, which typicafly use dominant colours 
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and imagery to highlight information the manufacturer deems salient, it was intended 
to demonstrate that by using similar principles it is possible to draw the user's 
attention to the drug name of generic preparations. 
In designing the new packaging the designer looked at existing drug packaging to 
see how infonnation was arranged and how colour was used. There was a 
temptation to classify the drugs according to the parts of the body on which they are 
used. However this course of action was rejected in favour of categorisation 
according to the action of the drug in a similar way to the categorization principles of 
anaesthetists. These categories are given in the British National Formulary (BNF, 
2005) but the list produced by the Food and Drug Administration (FDA) is more 
readily suited this purpose (appendix B). In both cases the drugs are grouped 
according to therapeutic effect. Using colour to represent categories of drugs is more 
practical as there are not enough colours to represent each drug individually nor 
would that be desirable as nurses are likely to use colour as a short-cut as argued 
above. 
The basic premise of the design was to position key pieces of information located in 
a fixed position on the package label regardless of the drug category. This would 
enable users once familiarised with the package to become accustomed to looking in 
a precise location to retrieve the relevant information. A concept package for a box 
of tablets is illustrated in figures 4.5. and 4.6. 
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Figure 4.5: Preliminary drawing of the concept design 
The generic name by which the drug is mom often known is positioned on the left of 
the Wwl. since in wesscm society. reading tiends to be dirmied fmm left to right 
dwrefore it would wx 1 lolocal to put the most important information either new the 
top of the label or on the left. A colour boWa comprising pattems and coloum 
highlighting the generic now serves to draw the eye to that part of the package, The 
placement of the Kon acts n an a"fional feetuve to sitnict attention to the generic 
nisme. A picture of the coribmts aid the number contained in the package appears 
next to the generic name. Akxq*& the contents infortnation a barcode or smart 
label is positioned which can be read by a portable scaruw. To the right of the panel 
is the bnmd name of the drug if it has one- Space is allocated on the package to 
enable inclusion of the patient's infwmabon when the rnedication is dispensed for 
individual patients. This space would also include additional information such as the 
warning rocorruncrWed by the Bntuh Phiarmaccut" Association (BPA) to keep 
medicines out of the reach of diiidrm dw due of dispensing. dosage instructions 
and the name. address and tielephosse number of the dispensing pharmacy. The other 
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surfaces of the packaging would be designed according to the manufacturer's 
preference. It was envisaged that the design could be produced as a label that could 
be printed out and applied to boxes as necessary. 
Ti 
Original 
&WAsoct. 
Figure 4.6: Mock-up of the concept design 
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4.4 MSTING THY DUSIGN 
it was necessar) to we if the aiq of the desigm were s4plicantly better than 
custing packages. The imWIM way to do dus was to lem how quick4- the printed 
infomation cowid be rmd 
4.4.1 Participasts 
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4.4.2 Materiab 
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selection criterion for the drug category (given the time constraints) was that it 
should be easily represented by a pictogram. The categories selected are shown in 
table 4.2. 
A two-dimensional image was designed for each of the five drug categories using the 
principles of the concept package. This was carried out to enable one face of the 
package to be shown on a computer screen. The package was designed with a row 
of text surrounded by a distinctive colour border, accompanied by a pictorial 
representation (see figures 4.8 - 4.12). The pictogram was intended to reflect the 
drug category. The shield was intended to represent the protective effect of 
antibiotics (figure 4.8). In the case of analgesics, the representation of a hand in the 
'halt' position' alludes to the ability of the medication to stop the progress of pain 
(figure 4.9). Pain is signified by the outward facing arrows or spikes encircling the 
lower portion of the 'hand' in addition to the spiral in its centre. The spikes and 
wavy lines of the icon in figure 4.10 represents a profile form of the human body in 
acute discomfort. Figure 4.11 displayed the complex image of a hip joint with water 
flowing from it and the outline of a woman's face in profile with her hair hanging 
loose. The image in Figure 4.12 was a depiction of a free-flowing motion along a 
channel indicative of the action of an anticoagulant. 
Drug Category Action 
Co-amoxiclav antibiotic fight infection 
Paracetamol analgesic pain relief 
Furosemide diuretic relieve water retention 
Warfarin anticoagulant prevent blood clots 
Diazeparn anxiolvtics relieve anxietv 
Table 4.2 Drug categories used to represent the concept (new) package 
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Figure 4.8: Experimental package for the drug category antibiotics 
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Figure 4.9: Experimental package for the drug category analgesic 
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Figure 4.10: Experimental package for the drug category anxiolytic 
Figure 4.11: Experimental package for the drug category diuretic 
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1 7-7 z 
cr- 
cm 
Ij 
L- 
-- -1- -1 
Figure 4.12: Experimental package for the drug category anticoagulant 
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A picture of the contents and the bar code were included as on the concept package. 
The branded name of the drug was placed on the right in a vertical orientation as on 
the concept package. A sans serif text font (Arial) was used throughout the design. 
For comparisons with existing packaging, scans were taken of the front face of five 
branded drug boxes. These were boxes of prescription drugs and were made into a 
PowerPoint presentation of five slides. The boxes with minimal colour were selected 
to provide a reasonable comparison with the concept packages. It was not possible 
to find 5 packages of branded drugs from the same drug categories as the concept 
packaging as many community and hospital pharmacies now use generic drugs. The 
drug categories tested were as given in table 4.3. 
Drug Category Action 
Doxazocin alpha adrenoceptor lowers blood pressure 
blocker 
Venlafaxine antidepressant relieves anxiety 
Fenofibrate fibrate lowers blood 
cholesterol 
Zopiclone hypnotic treats insomnia 
Rosightazone antidiabetic treats diabetes 
Table 4.3: Drug categories used to represent existing (old) packages 
CARDURA*,, XL 
8mg !,. If> 
r. --i -7 ýIý-'.. I, .. 
-ý, 
Figure 4.1 -3 ) -. Experimental package for the drug category 
alpha-adreno-ceptor blockers (lowers blood pressure) (Source- Clark, 2000) 
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Figure 4.14: Experimental package for the drug category 
fibrates 
Figure 4.15: Experimental package for the drug category 
antidiabetics (Source- Clark, 2002) 
ZiMovane' tablets 
ZOPiclone 
Each tablet contains 7-5 mg 
ZoPidone 
28 tablets 
ý-- 
0 
Figure 4.16: Experimental package for the drug category 
sleeping drugs (Source- Clark, 2002) 
30 EFROR Xl 150MG CAPSULES 
(VENLAFAXINE) 
Each capsuk- contains is" ol 
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Figure 4.17: Experimental package 
for the drug 
category antidepressants 
11" 
Lane, R Chapter 4: Design Solutions 
4.4.3 Procedure 
Participants were asked if they were prepared to take part in the study and were 
given a brief explanation of what the task involved. They were told that they 
would be required to look at slides of drug packaging presented on a computer 
screen and would be required to state the drug name and the drug strength. As the 
participants also possessed no specialist knowledge of drugs they some time 
studying two printed sheets on which were printed the drug names they would be 
required to state. The participants were also given written instructions (appendix 
E) and were afforded the opportunity to ask questions before commencing the 
task. 
Microsoft PowerPoint presentations of five slides was prepared for each type of 
the package (old vs new) with one slide presented on each page. There were four 
conditions in which the time delay between the slides was varied. The intervals 
were one second, three seconds, 7 seconds, 10 seconds, giving a2 (new vs old 
packages) x4 (presentation interval) within subjects design. To counteract the 
effects of practice, the order of the slides within each slide show was randomised 
for all participants, as was presentation of the timed conditions as well as the label 
type. Participants were required to state both the generic drug name and the drug 
strength. It was expected that higher scores would be recorded for both drug 
naming and drug strength naming with the new packages in all conditions. It was 
also expected that scores would be higher during the longer intervals as 
participants would have longer to look at the packages. 
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4.4.4 Results 
Participants were required state the drug name and the drug strength. Scores were 
recorded by measuring how many drug names and drug strengths participants 
were able to state in each condition and recorded separately. Thus for each 
presentation of slides shown during a timed interval the participants could score a 
possible maximum of 5 correct responses. The results are summarised in figure 
4.18 and figure 4.19. Tables of results are listed in appendix F. As expected, 
participants were able to pick out more information in the 7 second (T3) and the 
ten second (T4) conditions than in the one second (TI) and three second (T2) 
conditions. Participants were able to state more drugs names from the new 
packages than the old packages in all but the shortest time interval (figure 4.18). 
In the shorter time intervals (TI and T2) participants performed better with the 
old labels. A Wilcoxon signed ranks test was carried out on the data (Greene and 
D'Olivera, 1993) but none of the results reached a level of significance. 
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Figure 4.18: Results for drug naming - comparison between existing 
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(old) and new (concept) packaging 
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Figure 4.19: Results for drug strength naming- comparison between 
existing (old) and new (concept) packaging. 
4.4.5 Discussion 
One of the reasons for the lack of significant differences between the existing and 
concept packaging was the orientation of the text within the colour panel. It 
would have been better to have positioned it horizontally rather than vertically. 
For comparison purposes this represented a confounding factor. In real world 
terms the vertical positioning of the drug names is not problematic as many boxes 
are turned on their sides for ease of storage. The vertical orientation should not 
present difficulty as the pack would be rotated when picked in order to check the 
patient information. In the present experiment the vertical orientation of the 
concept packaging slowed recognition of drug strength naming. 
It is also possible that the mixed colours of the panel served to distract 
respondents, a finding reported by Wogalter et al (1999). The white space around 
the text could have been manipulated as part of the experimental procedure. 
115 
Lane, R Chapter 4: Design Solutions 
However this would have been likely to produce no more than a minimal effect 
(Adams and Edworthy, 1995). 
It is likely that the distance between the brand name and the generic name was a 
major factor in the lack of significant results. In the case of the existing packages 
although the brand name is much larger than the generic name with the exception 
of venlafaxine, the generic name is printed close to it. Thus the brand name acts 
as the target attracting the viewer's attention to its position. This effect is 
enhanced by the colour print of the letters. Since the generic name is not separated 
by a great distance as in the case of the concept packaging it is easily picked out. 
In the case of the concept packaging the viewer has to search a greater distance in 
order to reject the incorrect drug name. The use of capitals may have made the 
text prominent but may also have slowed down reading times, thus the labels 
would have to be redesigned to address these shortcomings. 
Interestingly, in the case of the fenofibrate package (figure 4.14) subjects were 
unable to pick out the drug strength even though it featured prominently on the 
front of the pack in orange. Comments made were that the 200 seemed more like 
part of a brand concept than a source of useful information. This supposition 
becomes more apparent when consideration is given to the way that the drug 
strength is signified on the other packets in much smaller print. 
The lack of significance of times upon naming was due to the effect of practise. 
This is was most evident in cases where the longer time intervals were presented 
first followed by the shorter intervals, participants seemed to make a concerted 
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effort to give both the drug name and strength than when the shorter intervals 
were presented first. Although the slides were randomised within the 
presentations and the order of the slide shows varied, participants saw the same 10 
slides in each presentation. The rationale of the tests was to elicit a forced 
response. As the interval in the one second condition was so short that 
participants did not realistically have time to give their response, the most salient 
aspects of each label type should have stood out. Those participants who were 
presented with this condition as their first task showed signs of being flustered. 
However this was not the case for all respondents. One participant memorised the 
words and gave his responses completely retrospective to the presentation. The 
practice effect could be overcome by increasing the number of drug categories 
represented. Alternatively using a between-subjects design may have yielded 
significant results. 
Another way to improve the design of the experiment would have been to display 
the slides for the relevant period of time and record response latencies - the time 
taken for participants to respond before showing the next slide. 
. -4 0- ew- IN- ý4 
Figure 4.20: Drug category icons 
One of the difficulties with this exercise was the lack of recognition of the icons 
on the new package. Not one of the participants was able to state a drug category 
for all five of the images. Those who did recognise the shield were at a loss as to 
117 
Lane, R Chapter 4: Design Solutions 
what it might represent in tenns of drug categories (figure 4.20d). The 
anticoagulant icon (figure 4.20b) was also not associated with anything either 
within the context of drug categories or elsewhere, however one participant did 
think it resembled a company logo. The icons for the anxiolytic (figure 4.20e) 
and the diuretic (figure 4.20a) had to be rejected as they were originally designed 
to be used elsewhere. 
The icons were included to provide a level of redundant coding in accompaniment 
to the text as recommended by Wickens (1992); the different formats intended to 
emphasise different properties of the information. In this case highlighting the 
drug category whilst the text accentuates the drug name. If icons were to be 
featured on the new packaging, they would need to be redesigned and this is 
discussed further in Chapter 5. 
4.5 THE THREE DIMENSIONAL DESIGNS 
4.5.1 A description of the 3D design 
Medications are frequently supplied in bottles therefore the designer adapted the 
concept so that it could be applied in a more three-dimensional format. The 
information on the concept label was rearranged so that it would fit onto a 'collar' 
that could be placed around the neck of the bottle allowing infon-nation to be read 
from a 'bird's eye view' as well as in the standard way when the bottle was 
picked up (figure 4.21). The icons were translated into three-dimensional tactile 
features so as to become an additional source of information. 
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Figure 4.22: Prospective designs for integrated tactile features 
Adding tactile cues to aid identification were considered useful as suggested by 
Sanders and McCormick (1993) and illustrated in figure 4.23. In industrial 
settings the tactile sensations act as an addition source of information. A similar 
principle could be added to bottles for medication preparations as a means to 
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distinguish different types of medication (Cohen, 1996, p3.7). The textures would 
not be replacements for conventional means of identifying drugs but would serve 
as purposely redundant features used in addition to the label. 
The swirl depicted on the bottle shown in figures 4.22 is intended to be a three- 
dimensional representation of the diuretic icon (Figure 4.20a) and to evoke an 
association with water (diuretics are used to regulate fluids). 
Class A Class B Clam C 
Multiple rotation Fractional rotation Detent positioning 
IIIIII 
0C)o 
0 ýD (D ( 
ED 
Figure 4.23: Examples of knob designs for three classes of use that are seldom 
confused by touch. 
The original intention was to manufacture a bottle that would incorporate the 
tactile feature on the main part of the bottle. A more elegant solution was to 
design a collar incorporating the haptic feature that would fit over the neck of a 
standard medicine bottle. In this way manufacturing costs could be kept down. 
However some manufacturers supply the medication in small polypropylene 
bottles which could be modified to incorporate the elements of the concept 
design. 
Three of the designs were produced as engineering drawings in the CAD package 
ProEgineer (ProE) (appendix B). One of the challenges with the tactile features 
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was how to model the elements of the less concrete images (figure 4.20 a and b) 
with (ProE). The wavy lines of the diuretic image (figure 4.20 a) had been used 
to signify both hair and water. For the three dimensional representation this was 
simplified to three vertical wavy lines denoting water. The thrombolytic icon did 
not have any features that would afford a meaningful three dimensional 
representation. Models of the collars were made in ABS using a Stratasys fusion 
deposition modelling rapid prototyper (model FDM3000) and are shown in figure 
4.24. 
Figure 4.24: Prototype of the medication collar incorporating tactile features 
4.5.2 Testing the 3D design 
4.5.2.1 The training session 
It was assumed that participants would be able use the tactile features to associate 
the drug categories with their shape. However, participants would need a brief 
period of training in order to associate the shape with the drug. This was carried 
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with a group of 25 Further Education students ranging in age from 16 years, 
however no demographic data were collected. The students were informed of the 
purpose of the task, that it was a short memory test involving tactile features on 
medicine bottles. The bottles were shown to the students as part of a psychology 
class and the shapes were described using a drug name as an example. It was 
stressed that it was not the drug names that were important but rather the 
association they made with the shape and the drug group it denoted. The students 
were able to look at the bottles and pass them around and ask questions for 
clarification. It was explained to them that they were required to make an 
association between the shape and the category of the drug. It was pointed out 
that the drug name had been included as an example and that on the following day 
they would be required to make a selection of the bottles without looking at them. 
4.5.2.2 A test of the blindingly obvious 
The following day the students were required to perform a repeated measures 
blind touch test. Three bottles with collars were placed in a small cardboard box 
inside a black plastic dustbin liner. This procedure was repeated but with three 
standard medicine bottles without a collar. Participants were asked to put their 
hand in the first bag and select the drug category requested and to do this without 
looking. The bag was held so as to provide a small opening through which a hand 
could be inserted. They were required to repeat the process for the second bag. 
The order of the bags from which they made their selection was alternated, as 
were the drug categories to control for the effects of learning. A total of 12 
students took part in this selection test and were debriefed after the task.. 
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4.5.2.3 Results of the 3D test 
Without any tactile cues there was a probability of one in three that the 
participants would be able to select the correct bottle. All 12 participants 
correctly selected the collared bottles on demand. In the absence of the collars 
five bottles were correctly selected. A Wilcoxon signed ranks test was carried out 
on the data in table 4.1 and achieved a level of significance (W= 3.5, <p. 01 ) 
Subjects Collar Standard 
1 1 1 
2 1 0 
3 1 1 
4 1 1 
5 1 0 
6 1 1 
7 1 1 
8 1 0 
9 1 0 
10 1 0 
11 1 0 
12 1 0 
12 5 
Table 4.4: Results of the 3D touch test 
4.5.2.4 Discussion 
This test indicated conclusively that tactile coding enabled participants to make 
the correct drug selections. No errors were made during the selection which 
accords with the findings of Sanders and McCormick (1993). The test also 
demonstrated that the 3D features could be easily learned. Further testing could 
be carried out to establish how long people are able to retain the information and 
the number of symbols they are able to remember before they suffer decrements 
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in performance. Similarly the effects of stress whilst making selections may have 
an influence on how well individuals are able to perform. 
Since the participants were able to effectively use the tactile cues to help identify 
drug categories, when used in conjunction with the labels the tactile features are 
likely to increase noticeability of the drugs. Given the success of this trial, judged 
by the ease with which participants learned to recognise the meaning of the 
shapes, there is scope for further development of the principle to include other 
categories of drugs. 
The 2-dimensional images on which the tactile features were based were not so 
readily recognised. This may have been due to general lack of the participants' 
knowledge of drugs. The use of icons was intended to increase conspicuity of the 
packaging as outlined in the SHERPA table in chapter 2 and to provide an 
additional source of information (drug category) on the drug package. It was 
therefore decided to generate more icons in the hope that these would prove more 
meaningfid imagery. 
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CHAPTER 5 
lr-% 
-vesigning and testing icons 
5.1 GENERAL POINTS 
There was poor recognition of the original icons illustrated in chapter 3. It was 
hoped that using some of the principles outlined in chapter 4 would produce icons 
that were both noticeable and meaningful. It was, therefore, decided to generate 
further iconsfior testing using the model outlined by Zwaga and Easterby (1984) 
and illustrated in Figure 6.1. Within the context of public information symbols, tile 
first part of the procedure, the production test, should be undertaken by users of the 
facilities. These individuals might be limited by their drawing ability therefore in 
the present study the decision was made to use designers to create symbols as they 
would be able to produce high quality, representative drawings and were likely to 
be able to produce several designs in a short period of time. To be considered 
successful the drawings would have to be tested for appropriateness (how well they 
fitted the context) and recognisability/comprehension. In this study 
comprehension - the degree to which the respondent understands the meaning of 
the symbol - would be more important than recognisability (i. e. the respondent has 
perceived it before), since the symbols would be created for specifically for the 
novel purpose of assisting in the identification of identifying medication categories. 
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Figure. 5.1: ISO procedure for the development of public infonnation symbols 
Zwaga and Easterby (1984) 
5.2 THE DESIGN WORKSHOP 
5.2.1 Participants and procedure 
Postgraduate designers from the School of Engineering and Design at Brunel 
University were invited to a one-day workshop for which they were paid E5 and 
given lunch. Six people attended, having been told previously that the purpose of 
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the workshop was to design logos for drug packaging. Three of the attendees were 
postgraduate students with professional design experience and the other three 
where undergraduate design students. There were three main strands to the 
workshop. The first part involved the author providing an outline of the research to 
date in order to provide some context for the task that the designers were to 
undertake. The second strand was centred on producing drawings representing 
drug categories, whilst the third area of focus revolved around discussing the 
drawings and ranking them in order of appropriateness. 
The issues surrounding drug packaging design were expounded. The designers 
were shown examples of existing packaging highlighting factors such as branding, 
the use of colour, the lack of differentiation between some of the packages and the 
use of logos. Graphic images, where used, tended to be abstract as shown in figure 
5.2 in the case of the imodium package. They also tended to highlight the 
manufacturer's name or were used to reinforce the brand name of the drug. Whilst 
the packages demonstrated bold use of colour, this was not done in a systematic 
way as pointed out in Chapter 4. Figure 5.3 shows the packages of two different 
generic drugs distributed by the same company. The colours used are quite 
distinctive but vary only slightly. The strength of the drugs is displayed 
prominently and is highlighted in both instances by a colour panel. The 
odiuM'" 
Figure 5.2: An example illustrating the use of imagery on packaging 
127 
I'ant, 
. 
A, ( -holpict S' 1h, mg1ling and frWing wolm 
Allopurinol Tablets BP 
II ý11ý01.., 
28. 
ittps, 
Ferrous Sulphate Tablets BP 
IIý-11. 
W- ý-. &" ! QW00ins 00- 
Kew OW of 010 "PKk 0" eigm of Cwtd. 
(Whift 0.90, -Cooood) as ýde" wwy 
be OwkA, 
Is 
-. robws APS 
I-IgUle 5.3: Exaniples of drugs tioni dif Icicni , ocp, i ies 
in similar coloured packaging 
manufacturer's logo (the Iciters APS inctwWrating the snakc) also featurcs. 
Significantly, when looking at these packages. one of the designer% admitted that 
initially he could not see the difference between the (wo drup. I h% experiencc 
emphatically demonstrated the potential for a selection error. 11 was also pointed 
out that large amounts of the package space could be used to provide infOrmation 
Io assist the task of selection. In the case of ferrous sulphate the manufacturer has 
used the available space to add a warning to the front of the package. 
I'lie designers were shown examples of safety signage and icons from ISO 
7001: 1990 (the specification for public infonnation symbols) and 13S 8501: 2(X)2 
which contains extensive examples of public information signs. They were advised 
to try to make the lines of their icons as bold as possible. The designers were then 
instructed to look at the list of drug categories shown in appendix A. and to select 
three items from the list to represent. The aim of the workshop was to generate as 
many drawings as possible from the list of drug categories in al)pendix A. Using 
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the descriptions given for the categories the task was to generate icons that 
reflected aspects of the descriptive paragraph. 
The designers worked in two pairs and as a single individual. One designer was 
forccd to leave the workshop to fulfil competing commitments. The remaining 
designers produced drawings as part of a process of collaborative discussion. First 
reading through the descriptors of the three categories they had collected (three 
categories between two). They tried to distil the description into a representative 
word either by selecting a word or group of words from the paragraph on which to 
hinge their idea or by thinking of a word that encapsulated the main aspect of the 
description. 
The drug groupings selected were: 
Anticoagulants 
Analgegicý 
Anticonvulsants 
Sleeping drugs 
Expectorants 
Vitamins 
Muscle relaxants 
Immunosuppressives 
A key feature of the session was the inforniality with which the designers worked 
whilst discussing their ideas with each other and with the author. They were free to 
move about the room and refreshments were available throughout the session. 
After approximately two hours of drawing and discussion several icons were 
produced for anticoagulants, analgesics, sleeping drugs, and expectorants. Icons 
were also produced for muscle relaxants, vitamins and inimunosuppressives. 
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DUring the drawing phase of the session it was evident that the designers found the 
task of representing drug categories challenging. One of the main issues that arose 
out of the drawing session was how to represent an abstract idea in a drawing. 
However this has been achieved in the domain of public inf6n-nation, consumer 
products and safety warnings so there was no reason to doubt the success of the 
process in this case. One designer commented that the design forrns he had 
produced were 'wrong. ' Some referents such as expectorants and sedatives, 
generated as many as 13 icons. This might be taken as indication of how readily 
these categories lend thernselves to representation. But a more likely explanation is 
that the designers had well-developed cognitive schema for these types of drugs 
and were able to call upon these in producing the drawings. 
All the drawings that were considered acceptable were grouped into their 
respective drug'categories by cutting them from the sheets of paper on which they I 
had been drawn and sticking them onto the relevant sheet of flip chart paper which 
had been laid out on tables. Intriguingly, this activity revealed how the designers 
thinking had been directed towards aspects of the descriptors for the categories 
such that, sleeping drugs became 'sleep', expectorants became 'coughing', 
anticoagulants became 'clotting' and analgesics became 'painkillers'. 
5.2.2 Explaining the conceptual ideas behind the icons 
5.2.2.1 The process of choosing 
There are different definitions for the graphical representations pictograms, 
symbols, icons and icons but for ease of discussion in the present study thesc terms 
will be used interchangeably to mean the same thing. 
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There were two rounds of discussion durinor which the 5 designers and the author 0 
took part. The purpose of the first round of discussions was to give all five of the 
creator designers the opportunity to explain the reasoning behind their designs and 
to allow their colleagues to comment on the drawings whilst the author took notes 
and asked for clarification when necessary. 
The second set of discussions progressed with the three professional designers as 
the undergraduates were unable to devote any more time to the project at that time. 
It was during the second round of discussion that the final designs for the referents 
were chosen. For case of discussion the standardised versions of the drawings are 
shown in figure 5.4 and some of the rough drawings and the drawings put forward 
for assessment but later rejected are shown in appendix G. 
5.2.2.2 Anticoagulants 
Central to this group of symbols was the notion of blockage which was represented 
by a circle that was shaded in some cases. Icons 28 and 29 and to a lesser extent 
icons 25 and 31 introduce the idea of the vein as a blocked tube. The designers 
were aware that their symbols signified the opposite of the descriptive passage and 
admitted this was because the idea of 'blockage' was more easily conveyed than 
'blockage released'. For instance, the arrow in icon 31 was described as 'pointing 
at the problem'. Another reason for the difficulties experienced was that the 
referent had been simplified to clotting which put a different emphasis on the 
concept. Icon 27 was described as being: 'a stylised version of a i, essel ivith 
something open in the middle. ' The depiction of free-flow is shown in figure G. 3 
131 
Lane, R Chapter 5: Designing and lesting icons 
(A and B) in appendix G and in the sarne figure the idea of a blockage being 
broken (C and D) is illustrated but these icons were not submitted for 
consideration. It did occur to the designers that icon 26 (figure 5.5) was similar in 
appearance to the ISO symbol for meeting point (figure 5.6) and therefore was not 
included among the icons put forward for appropriateness testing. 
Expectorants 
1235 
Sedatives 
18 20 21 22 
Anti-Coagulants and thrombolytics 
25 27' 28 29 
Painkillers 
F7 7P ýk 
32 33 
Immunosuppressants 
40 41 
34 35 36 37 
Muscle relaxants 
(11 
42 43 
38 
Figure 5.4 Standardised workshop icons 
Wn 
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Figure 5.5: Anticoagulant icon 26 (rejected) 
71 1%, 
Figure 5.6: ISO symbol 7050 for the referent meeting point 
5.2.2.3 Sedatives 
The idea of sedation was symbolised by gentle undulations in icon 18 (figure 5.4), 
which was intended to invoke comparisons with calm water as a metaphor for a 
state of tranquillity and repose. The bottom part of this icon was thought of as 
conveying the idea of relaxation, as the icon designer remarked: 'Things at the 
bottom are more relaxed'. 
Icon 20 was based on the notion of hospital monitoring machines used to measure 
vital signs such as heart rate and blood pressure. Though it was commented upon 
that sleep is not normally measured like this. The peaks and troughs represented 
alertness which was interrupted by the introduction of the medicine (depicted as the 
drop) which induces sleep as indicated by the near flat line of the display. Icon 22 
also depicted movement from a state of alertness towards sedation. In this icon the 
key feature was the contrast between the high and the low point. 
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The moon was instantly recognizable in icon 21 (see also appendix G, figure G. 1) 
21 but was considered by the designers as potentially frivolous given tile serious 
nature of the task. They felt the icons had nursery colinoWions and a similar 
criticism was levelled at the rejected icons (shown in item 24 appendix G, figure 
G. 1). This was felt to be particularly the case for those images portraying clouds as 
seen tlu-ough a bedroom window. 
Icon 23, though considered frivolous, was not rejected. The icon commonly 
Zzz 
23 signifies sleep in cartoons and comic books and for that reason was deemed to be 
instantly recognisable. Nevertheless, doubts about its suitability were expressed in 
tenns of how well it would be accepted within the present context. Two of the 
designers were Korean nationals and pointed out that the moon is not an icon 
traditionally associated with sleep in Korea. However many Koreans have learned 
to recognise it and attach the correct connotation to the symbol through the 
influence of western media. 
5.2.2.4 Painkillers 
Although readily selected by one of the designers, this category was difficult to 
represent, with only four icons originally put forward into the general pool for 
consideration. It was difficult to convey the notion of relief Icon 32 was created 
to represent a non-descript 'bag' of discomfort on the verge of an explosion. The 
drops above it were intended to convey the action of the medication. 
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1con 33 was a representation of a blue spherical object with its outer red layer, 
signifying pain being stripped away. Red w C) I as chosen to convey the intensity of 
pain whilst blue represented the calmness of relieved pain. Interestingly, many 
existing analgesic packages incorporate a circle as part of their iconography. 
The jagged waves of pain were depicted in icon 34 with the shading emphasising 
the intensity and the crest of the waves indicating its rising and advancing nature. 
Icon 35 is based on the Chinese characteristic for the whole person. The element in 
IN 
the bottom left/top right orientation representing the drug breaking the pain which 
: 
ý3 
5 
is the dominant element and represented by the character underneath in the top 
left/bottom light orientation. This was depicted as being 'split. ' 
Discussions about how to represent pain dominated the second round of I 
discussions. This was because although the designers agreed that it was possible to 
signify pain in drawings, the situation became more complex when attempting to 
convey the relief of such an abstract entity. Part of the difficulty was attributed to 
the fact that we tend to think of pain as associated with parts of the body, that is 
headache, stomach ache, toothache, arthritis and so on. 
As there were only four icons for this category, it was felt that more icons would be 
better for appropriateness testing. Thus, in a short 10-minute brainston-ning session 
the remaining three designers were asked to quickly create more icons without too 
much regard for forrn or structure. One designer, intending to emphasise a 
soothing effect of the medication drew a pair of pictures; one depicting a clenched 
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fist with shards of pain escaping from it whilst the second picture showed a 
soothing open hand was drawn (appendix G, figure G5 (13)). The images were 
considered tenuous and were not put forward for assessment. Icons 36,37 and 38 
resulted from the doodles shown in (appendix G, figures GA and G. 5). Icon 37 
re esent d the drug as a bullet smashing through pain. This was considered 
ironic by the designers as bullets predominantly have the opposite effect. The 37 
jagged edges of icon 38 are illustrated as being broken by the action of the drug. 
5.2.2.5 Expectorants 
This category of drugs stimulates the flow of saliva thereby promoting coughing, 
however the coughing is essentially a secondary action produced by the drug and it 
was this that emerged as the main feature of the icons produced. Figure G. 3 in 
appendix G shows the evolution of icons I and 3 which depict a cross-sectional 
view of the upper respiratory tract with an explosion of air outside the mouth. In 
the early drawings the profile of a nose helps the viewer identify the icon as a 
human head in cross section. With these drawings as a basis it is easy to recognise 
stylised versions of these concepts in the icons. The other icons are representations 
of expulsion of air from the mouth, again in cross section. In discussing these 
icons, the designers expressed the difficulty they experienced when attempting to 
depict air. They pointed out that the elements depicting the expulsion of air could 
equally be representations of sound. But since the production of sound is 
commonly represented by air movement, this might not be entirely unacceptable, as 
coughing is accompanied by sound. 
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5.2.2.6 Muscle relaxants 
The muscle relaxant (icons 42 and 43) were considered ambiguous in that the 
(ýt 
42 imagery could represent a product that might be used to enhance physical strength 
or as a muscle builder. These depictions were drawn as pictograms and the 
4)3 
designer was unable to think of a way to simplify the drawings. They were 
submitted to the final set of icons to see if they would be recognised. Icon 42 
shows the muscle under strain whilst icon 43 indicates a relaxed muscle. 
5.2.2.7 Immunosuppressants 
Icon 40 depicts an object seen in cross-section that is vulnerable on its right side 
+40 
and under attack from an external source. The left side has a protective 
Icovering 
41 
that acts as a defence. The rough drawings for icon 41 are shown in appendix G, 
figure G. 6 and are based in the notion of lowered protection (represented by 
removing the armour). Icon IS2 was not selected for testing as it was felt to be too 
tenuous. 
IS3 
5.2.2.8 Vitamins 
k The symbol for vitamin (figure 5.7) was very similar to icon 35. Again it was 
35 based on Chinese symbolism. In Eastern tradition Man 
is believed to be 
inextricably tied to vitamins which are held to be his life-force and it is this belief 
that is represented in this symbol. The larger element on the left represents Man 
and the smaller element on the right is the vitamin. This drug category was 
perhaps the most difficult to represent and the designer who selected this referent 
was unable to produce further icons for vitamins. Interestingly, a logo was found 
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on the packaging of Boots effervescent vitamin C that incorporates the notion of 
protection depicted in the immunosuppressant icons discussed in paragraph 5.2.2.7. 
This is conveyed by the faint outline surrounding the representation of the human 
form (figure 5.8). Vitamin C is recommended as an aid to boost the immune 
system and is commonly held to act as a defence against colds and flu 
N 
Figure 5.7: Chinese symbol for vitamin 
Figure 5.8: Logo used on existing vitamin package 
5.2.2.9 The Anticonvulsant icon 
Another professional designer who was interested in the project and prepared to 
help with the designs but had been unable to attend the workshop looked at the 
designs and commented on the anticonvulsant icon. This was left as the onginal 
pictogram as there were no alternative designs for this category. The designer, D5, 
observed that although the picture told a story and did indicate the condition the 
drug would be used for, a symbolic representation would be more recognisable but 
would not give as much information about the drug grouping as the pictogram. 
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When asked what the pictograrn in figure 5.9 might represent D5 remarked: 'it I 
looked like someone having a fit' and Correctly identified the dru category as I! > 9 
anticonvulsant, as the original designer had intended. 
.7. Li 
1,1 1/ 
( -3Tii, 
11/ 
c 
-- 
Figure 5.9: Anticonvulsant icon 
5.2.3 The designers' assessments 
Both pictograms and symbols were present in the drawings - as the designers 
pointed out there. should be some consensus resolution. In order to resolve this 
conflict there needed to be a decision to use either pictograms or symbols and to 
adopt a single style so that the icons looked similar. Another pointed out that if 
people were to use the icons to cluster together pieces of information then in terms 
of cognitive processing their task would be made easier by the use of symbols as 
these tend to be simpler and therefore are more readily recalled. Similarly, 
designer D5 said that whilst a pictogram could convey more information than icons 
or symbols it would be easier for people to remember symbols. 
What did become apparent among the professional designers was that they 
attempted to invent some kind of 'vocabulary' to express aspects of the drug 
categories and whilst this might have been more readily achieved in other domains 
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it was hampered in this context by their general lack of knowledge of drugs. The 
discussion frequently, though not unexpectedly, centred on their own experiences 
of over the counter (OTC) preparations. There was an impression that the symbols 
should have some kind of extrinsic meaning in the same way that the logos of 
international consumer brands evolved significance beyond their visual appearance. 
The example was given of the Nike 'swoosh' which was said to have becorne 
associated with perceptions of high quality and technical expertise. '... These 
things are brought to mind by the appearance if the brand symbol, ' (D3). It was 
felt that a similar process should prevail in the case of medication icons. 
Lin (1992) suggested that there are six important items and three cognitive factors 
of importance in the design and comprehensibility of icons. The important items 
are that the designs should be: associable, symbolic, meaningful, concise, eye- 
catching and identifiable. The cognitive factors are related to these and the first 
one, communicativeness comprises identifiable and meaning , 
ful. The second - 
design quality relates to concise and eye-catching and the third - icon function is 
linked to associable and symbolic. 
After some time spent discussing the features of the designs and how best to 
represent the drug categories the designers were asked to rank the icons for 
appropriateness (to select the icon that they think best represented that drug 
category in terms of conveying information). One of the undergraduates from the 
first workshop session returned to do this and a professional designer (D5) who did 
not take part in the workshop agreed to assess the drawings. The results are shown 
in figures 5.10 - 5.13 and appendix 1. 
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Figure 5.10: Designers' rank totals for anticoagulant icons 
The lowest total represents the preferred icon. 
Figure 5.11: Designers' rank totals for painkiller icons 
Figure 5.12: Designers' rank totals for sedative icons 
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Figure 5.13: Designers' rank totals for expectorant icons 
5.3 APPROPRIATENESS TESTING 
5.3.1 Former Approaches 
The next stage was to see how well the icons represented the referents and to test if 
people would be able to understand the meaning of the symbols. Many studies 
have used paper and pencil methods to evaluate symbols, as these are generally 
inexpensive and easy to administer. Dewar and Ells (1974) employed a series of 
studies to investigate the suitability of symbols. Their first procedure designed to 
test the comprehension of 70 symbolic traffic signs entailed using open-ended 
responses. Subjects were required to indicate the meaning of each symbol 
projected as coloured slides on a screen. A second technique involved a matching 
procedure in which subjects were required to indicate which of the three symbols 
represented a specific message. The third approach required subjects to choose the 
correct interpretation from a set of four meanings for a specific symbol. The 
results of these tests indicated general agreement across the three methods of 
measunng comprehension of symbols. 
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Symbols have also been evaluated by rating procedures, in which participants were 
asked to make a selection of which symbolic version of a message they think most 
adequately conveys that message. During this process participants may be required 
to select the symbol they like best, or they may be asked to rank the target symbols 
in order of preference. Yet another method might be to ask participants to rate the 
'clarity of meaning' of symbols, to indicate how well symbols convey their 
intended meanings. 
Easterby and Zwaga (1976) in an evaluation of public information symbols, used a 
rank ordering technique to select three versions of each of several messages for 
further testing by the recognition/cornprehension and matching procedures. The 
preferred symbols were then tested for comprehensibility with a new set of 
participants. The symbol was deemed acceptable if it was identified correctly by 
50% or more of the participants (ISO, 9186: 2001). 
1 
5.3.2. Methodology 
A total of sixty participants were selected at random fTom among the undergraduate 
and postgraduate students and staff at Brunel University. Several staff members at 
Farnborough College of Technology also took part and were given the assessment 
sheet shown in appendix H. 
Participants were asked for their verbal consent and the purpose of the task was 
explained to each participant individually; namely, that it formed an assessment of 
part of a PhD thesis regarding assessment of a set of icons that might be suitable 
for use on drug packaging and that their task was to rank the icons in order of how 
well they thought the pictures fitted the given description of types of medication. 
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Most of the assessment sheets were completed in the presence of the author and 
participants were given clarification of the task if this was requested. However 
there were several instances in which participants were unable to complete the 
sheet at that time and these individuals were directed to return the form using the 
internal post. Only one assessment sheet was returned by this method and one by 
email. 
5.3.3 Results 
Of the 60 forms given out 50 were returned and two were discarded because one 
had been partially completed and the other contained tied ranks. The demographic 
analysis of the remaining 48 participants revealed a mean age of 26.76 years with a 
standard deviation of 10.05 The minimum age was 18 years and the maximum was 
52 years. Although randon-fly selected, 31 males and 17 females took part. 
The results are surnmarised in figures 5.14 - 5.17. The lowest total represents the 
more favourably ranked icons, thus if all participants ranked an icon in first place it 
would obtain a maximum total of 48. 
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Figure 5,14: Appropriateness ranking of anticoagulant icons 
by the experimental group (n=48) 
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Figure 5.15: Appropriateness ranking of sedative icons by 
the experimental group (n=48) 
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Figure 5.16: Appropriateness ranking of expectorant icons by 
the experimental group (n=48) 
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Figure 5.17: Appropriateness ranking of painkiller icons by 
the experimental group (n=48) 
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the experimental group (n=48) 
87.5%(42) 
40 
41 1111 12.5%(6) 
Figure 5.18 Preference for immuno- 
suppressant icons 
75%(36) 
42 
43 25% (12) 
Figure 5.19 Preference for muscle 
relaxant icons 
Appendix I shows the ranks assigned by each participant to the icons listed by 
category. The degree of agreement between the participant rankings reflects itself 
in the variation of the rank sums. In the case of maximum disagreement the rank 
sums will be equal or thereabouts. It is this circumstance that provides the basis for 
the definition of a coefficient of concordance. Kendall's Coefficient of con- 
cordance (W) was carried out to determine the variance within each of the 
categories expectorants, painkillers, anticoagulants, and sedatives. The 
concordance among the sets of ranks may be described by calculating Spearman's 
rank-order coefficient (Ferguson and Takane, 1989). Both sets of results are given 
in table 5.1. 
Referent w ;5 
Anticoagulants 0.134 0.118 
Expectorants 0.456 0.454 
Painkillers 0.241 0.230 
Sedatives 0.630 0.635 
Table 5.1: Kendall's Coefficient of concordance (W) converted to 
Spearman's Rho (15) 
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A chi square test was carried out to test the value of W using the formula: 
X2 
= N(k- 1)W 
Sedatives: X2 = 48(5-1)0.63 = 120.96 
Expectorants: X2 = 48(7-1)0.456 = 131.28 
Painkillers: X2 = 48(7-1)0.63 = 69.4 
Anticoagulants: X2 = 48(6-1)0.134 = 32.16 
The values obtained were significant for sedatives df47, P< 0.001, expectorants df47, 
p< 0.001 and painkillers df47, p< 0.005 indicating that there was significant 
agreement among the participants with regard to these icons but not for painkillers. 
Kendall's Coefficient of concordance was carried out on the data as recommended 
by Ferguson and Takane (1989). A Friedman test would have been equally 
applicable to this type of data. The test looks for variance in the ranked column 
totals, an indication of bias towards one particular design. This was observed for 
sedatives : W= 0.63 but less so for expectorants: W= 0.46, painkillers: W= 0.24 
and sedatives: W= 0.13. If all the participants were in perfect agreement on the 
degree to which the icons represented the category they would rank the icons in the 
same order and the value of W would be 1. Inability to agree that any of the icons 
were appropriate indicators of their category would yield aW value of zero. The 
values obtained indicate that there was a good level of agreement for sedatives and 
that the designs ranked lowest (those ranked in first or second place) were 
considered the most appropriate. There was less agreement of the placing of the 
icons in the other groups, an indication that the participants' choices were not 
directed towards any particular design. 
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Figure 5.21: Comparison of median values for expectorant icons 
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Figure 5.22: Comparison of median values for sedative icons 
Zero values recorded because icons 15 and 17 were not submitted for 
assessment ranking 
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Figure 5.23: Comparison of median values for painkiller icons 
+40 
The results for immunosuppressants and muscle relaxants were analysed as 
04 percentages asere were only two designs for each category. Over 87% of 
participants considered icon 40 better than icon 41 and 75% preferred icon 42 over 
icon 43. 
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5.3.4 Discussion 
There was significant agreement between the judges for the categories for 
sedatives, expectorants and anticoagulants. Comments made by participants during 
the appropriateness ranking task were that within the categories one or two 
symbols stood out as being significantly better than the others. They then struggled 
to order the others among the lower ranks as the icons were considered to have 
equally indefinable characteristics. This was that there was low discriminability 
between the lower ranking symbols or low levels of associability. 
Zýý 
Icon 23 was the preferred icon among the sedative category and achieved a high 
ý7)32 
OF, 
number of first place rankings. Icon 21 was ranked second by 75% of the 
participants a clear indication that these were considered most representative of the 
5 category. There were only two icons to choose from in the immunosuppressant 
and muscle relaxant categories. Among immunosuppressants participants preferred 
2 
[+40 
the symbolic representation over the pictograrn. The muscle relaxant images are 
similar but preference was shown for the image showing the distressed muscle. 
There were differences in the preferred icons of the designers and the larger test 
group (table 5.2). Icon 2 (expectorants) achieved a mean rank of I among the 
ýj I 
21 designers who had created the images but only 3.15 among the larger participant 
ZZZ 
_ 
231 group. Whilst icon 21 (sleeping) achieved a mean rank of 1.8 whereas icon 23 was 
preferred in the appropriateness test (mean rank 1.25). 
The asterisks in table 5.2 indicate the icons that were not standardised for the 
appropriateness ranking test, as they were considered too similar to others within 
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the set. For instance icons 15 and 17 (appendix G) were similar to icons 21 and 20 
26 respectively (figure 5.4). Icon 26 (figure 5.5) was rejected as unsuitable to the 
general context for the reasons highlighted previously in section 5.2.2.2. 
5.4 THE COMPREHENSION TEST 
5.4.1 Icon selection 
There was a wide variation among the designers and the large participant group 
regarding the appropriateness of the icons. Therefore it was decided to select the 
Wr 
two items from each of the categories expectorants, anticoagulants, painkillers and 
5 sedatives for comprehension testing; that is, the two icons from each category with 
the highest number of first and second-place rankings appendix 1. Among the 
2 
[+40 
expectorants icons 8 and 5 each recorded the lowest median ranks of 2. However 
due to their similarity it was decided to substitute icon 2. Icon 8 received a higher 
number of second place rankings (41.7%) than icon 5 (27.3%) and was thus 
retained. Icon 5 was rejected in favour of icon 2 (median rank 3). A single icon 
was included for each of the referents immunosuppressants and muscle relaxants 
(icons 40 and 42 respectively). 
The assessment sheet used for the comprehension test is shown in appendix J. The 
majority of subjects who carried out the appropriateness test were design students 
most if not all of who had no medical training or specialist knowledge of 
medications. As the icons were primarily intended to assist nurses it was decided 
to enlist nurses to carry out the comprehension test. Fourteen test sheets were left 
at general practitioner surgeries in the Fleet area of the Blackwater Valley and Hart 
Primary Care Trust. These were left for the practice nurses and were accompanied 
by letters outlining the purpose of the research (appendix J). A further 36 test 
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sheets were left in the training room of the Great Western Hospital, Swindon for 
nurses to complete. All the sheets were accompanied by stamped addressed 
envelopes to facilitate prompt return. 
5.4.2 Results 
A total of thirty three assessment sheets were returned from a total of 50 sent out, 
giving a response rate of 66%. Participants were asked to indicate the number of 
years they had been practising and of the 19 who responded to this question, 6 had 
been practising for more than 20 years. The mean was 12.66 years (median 10 
years, st dev 7.38). 
The table for the comprehension test results can be seen in appendix J and is 
2'1 presented 
in summary form in figure 5.24. Icons correctly identified were marked 
Zzz with 'I' whilst errors and missing responses were signified by dashes. Icons 21 
23 
and 23 (sedatives) were the most universally understood, scoring correct responses 1+40 
of 88% and 100% respectively and were the only symbols to reach the minimum 
50% recognition/comprehension rate recommended by BS ISO 9186. Icon 40 
(immunosuppressants) achieved a comprehension level of 48% and icon 42 
(muscle relaxants) reached 45%. The least understood were the symbols for 
anticoagulants, icons 25 and 27 which as many as 60% of respondents left blank 
(figure 5.25). Similarly the painkiller icons generated a comparable level of blank 
responses. 
A Cochran Q test (Cohen and Holliday, 1996) was carried out to test whether the 
frequency of responses differed at a significant level. The value of chi square df 9, 
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21 
I+T 
40 
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42 
27 
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2 
36 
Zzz 
23 
74.56 <0.001 demonstrated that icons 21 and 23 (sleep) were better understood 
than the other icons. 
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Figure 5.25: Comprehension test - comparison of responses (n=33) 
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5.4.3 Discussion 
There was significant agreement between the judges for the categories for 
F I, 
WOD 
8 sedatives, expectorants and anticoagulants. Comments made by participants during 
21 the appropriateness ranking task were that within the categories one or two 
40 symbols stood out as 
being significantly better than the others. 
FiLl 31 
The sleep icons 21 and 23 were readily recognised despite initial concerns among 
42 
the original designers that these representations might be considered too frivolous 
27 
within the context of medication labelling. Icon 42 for muscle relaxants was often 
2 
mistaken for a painkiller (12 occasions) whilst icon 27 was erroneously assigned to 
36 
the muscle relaxant category in 15 instances. The possible reasons for these errors 
23 
37 
are discussed below. 
The relatively high proportion of blank spaces on the assessment sheets indicated 
that participants felt the symbols were inappropriate to the descriptive headings 
given. Talking about the icon designs with one of the practice nurses revealed that 
they did not convey any meaningful information and consequently many of the 
symbols were not assigned to a category. This nurse offered ideas about how two 
of the icons could be redesigned. 
The following remark was made by a 60 year-old full-time dermatological nurse: ' 
'I am afraid these icons totally foxed me! ' The comments received from other 
participants were in the same vein: 
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S13: 'I don't think any of these symbols are any good, except I (icon 23) and 7 
(icon 2 1) - all very difficult to understand. ' 
S26: 'Sorry couldn't make out some of the icons. ' 
S 12: 'Ifind them very confusing. ' 
One of the reasons for the low comprehension rate for painkillers is that the 
MW 
8 symbols were created in a post hoc manner largely to balance the number of 
21 referent icons. Therefore it was surprising that in the appropriateness ranking test 
icon 36 received a median rank of 3 and icon 37 a median rank of 2. As 40 
31 individuals most of us struggle to find words to describe the nuances of pain, 
42 therefore 
it is almost impossible to convey to others levels of pain relief. Without a 
27 
highly defined semantic representation it is difficult to depict such a highly 
subjective entity. As referred to above, pain is often related to aspects of the body 
2 
F7 
1LI which may explain why icon 42 with its clear depiction of a body part caused 
-1-] 
36 
H- 
23 
people to think of pain and its associated relief. The anticoagulant symbol (27) has 
F; ý the appearance of a muscle fibre, hence the attribution of this symbol to the 
category muscle relaxants. 
The form in which the comprehension test was administered makes the assumption 
that the drug category headings used had the same meaning for each person. As 
the participants were trained in the knowledge of drugs, it might have appeared 
patronizing to supply a descriptive phrase for each category, as was the case in the 
appropriateness ranking. However standardized descriptions for symbols have 
been advocated by ISO 7001 and may have helped participants in this test to think 
155 
Lane, R Chapter 5: Designing and testing icons 
of aspects of the drugs the symbols might be attempting to represent. This lack of a 
formal description may have influenced responses. 
There seemed to be differences in the way the nurses thought about drug 
categories. Most lay people are familiar with OTC preparations such as cough and 
cold remedies, painkillers and prescription drugs for relatively minor ailments such 
as antibiotics and all of which tend to be self-administered. This causes them to 
think of drugs differently to professionals. Nurses, on the other hand need to be 
aware of both a drug's therapeutic effect as well as contraindications both in terms 
of the patient's immediate condition and in the event of underlying physical states. 
Many patients take several drugs and this would have a huge impact on how they 
are construed by nurses. Consequentially nurses may not cluster drugs together in 
such neat discrete categories. 
L 
for anticoagulants 
Figure 5.26: Alternative design 
for expectorants 
Figure 5.28: Icon 2 
tested for comprehension 
Nlow- 
Figure 5.30: Altemative dcsign 
Figure 5.27: Rough design 
for expectorants 
Figure 5.29: Rejected design for 
anticoagulants 
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Altemative symbols for two categories (expectorants and anticoagulants) were 
drawn by a nurse and are shown in figures 5.26 and 5.30. Intriguingly, the icon in 
Figure 5.26 is pictorial rather than symbolic but does possess similar elements to 
those of one of the rough designs for expectorants from the workshop that was not 
put forward for appropriateness ranking (figure 5.27). This symbol was simplified I 
giving rise to icon 2 (figure 5.28), a depiction of a mouth in the action of coughing 
and perhaps too concise a depiction to be recognised by the comprehensibility 
testers. As pointed out in section 5.3.4, this icon was highly rated by the designers. 
Figure 5.30 has similar elements to figure 5.29 (also shown in appendix G, figure 
G3). This rough drawing was not submitted for appropriateness ranking but shows 
arrows indicating blood flow in common with the alternative design of figure 5.30. 
Figure 5.30 differs in that the walls of the vein are emphasised and balanced 
against the notion of the impending blockage rather than dominated by it. 
Participants had been asked to indicate the number of years experience they had 
and in the cases where this was given it seemed to have little impact on ability to 
comprehend the icons. 
The comprehension test may more accurately be considered a matching test as the 
participants were required to match the symbols to the correct drug category. The 
test might have yielded a greater degree of recognition if participants were asked to 
consider only one example symbol of each category as in the case of muscle 
relaxants and immunosuppressants, which would have entailed using a greater 
number of participants. 
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5.4.4 Improvements 
There are several ways the design of this study could have been improved. A 
commercial designer would spend several months developing icons of this nature 
whereas those designed and tested in the present study were designed in a single 2- 
hour session. With more time it would have been possible to design more icons 
and to involve nurses in this process. 
Many of the participants in the appropriateness-ranking test were designers they 
could have been asked to draw symbols they considered appropriate for the drug 
categories. Similarly the participants in the comprehension test could have been 
asked to design representative symbols. This would have given some insight into 
how nurses conceptualise drugs and it might have proved a more effective strategy 
to have involved them at the earlier stages of design and appropriateness ranking. 
A paired comparison technique might have yielded significantly better results as 
candidates would have been forced to make a choice. However as many people felt 
the designs were inappropriate in the first instance it is doubtful whether this 
method would have been an improvement. 
A major factor for both assessors of appropriateness and comprehensibility was the 
lack of context. Had the icons appeared on the packaging of the relevant drugs, a 
greater degree of association may be been observed between the drug categories 
and the symbols. 
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Despite the advantages afforded by symbols there are still several problems 
associated with their design and use. Many are too small, have indistinct detail and 
are difficult to see clearly from a distance or they have small and unnecessary 
detail. Similarity between the icons and lack of syntactic and semantic rules such 
as those in verbal language often leads to confusion. Considering that symbols are 
often intended to be used to convey information to people regardless of their 
language, this is a major drawback (Dewar, 1999, p289). 
In the present study symbols were not to be used in the absence of text, however 
they would appear to do little to reinforce the identification of drug categories. 
This may be due in part to the fact that drug categories are highly abstract in nature 
and contain few discemable elements that are universally acknowledged. A 
parallel situation has existed for some time in computer applications and more 
recently in telecommunications messaging. Within these contexts icons are used to 
represent abstract infon-nation and in most cases individuals learn the meaning of 
these by associated action. The same success rate might reasonably be expected 
within the present context. The icons were added to the concept packages as 
recommended by the SHERPA analysis (chapter 2) to increase conspicuity in order 
to prevent errors associated with reading labels. However, further work needs to be 
done to explore the conceptions nurses have about drugs and drug categories in 
order to develop SUitable semantic ten-ns with which to assess the imagery and to 
test the effects of training on ability to learn the symbols. The SHERPA analysis 
also recommends the use of technology to resolve the issue of reading labels and 
this is the subject of the next chapter. 
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Chapter 6 
Applying technology to the problem 
6.1 BACKGROUND 
This chapter considers how technology has been used to address errors and 
describes the design and development of a novel technological device. 
Technological solutions such as bar coding were suggested by the SHERPA 
analysis in chapter 2 to mitigate the errors associated with: reading medication label 
or the medication chart, giving medications to the wrong patient and failing to 
check the patient's identity. The summary table (table 2.4) highlights that 
technological solutions address the greatest number of errors. RED tagging 
systems were suggested for locating charts in the SHERPA analysis however in 
practice these are more likely to be used as part of a larger automated process. 
Tagging systems have been used in various aspects of medication management 
most notably at the prescribing and dispensing stages. Computerized physician 
order entry (CPOE) systems have been used in Brigham and Women's hospital, 
Boston and have been cited by Bates et al (1999) as contributing to a reduction in 
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medication errors of over 80%. Similarly, Ragan et al (2005) and Potts (2004) have 
reported lower error rates after the introduction of computerised systems. 
6.2 BAR CODING SYSTEMS 
Barcoding has been used successfully for some time in retailing and in health care 
for labelling blood products. With a view to improving medication error rates in 
US hospitals the Food and Drug Administration (FDA) published a final rule 
entitled Bar Code Label Requirements for Human Drug Products and Biological 
Products (FDA, 2004). This rule obliges manufacturers to ensure that all 
prescription and certain non-prescription drugs are bar coded. The rule requires that 
manufacturers comply within two years. Although bar coding technology is not 
mandatory the Commission on Accreditation of Healthcare Organizations (JCAHO) 
has noted a decrease in medication administration errors that is attributed to its use 
(JCAHO, 2004). When used with a scanning system and computerised database the 
steps are as follows: 
1. The patient is admitted to hospital and is given a bar-coded 
identification bracelet that links with his or her computerized 
medical record. 
2. Prescription drugs and certain over-the-counter drugs would 
have a bar code on their labels. The drug is identifiable by it 
unique NDC number. 
3. The hospital's bar code scanners or readers linked to the 
hospital's computer system of electronic medical records enable 
identification of the required drug regime. 
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4. The patient's bar code is scanned before the drug is 
administered enabling the computer to access the patient's 
computerized medical record. 
5. The nurse worker then scans the drug(s) dispensed by the 
hospital phannacy for that patient. This scan informs the 
computer which drug is being administered. 
6. The computer looks for a match between the patient's medical 
record and the drugs being administered. If there is a problem, 
the computer sends an error message, and the nurse worker 
investigates the problem. 
The system is intended to ensure the requirements of drug 
administration are fulfilled: 
s The appropriate medicine 
* In the appropriate formulation 
* By the appropriate route 
e At the appropriate dose 
e At the appropriate time 
9 At the appropriate rate 
s For the appropriate duration of the therapy (Dougherty and 
Lister, 2004). 
In the United States, the Veterans Health Administration (VHA) has 
used a bar code medication administration (BCMA) system for some 
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time. Between 1993 and 1999 a 64.5% reduction in errors was 
observed (Johnson et al, 2002). Currently, over 150 VHA use BCMA 
systems. Sublett (2002) describes how a barcoding system operates in 
practice at 350-bed acute hospital in a 38-bed urology and nephrology 
ward where up to 450 medications are dispensed each day. 
6.3 RFID 
RFID point of administration systems are currently undergoing trials in the LTK 
although they have been used in the US for some time and work in a similar way to 
bar code systems. Fowlie et al (2000) describes how an electronic prescribing and 
administration (EPA) has been used effectively in a British hospital. The Swedish 
company Cypak has developed a form of intelligent packaging system that is able to 
monitor the patient's drug usage and can alert the user with an auditory signal when 
the next dosage is due. Each time a dose of the medication is pushed out of the 
packaging the event is recorded. Information from the packaging can be retrieved 
by placing the package on a scanner connected to a PC. 
6.4 IBUTTONS 
An iButton is a mobile memory silicon chip encased in a stainless steel covering 
that communicates by touch. The casing gives it the advantage of durability which 
means it can be mounted on almost any surface and is able to withstand harsh 
indoor or outdoor envirorunents such as high temperatures or high humidity. This 
is an important consideration for use in a hospital identity bracelet as in a health 
care environment these items can come into contact with various bodily fluids and 
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hospital chemicals or drugs and remain attached for bathing. The bracelet might be 
dropped, knocked, scratched or stepped on, therefore a robust design for the 
memory is of considerable importance. 
Figure 6.1: iButton 
The computer chip possesses a unique identity and depending on the type of button 
selected can be used in to various applications. Infonnation can be written to, read 
from it and stored in accordance to the size of memory. Ibuttons are low-cost, use 
low power and are able to operate as a mobile database, either as standalone devices 
or as part of a networked system. They have various capabilities such as a 
microprocessor, clock or environmental sensors and might typically be used as a 
key to control access, as a location identifier for route compliance or equipment 
identification for inspection tasks. 
NVRAM iButtons are read/write devices available in sizes from IK bits to 64K bits 
used in applications where the data need to be updated frequently and the memory 
is capable of being rewritten millions of times. Memory updates, once initiated, 
will always be completed because the power to finish the transfer is supplied by the 
integrated lithium cell, not the reader/writer therefore these devices are useful in 
conditions of intermittent power. 
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EEPROM iButtons are read/write devices available in sizes from 256 bits to 32K 
bytes but have a lower write cycle limit than NVRam iButtons. They are used for 
applications that need data updated on a less frequent basis than NVRAM type 
applications, but can be used for over 10 years. Given their characteristics iButtons 
are a good alternative to barcoding and RFID identification systems. 
lbuttons connect with other components through a 1-wire MicroLan which is an 
inexpensive, easy-to-install network standard with multi-drop capability. It uses a 
microcontrollers as a master, and can supply both data and power over low-cost 
twisted-pair cable. It has a multi-drop capability and an identify and read 1-wire 
devices permanently attached to structures along the bus, as well as roving devices 
such as ID tags or decoder rings. One-wire parts with memory capability allow data 
to be collected off a bus and transferred to the computer master by touching a port 
somewhere along the MicroLAN bus. Functionally, a port consists of little more 
than elegant exposed sections of the twisted pair constituting the bus that touches 
both the lid and case of the iButton or decoder ring. Wlien connected, the master 
can address and begin transferring data with the device in about 7 ms (Awtry, 
1997). 
6.5 BRILLIANT 
6.5.1 Outlining the technology 
This chapter now goes on the describe an intelligent hospital identity bracelet which 
was designed and assessed by Claire Dunne (2005) in consultation with the author 
who provided the literature sources and the background information relating to the 
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problems of medication administration errors that enabled the designer to devise a 
preliminary questionnaire that was circulated to nurses. The author advised on the 
physical dimensions of the device and the type of information that would need to be 
displayed. The testing methodology was also devised by the author, whilst the 
ensuing discussion and evaluation of the design by the author brings the chapter to 
its conclusion. 
The bracelet named Brilliant uses iButton technology to make a direct link between 
the patient and the drug packaging (figures 6.2 and 6.3). The patient's details such 
as name age, hospital number and medications are programmed into the bracelet. 
The drug package contains the iButton which is programmed with the drug name 
and dosage. When the drug bottle or box containing the selected drug is touched 
against the reader in the patient's identity bracelet the system checks the stored data 
looking for a match between the drug name and dose. If the drug selected by the 
nurse is the correct dosage and the drug name are shown on the screen, the date and 
time, of administration are recoded and stored to enable comparisons to be made 
when the drug is next scanned into the device. In this way the system prevents a 
possible overdose. The medication administration record is stored in the device and 
can be can be downloaded to a computer at the end of the patient's stay. 
The bracelet possesses two LCD screens to enable both the nurse and patient to 
observe and become involved in the medication administration process. In this way 
the patient becomes involved with the procedure. The double screens also enable 
the bracelet to be worn on either wrist. 
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100007 
Figure 6.3 Aesthetic model of 
'Brilliant' 
Computer 
Figure 6A The system diagram for'Brilliant' 
6.5.2 The Design 
The design of the system is shown in figure 6.4. The iButtons used in the system 
were identifiable by a unique factory assigned serial number which enabled them to 
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be used to represent medications. They were then read into the PIC so that each 
could be identified. A small circuit was created with the iButton reader connected 
to the PIC. The artwork for the printed circuit board can be seen in appendix L. 
The PIC was programmed to accept the serial number matching that which had 
previously been programmed. A Real Time Clock (RTC) was incorporated as a 
separate chip to record the patient's date of admission and the duration of stay in 
hospital. Its high level of accuracy made it suitable to record medication 
administration times. 
3 
Figure 6.5: The prototype 
The circuit board along with its peripheral components was mounted in an acrylic 
box in order to demonstrate and test the principle (figure 6.5). Using the device it 
was possible to the to select two drugs from a range. Perhaps most importantly, the 
system prevented additional doses of the same drug being given for an interval of 
one minute. This time interval, though small, was sufficient for demonstration and 
evaluation purposes. For real-world application it would be changed to a more 
appropriate time interval. The system was able to store logbook information such 
as date, time, drug name and dose. Data transfer was carried out though a USB port 
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and could be stored on a computer as a single-button operation and printed out at a 
later time as necessary for billing or audit purposes. The USB port also afforded 
the possibility to incorporate the device into other systems to the extent that with 
suitable modifications and further development, it could be used to display 
laboratory results from patients' tests. 
6.6 BRILLIANT EVALUATION 
6.6.1 Test 1 participants 
The tests carried out by the designer attempted to create in part some of the 
conditions that were likely to produce the errors identified by the SHERPA 
analysis. The initial tests with ten student participants from Brunel University 
using protocols outlined by the author of this project to deterniine how easy the 
device would be to use compared to other types of wristbands. The purpose of the 
test was to assess whether or not participants were able to use the device to retrieve 
the salient elements of patient infori-nation which is normally found on patient 
identification bracelets (items such as the patient's name, date of birth and hospital 
identification number. It was expected that a higher number of correct responses 
would be recorded for the Mutton device. 
6.6.2 Test I method 
A test was devised to assess the performance of Brilliant against 3 other types of 
wristband. These were write-on, insert and RFID. The participants were presented 
with the following information on the wristbands: 
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Wristband Name Date of Birth Hospital Number 
Write - on Ben Howard 16/09/1981 84579S6 
Insert Julie Redman 23/05/1973 037642S 
RFID Michael Cooke 01/01/1956 123-4S-6789 
ibutton Amy Wood 04/01/1942 7642984 
Table 6.1: Patient information given to participants 
The participants were asked the following 
9 what was the patient's first name? 
9 What was the patient's surname? 
"at date in the month was thepatient born? 
9 In what month was the patient born? 
o In what year was the patient born? 
What were the last the last two digits of the patient's hospital number? 
What were the last the last two digits of the patient's hospital number? 
The participants were given intervals of one, two, three and four seconds to look at 
each bracelet and the bracelet was shown four times for each of the intervals. They 
were then asked to provide a specified piece of information ftom the bracelet. The 
order of the questions and the presentation of the bracelets were randomised and the 
presentation of the intervals was reversed. 
6.6.3 Test I results 
Overall, the highest number of correct responses were recorded with the iButton 
bracelet (Brilliant) (figure 6.7). 
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Figure 6.6: Total number of correct responses for each wristband 
- maximum total score is 40 (n= 10) 
A Friedman test (Greene and D'Oliveira, 1993) was carried out on the total scores 
(figure 6.8). The observed value of Chi Square was 6.06 which did not quite reach 
the level of significance (p<. 1.0) given as 6.25. 
6.6.4 Test 1 discussion 
The participants recorded the highest number of coffect responses with the iButton 
bracelet however the differences observed were not significant. This may be due to 
the fact that the data contain zero scores which have the effect of lowering the rank 
sums (appendix M). The prototype compared favourably to write-on patient 
identification systems and the nurses were able read the standard items of patient 
information from it. One of the reasons that Brilliant performed better than the 
other wristbands is that standardised text such as printed or computer-generated text 
is generally much easier and quicker to read whereas hand written text is variable 
and difficult to read. 
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6.6.5 Further testing 
Tests were carried out with nurses in a ward situation in order to assess how well 
nurses interacted with the intelligent hospital identity bracelet in a ward setting. 
6 6.5.1 Test 2 method 
Eight nurse participants were given a written scenario as follows: 
The drug chart has been lost but You know that the patient is due 
another dose of an it-regular drug but do not know whether they have 
been given it already. Find out what irregular drug they are taking and 
if it is due what the dosage is to be given and what regular drug they are 
due and the dosage to be given. 
The nurses were given the iButton prototype, and six bottles labelled A-F each with 
iButtons attached to the top. Their task was to use the iButton device to ascertain 
which of the drugs the patient was taking and whether or not it was due. 
66.5.2 Test 2 Results 
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Figure 6.7: Time taken to determine which drug is due for administration 
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The nurses were able to use the Brilliant prototype to search for patient infon-nation 
and after a short period of familiarisation all were able to complete the required task. 
The results are shown in figure 6.7. 
6.65.3 Test 3 method 
Six nurse participants were given the following scenario: 
You have three drug charts but two are out of date 
and incorrect. Find out which is the correct drug 
chart. 
Three drug charts were provided and six bottles labelled A-F. The nurse was 
required to touch the iButton on the bottle against the reader on the prototype 
device in order to determine which medications the patient was taking and match 
these to the current chart. In this way the obsolete charts would be identified. 
200 
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E 60 
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0 
Figure 6.8: Time taken to determine which of three drug charts 
is current 
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The nurses were able to use the Brilliant prototype to identify the current drug chart 
and to reject the two that were not longer current. The results are shown in figure 
6.8. 
6.6.5.4 Combined test 2 and 3 discussion 
The nurses were able to use the prototype to ascertain whether or not a medication 
was due for administration and to check for those medications that were no longer 
required. However some of the nurses did not correctly identify the drugs that were 
no longer needed. For these individuals the difficulty arose fTom the fact they 
experienced difficulty distinguishing the various dosages written in the chart when 
making comparisons with Brilliant's programmed information. This difficulty is 
marked by the peak in figures 6.9. This problem palpably highlights the difficulties 
of reading medication charts in a working environment as outlined in chapter 2 
(p26). 
1 Check chart for 
mocilcaticm details 
Man 1: do 1.1 thety 1.2 
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Figure 6.9: Extract ftom the 
drug administration HTA 
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Test 2 presents a lost chart scenario which participants resolved in less than 2 
minutes by checking drugs against the iButton device. In a real-world situation a 
lost chart is likely to result in several drug doses being missed as nobody could be 
sure which drugs are due or if a colleague on a previous shift had given the patient 
the correct drugs. As illustrated in the extract from the drug administration HTA 
looking for the chart and organising a new one could take a few hours. In 
organising a new chart the drugs would have to be written up and signed by a 
doctor. The results from test 2 demonstrate how this process is reduced to a matter 
of minutes with the iButton device as the relevant information is in located within 
the patient's identification device. 
Test 3 demonstrates that the nurses were able to be confident in their rejection of 
obsolete charts. Although time to complete the task was recorded this is irrelevant. 
In the event that an original chart reappears after a new one has been written can 
result in confusion. This is particularly the case where different members of staff 
do not know that more than one chart is being used for the same patient and 
continue to administer medication from an old one. Dates and times of 
administration may not offer much clue as to which is the most recent chart as they 
may overlap. Depending on the complexity of the drug regime, it might be possible 
to determine which of three charts for the same patient is current in less than three 
minutes. In test 3 the slowest participant recorded a time of 175 seconds. However 
in order to be confidant that the rejected charts are indeed obsolete it is likely to 
take a nurse much longer than this. The certainty that the iButton device brings is 
worth the possible extra time spent engaged in this task. 
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6.7 OVERALL DISCUSSION 
Cullen et al. (2000) cite the most common type of error as wrong dose which 
occurred more than three times as often as wrong choice errors which was the next 
most frequently occurring error type. With use of the iButton device these errors 
are completely eliminated. Transcription errors have been reported by Dean et al 
(2002) and Taxis et al (1999). Since the patients drugs are programmed into the 
device upon entry to hospital the need to transcribe medications is eliminated. 
The strengths of the Brilliant design are that it can: 
9 reduce errors identified in the SHERPA analysis (summarised in table 6.2); 
e it be added to a more complex automated drug delivery system that 
incorporates COPE and robot unit dose dispensing from the pharmacy; 
be used as a programmable standalone device in cases of limited financial 
resources; 
be used in organisations where it would not be desirable or appropriate to 
use a fully automated system. 
There are very few standalone products that perform in this way. Most systems rely 
on a scanner and computer to read the patient's infon-nation from a bar coded label 
or RED tag. This iButton device dispenses with these expensive items of 
equipment by making a direct link between the patient and the drug thus reducing 
expenditure. 
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Once programmed the device is simple to use, tamper proof and the data stored in 
its memory can be easily downloaded to a computer for analysis, billing or chart 
review. It goes further than some systems - rather than displaying an alert that the 
nurse is about to give an overdose in the event that the medication is not due, it has 
the ability to prevent administration of the drug. However in its present state it 
would not prevent malicious use and it should be pointed out that there is potential 
for errors to occur at the programming stage. Administering drugs using a 
computer can be a time-consuming process as nurses spend excess amounts of time 
scrolling through display screens to find the relevant one (Sublett, 2002). In the 
case of the Mutton, as soon as the drug is presented to the reader the relevant 
information as to whether or not that drug is due is available. 
There were some issues that needed to be resolved before this device could be 
rolled out on a larger scale. The first concerns partial accumulation of the required 
information. If, for example, a nurse scanned a drug using the device and read the 
name but did not read the drug strength and looked away to check the patient's 
chart the device would revert to default mode - showing the patient's name and 
hospital number. When the nurse looked at the device again she would no longer 
see the drug name or dose displayed and would be unable to access that information 
as the device assumes the drug has been given. This might be construed as a fault 
in the system but is more a reflection of how nurses routinely perform the checking 
aspect of medication administration. In this example it is by a series of matching 
small pieces of information. A small adjustment to the device that enabled the drug 
details to be displayed for a longer interval would resolve this issue. Alternatively 
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the nurse could spend a slightly longer time studying the medication requirements 
of the patient prior to commencing the administration sequence. However in the 
real world it is more likely that in a system such as this the patient's information 
would also be linked to a computerised physician order entry system that would 
perform the check automatically. 
In its present form Brilliant does not prevent errors arising from missed doses. It 
could be programmed to signal when a dose has been missed. The Brilliant 
prototype demonstrated it has great potential for further development as a 
commercial product as it can be integrated into a large automated drug delivery 
system or used as a discrete arrangement to match the correct patient to the correct 
drugs. 
Table 6.3 (p178) indicates that using the ibutton device has the potential to reduce 
100% of medication administration errors. Using the example of errors arising 
from failure to read or of misreading the drug label (step 1.2.1), the ibutton device 
allows the nurse the opportunity to check the medication after initial selection by 
comparing it with the original patient chart. Presenting the drug to the patient offers 
the last opportunity for checking. Touching the drug to the reader in the bracelet 
enables the device to perform the necessary check and the nurse is simply required, 
at this final stage, to observe that the match has been made. If the wrong drug has 
been selected in error the nurse has the opportunity to recover. 
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Using the ibutton device to resolve failure to check the chart error (stage 3.1.2 in 
table 6.3) is likely to result in a 90% error reduction because without referring to the 
chart the nurse would have no way of ascertaining which medications were due, 
which were omitted and which had previously been administered as in its present 
form the device does not allow the nurse to register a digital 'signature' in the same 
way as she would on a chart. The feasibility of adding such a function is a good 
topic for future research. Further suggestions for research are discussed towards the 
end of the next chapter. 
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Chapter 7 
Conclusions 
7.1 SUMMARY 
This thesis began by establishing that there is an issue concerning medical errors in 
the health care system and that these cause problems for both staff and patients. 
The prevalence and in some cases the severity of these problems have serious 
implications for the delivery of safe and effective health care. Several large studies 
have indicated that these errors are not only a major cause of death in the UK but in 
many countries around the world and in cases were patients are not killed, errors 
may lead to temporary or permanent disability or to an extended length of stay in 
hospital. 
This Thesis contributes to knowledge by presenting a study of medication error at 
task level. Many studies have focussed on describing and categorising error types 
first and have considered causal factors such as the nature of nurses' tasks as a 
secondary issue. In presenting a task analysis of the hospital drug administration 
task this study is offering something that has not been done before. In 
systematically analysing medication errors using the SHERPA technique the study 
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applies a well- established human error identification technique to a novel domain. 
It then goes on to develop and test novel design products. 
The misapplication of medications accounts for a large number of errors and there 
is a high level of similarity among the types of reported medication errors across the 
world despite the use of different systems of medicines management and 
administration. These errors include giving medication to the wrong patient, giving 
an incorrect dose, giving an incorrect drug, administering a drug by the incorrect 
route or in the wrong form. In many cases doses are omitted altogether. 
Medication usage is complex and is dependent on the interaction of health 
professionals functioning within different disciplines. This means there are many 
opportunities for error during any one of the five major stages of prescription, 
documentation, dispensing, administration and monitoring. The responsibility for 
error is often placed on the nurse as she is often the last person in the drug 
administration chain. However there are many causes of medication errors and 
these often combine to cause the incident. Commonly reported reasons are 
workload, constant interruptions, shift patterns, communication failures, long 
working hours (Ferner, 1995; Fiesta, 1998, DoH, 2000). Factors associated with 
the individual include poor skill in calculating doses and compounding drugs. 
Reason' s (1990) model demonstrates how defence barriers can be penetrated by an 
accident. These might be a lack of computerised prescribing technology systems 
that have in-built alerts to highlight errors in prescribing, not following 
recommended practices, lack of communication between departments or when 
transferring from community care to hospital and vice versa. 
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Labelling and packaging are often poorly designed making it difficult for nurses to 
distinguish between different categories of drugs and routes of administration. The 
relevant information is often written in small lettering making it difficult to read. 
Similarity of drug names creates confusion and gives rise to selection errors which 
in turn have caused patient fatalities. 
Attempts have been made to address this problem by adding visual cues to the 
packaging in order to help selection. Such as adding conspicuous labels, using 
upper case lettering at various salient positions in the letter string of the drug name. 
Reporting systems have been set up in both this country and abroad in an effort to 
expose the underlying causes. One of the largest, the MedMarx system operated in 
collaboration with the US Phan-nacopeia (USP) and Institute For Safe Medication 
Practices (ISMP) has monitored medication errors since 1991. A national non- 
punitive reporting system has recently been set up in the UK by the National Patient 
Safety Agency (NPSA) in an effort to garner lessons from these errors. 
Failure mode and effects analysis (FMEA) has been applied to the problem of 
medication errors. It is a technique originally developed for use in the field of 
reliability engineering and is based on the assumption that errors will occur 
regardless of how knowledgeable or careful the individual is. A FMEA anticipates 
what errors can be made during medication usage and predicts what the results will 
be. The analyst then goes on to consider how best to prevent incorrect actions 
being completed or how to minimise their effects if they are completed. 
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Root cause analysis (RCA) is another method that has been applied to the problem. 
Using a single adverse incident a multidisciplinary team of practitioners use the 
technique to work backwards from the event though the sequence of actions and the 
events that led up to it. The strength of RCA is that it is a well-structured approach 
that focuses on processes and thus is a useful tool to address organisational and 
systems issues. Its major disadvantage is that it can be a labour intensive and time- 
consuming technique and whilst it can uncover the root causes of apparently 
separate incidents, these may result from hindsight bias. 
Technological solutions have been implemented in an effort to counteract the 
limitations of human performance that arise when dealing with complex tasks that 
rely on high memory resources and most of these systems have been used in the 
us. 
Many UK hospitals use a ward based pharmacy system however this is in a state of 
transition to a system that uses the patient's own drugs. In the ward system, a large 
proportion of the medications administered are held as ward stock. These drugs are 
the most fTequently used and are kept in a locked trolley along with non-stock 
items. Nurses make a drug administration round four to six times daily depending 
on the ward during which the trolley is taken to each patient's bed. The patient's 
own drug system enables the patient to continue using medication they would 
normally use at home whilst in hospital. This is kept in a locked cabinet at the 
bedside. 
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Physicians use the patient's chart to indicate to the nurse which medications the 
patient is to receive. This is kept with the patient and used to record drug 
administration. Each dose administered is recorded on the medication chart, which 
usually allows 14 days of documentation. This allows the patient's most recent 
drug history to be viewed. If a drug is ordered that is not held as ward stock or is 
not in the patient's bedside drug cabinet, the ward pharmacist makes a note on the 
medication chart and a supply sufficient for several days is dispensed from the 
hospital pharmacy with the patient's name on the container. Dean and Barber 
(2000) have demonstrated the occurrence of similar rates of error between the two 
systems. 
Many medication error studies have systematically analysed the context of drug 
administration. However there are very few published studies that have analysed 
the drug administration process at task level. A Human Factors approach offers a 
range of techniques that can be employed to address the issue of errors at task level. 
One such approach, task analysis, is a useful way of breaking a task down into its 
constituent parts and is a practical way of looking at how people interact with 
various aspects of their working environment. The technique has been used 
extensively in several domains to identify training needs but has been an underused 
technique in the health care dornain. 
Task analysis is defined as the study of what an operator is required to do in terms 
of observable physical actions or cognitive processes to achieve a system goal is a 
way of breaking the task down into its component parts. It is also a useful way of 
looking at how people interact with equipment and with various aspects of their 
L 
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working environment and enables information to be collected in a systematic way 
to inform decisions. Implicit in the term Task Analysis is the notion of the task as a 
definitive entity whereas it might be described as a group of related discriminations, 
decisions and activities linked by temporal proximity, immediate purpose and 
common machine output (Miller et al (1953). A more useful overview of the 
elements that comprise a task is provided by Starnmers and Shepherd (1995): 
The terni 'task' generally applies to a unit of activity witl i work it 
ations 
A task may be givcn to or imposed 1.111011 an individual or alternatively 
carried out on the individual's own initiative and volition 
" It is a unit ofactivity, requiring more than one simple physical or mental 
operation for its completion 
" It is Oftell LISCd With the connotation ofan activity which is non-trivial, 
or even in soine cases oncrous in nature 
" It has a defined ob. icctive. 
Task analyses can be organised in a variety of ways and a commonly used format is 
to arrange infon-nation in a hierarchical form which models the goals of a system 
and enables the analyst to identify each feature that is pertinent to making design 
decisions. Using this technique the system goals are re-described in increasing 
detail until each aspect of the task is understood. 
Hierarchical task analysis (HTA) has been applied to problems associated with 
issues of task design, training, documentation and human reliability analysis. HTA 
describes a task from its top-level goal down to individual operations. Each of the 
tasks must completely define how to achieve the top level goal. The HTA has three 
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structural components: the plan which determines when to move to the next part of 
the task, the stopping rule - the point at which further re-description will not add 
value to the process and a numbering system. 
The top-level goal of the drug administration system is to deliver drugs to the 
patient. The task steps necessary to do this are listed as tasks on the subsequent 
lower levels of the hierarchy and are carried out in the order of the plans. The task 
analysis begins with activities related to acquiring the relevant drug information 
from the patient's chart, acquiring the medication and administering the medication. 
The operations that occupy the lower levels are the focus of the next stage in the 
process of human error identification. 
The Systematic Human Error Reduction and Prediction Approach (SHERPA) is a 
human error identification technique that analyses tasks and opportunities for errors 
and was developed for use in the process industries. It identifies potential solutions 
in a structured way enabling the analyst to define the information that is useful for 
error reduction strategies. The approach has been validated against other human 
error identification approaches and has been used in various other domains. It 
performs well in terms of comprehensiveness, accuracy, consistency, validity, and 
auditability. It has also been used in health care to analyse the nature and incidence 
of errors enacted during keyhole surgery as a means of identifying training needs 
and infon-ning prospective research areas. 
SHERPA uses the bottom level outputs, (the actions or operations) of the HTA as 
its units of infon-nation. These were classified into one of a series error modes 
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using a taxonomy. The consequence of not performing that action or performing it 
in one of the error mode descriptors is considered and is all recorded in tabular form 
together with the stage at which the error might be recovered. The probability of the 
error occurring was also considered and remedial measures to reduce to opportunIty 
for the error noted. 
Several design features were suggested which included adding salient features to 
drug packaging in order to make them more conspicuous and utilising computerised 
systems such as bar coding technology to overcome errors associated with selecting 
the correct drug for administration and matching the right patient with the right 
drug. 
Warnings have made extensive use of various visual and cognitive devices in an 
attempt to capture the attention of the individual, facilitate recognition and 
comprehension of the message with the intention of influencing their behaviour to 
bring about compliance. These devices include the use of shape, colour, borders, 
panels, graphics and text words that are semantically associated with levels of 
hazard such as the words "deadly", "warning", "caution" or "attention". In some 
instances these are written in different colours or various font sizes. 
Graphics in the form of icons and pictograms have been demonstrated their ability 
to enhance the semantic meaning of warning messages and facilitated 
comprehension and memory. In cases of poorly understood pictorials, brief training 
can improve comprehensibility. 
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Noticeability is not solely influenced by these factors alone. People who are more 
familiar with a situation or with the use of a product tend to read, comply with and 
recall the warning less than those who are less familiar. However people who have 
had an accident or know someone who has been injured using a product are more 
likely to exercise caution when using that product. Similarly compliance is not 
merely a function of noticeability but is influenced by factors such as how much 
effort or time observance of the message will cost individual. Other issues include 
stress, perception of risk, training, age and culture. 
Some of these factors have been taken into account when assessing the readability 
of prescription drug labels which should be designed in a way that captures 
attention. This can be achieved by increasing the overall surface area of the 
package, adding pictorials or legible print. 
A designer was consulted and the issues surrounding medication errors that have 
appeared in the published literature were outlined. After a brief consideration of 
existing packages conceptual designs for new packaging were put forward. Colour 
is used extensively in both branded and generic drugs but its application is arbitrary 
and is more likely to emphasis insignificant aspects of the package rather than assist 
users in identifying the drug name or strength. A concept package was designed on 
which the key pieces of infon-nation were located in fixed positions on the package. 
This would aid users once fainiliarised with the package to become accustomed to 
locating relevant information in a precise position on the package. 
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The concept design was modified enabling it to be applied to medicine bottles in a 
more three dimensional representation of the design using elements of the 
iconography to form tactile features. Comparisons of the two-dimensional design 
were made with existing packaging as part of a testing procedure. The results were 
not significant but this may have been due to the experimental design rather than 
the designs of the concept packages. - 
Modelling the designs in a CAD package facilitated the construction of prototypes 
of the three dimensional design. These took the form of tactile shapes representing 
the three drug categories diuretics, analgesics and antibiotics constructed such that 
they fitted the neck of a standard medicine bottle. A blind touch test indicated that 
tactile features to medication bottles produced a good success rate and were 
demonstrably learnable. 
One of the features of the design that caused participants difficulty was the design 
of the icons used on the labels. These were intended to facilitate recognition of the 
relevant drug category therefore a one-day design workshop was organised to 
generate further designs for icons. The selection of drug categories on which the 
icon representations would be based were made largely on the description of the 
various drug categories. The designers selected those categories they believed to be 
within their ability to represent graphically. For some dr-ug categories this 
transpired not to be the case and even through a process of simplifying the 
description of the category there still remained difficulties in attempting to represent 
the pharmacological function of the medications in a concise way. Some drug 
categories lent themselves to different levels of description and a wide range of 
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different images were produced. Others drug categories such as vitamins seemed to 
possess simple descriptors that were more complex when attempts were made to 
represent them graphically. Whilst the designers recognised that abstract concepts 
were easier to depict in symbolic form and that symbols tend to be recalled more 
easily by users, the level of detail required for some categories was best captured 
pictorially. 
Despite the challenge of producing representative icons in a short space of time the 
designers did generate several images that were standardised and then ranked for 
appropriateness. There were differences between the designers and the larger 
participant group as to which of the images were most representative of the drug 
categories. A selection of the icons was ranked by nurses and medical professionals 
for comprehension. It was noted that with the exception of the icons for sedatives, 
the images were not well understood which suggests the icons would need to be 
redesigned in an attempt to improve comprehension scores. Further investigation 
into how nurses view medications might yield useful findings that could be used to 
inform further designs of icons. The effects of training may need to be analysed in 
order to facilitate understanding of icons. 
In the SHERPA analysis technological solutions in the form of barcoding and RFID 
tagging were suggested to address the problem of errors caused by failure to acquire 
the appropriate infort-nation from the medication chart, errors associated with 
selection of the wrong drug and errors related to patient identity. Such systems 
have been used for some time in the US and at the present time are undergoing 
trials in the UK. Chapter 6 assesses the design of a drug administration system that 
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links the patient information with the drug package by way of a device that uses an 
Mutton. The patient's identity and drug requirements are programmed into the 
device upon admission and the patient wears the device as an identity bracelet on 
their wrist. Drug packages to which an iButton has been attached are held against 
the reader in the bracelet at the time of administration. If the drug is the correct one 
this is indicated on the identity bracelet. The device performed well against other 
types of identity bracelet. Nurses were able to use it to read patient infon-nation and 
to check for expired drugs. The effect of the design solutions is illustrated in figure 
7.1. 
I Defence in depýlh] 
Psychologicai Unsafe 
precursors ac Ls 
Colour Tactile ibutton 
label.,; fca tu res bracelet 
Figure 7.1: Model of how the design products reduce the 
accident trajectory 
7.2 DIRECTIONS FOR FURTHER RESEARCH 
7.2.1 Mental constructs of medication administration 
When designing the labels it was assumed that using icons to signify the therapeutic 
categories into which medications are grouped would simplify the recognition of 
drug names. This was not the case. One reason for this finding may be that in 
reality people have more complex mental models of medications. A series of 
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further studies may uncover what these might be. Investigation into how nurses 
construct their working knowledge of drugs would give insight to the semantic 
elements of those models and would inform designers new systems. 
7.2.2 Tactile features 
Whilst carrying out this research the author was struck by how many observers 
remarked on how well the tactile features designed for the medication bottles would 
suit the needs of older people, who often take multiple medication preparations. 
Extending the range of tactile devices to include other drug categories would be 
beneficial as these features are likely to lead to easier identification. It is not 
uncommon for patients to refer to their 'heart tablets' or their 'water tablets'. The 
tactile feature makes it easier to differentiate between the categories of drug both as 
an aid to vision and by touch. 
7.2.3 Expanded application 
The limitation of this study is that it was based on a model of nurses' drug 
administration. Observations carried out to identify human error at the task level 
may reveal other types of errors. In Chapter 2 reference was made to the patient's 
own drug delivery system which is often used in preference to the ward phan-nacy 
system. It might be beneficial to compare the types of errors that occur between the 
two systerns using SHERPA. 
This study has considered how packaging might be applied to tablets and 
medicines. However, it is injections that give much cause for concern as there are 
more opportunities for error during preparation since some of these have to be 
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reconstituted or diluted prior to administration. A detailed HTA of injections would 
yield an interesting examination of this process. Similarly the programming of 
infusion devices is an area that would greatly benefit from analysis using human 
error identification techniques. These devices have proved troublesome for nurses 
as it is often difficult to verify that the programme is correct due to lack of feedback 
systems. The interfaces of these devices have undergone redesign in the past few 
years, yet errors are still being reported. Error prevention becomes ever more 
critical with the increased use of patient controlled analgesic pumps. An HTA 
combined with a SHERPA analysis might reveal whether or not current interfaces 
are functioning as the designer intended. 
Infusion pumps have palpably highlighted how much technology has altered the 
nurse's task and this is ever more so with the increased use of barcoding and RFID 
systems. However errors are still apparent within these systems. Whilst it is the 
case that there are fewer wrong dose, wrong drug, wrong time errors as there is less 
reliance on the nurse's memory with regard to these issues, computer systems still 
have to be programmed and backed up. Communication still has to be maintained 
between individuals on the same ward as well as between colleagues in other 
departments and whilst technology can facilitate this process, it also brings changes 
in the quality and salience of the information exchange. A cognitive task analysis 
may indicate the effects of the technology on communication and working practices 
and serve to inform second and third generation products of this type. 
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Analgesics: Drugs that relieve pain. There are two main types: non-narcotic analgesics 
for mild pain, and narcotic analgesics for severe pain. 
Antacids: Drugs that relieve indigestion and heartburn by neutralizing stomach acid. 
Antianxiety Drugs: Drugs that suppress anxiety and relax muscles (sornetin-les called 
anxiolytics, sedatives, or minor tranquilizers). 
Antiarrhythinics: Drugs used to control irregularities of heartbeat. 
Antibacterials: Drugs used to treat infections. 
Antibiotics: Drugs made from naturally occurring and synthetic substances that combat 
bacterial infection. Some antibiotics are effective only against limited types of bacteria. 
Others, known as broad spectrum antibiotics, are effective against a wide range of 
bacteria. 
Anticoagulants and Thrombolytics: Anticoagulants prevent blood fTorn clotting. 
Thrombolytics help dissolve and disperse blood clots and may be prescribed for patients 
with recent arterial or venous thrombosis. 
Anticonvulsants: Drugs that prevent epileptic seizures. 
Antidepressants: There are two main groups of mood-lifting antidepressants: tricycilics 
and monoamine oxiclase inhibitors. 
Antidiarrheals: Drugs used for the relief of diarrhoea. Two main types of antidiarrheal 
preparations are simple adsorbent substances and drugs that slow down the contractioils 
of the bowel muscles so that the contents are propelled more slowly. 
Antiemetics: Drugs used to treat nausea and vomiting. 
Antifungals: Drugs used to treat fungal infections, the most common of which affect 
the hair, skin, nails, or mucous membranes. 
Antihistamines: Drugs used primarily to counteract the effects of histamine, one of the 
chemicals involved in allergic reactions. 
Antiltypertensives: Drugs that lower blood pressure. Tile types of anti hypertensi ves 
currently marketed include diuretics, beta-blockers, calcium channel blocker, ACE 
(angiotensin- converting enzyme) inhibitors, centrally acting antihypertensives and 
sympatholytics. 
Anti-Inflaminatories: Drugs used to reduce inflamination - the redness, heat, swelling, 
and increased blood flow found in infections and in many chronic noninfective diseases 
such as rheumatoid arthritis and gout. 
Antineoplastics: Drugs used to treat cancer. 
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Antipsychotics: Drugs used to treat symptoms of severe psychiatric disorders. These 
drugs are sometimes called major tranquilizers. 
Antipyretics: Drugs that reduce fever. 
Antivirals: Drugs used to treat viral infections or to provide temporary protection 
against infections such as influenza. 
Barbiturates: See "sleeping drugs. " 
Beta-Blockers: Beta-adrenergic blocking agents, or beta-blockers for short, reduce tile 
oxygen needs of the heart by reducing heartbeat rate. 
Bronchodilators: Drugs that open up the bronchial tubes within the lungs when the 
tubes have become narrowed by muscle spasm. Bronchodilators ease breathing in 
diseases such as asthma. 
Cold Cures: Although there is no drug that can cure a cold, the aches, pains, and fever 
that accompany a cold can be relieved by aspirin or acetaminophen often accompanied 
by a decongestant, antihistamine, and sometimes caffeine. z: - 
Corticosteroids: These hormonal preparations are used primarily as anti-inflaillinatorics 
in arthritis or asthina or as immunosuppressives, but they are also useful for treating 
some malignancies or compensating for a deficiency of natural hormones in disorders 
such as Addison's disease. 
Cough Suppressants: Simple cough medicines, which contain substances such as 
honey, glycerine, or menthol, soothe throat irritation but do not actually suppress 
coughing. They are most soothing when taken as lozenges and dissolved in the mouth. 
As liquids they are probably swallowed too quickly to be effective. A few drugs are 
actually cough suppressants. There are two groups of cough suppressants: those that 
alter the consistency or production of phlegm. such as mucolytics and expectorants; and 
those that suppress the coughing reflex such as codeine (narcotic cough supprcssants), 
antihistamines, dextromethorphan and isoproterenol (non-narcotic cough suppressants). 
Cylotoxics: Drugs that kill or damage cells. Cytotoxics are used as antineoplastics 
(drugs used to treat cancer) and also as immunosuppressives. 
Decongestants: Drugs that reduce swelling of the mucous membranes that line the nose 
by constricting blood vessels, thus relieving nasal stuffiness. 
Diuretics: Drugs that increase the quantity of urine produced by the kidneys and passed 
out of the body, thus ridding the body of excess fluid. Diuretics reduce water logging of 
the tissues caused by fluid retention in disorders of the heart, kidneys, and liver. They 
are useful in treating mild cases of high blood pressure. 
Expectorant: A drug that stimulates the flow of saliva and prornotes coughing to 
eliminate phlegrn from the respiratory tract. 
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Hormones: Chemicals produced naturally by the endocrine glands (thyroid, adrenal, 
ovary, testis, pancreas, parathyroid). In some disorders, for example, diabetes rnellitus, 
in which too little of a particular hormone is produced, synthetic equivalents or natural 
hormone extracts are prescribed to restore the deficiency. Such treatment is known as 
hormone replacement therapy. 
Hypoglycemics (Oral): Drugs that lower the level of glucose in the blood. Oral 
hypoglycemic drugs are used in diabetes mellitus if it cannot be controlled by diet 
alone, but does require treatment with injections of insulin. 
Inintunosuppressives: Drugs that prevent or reduce the body's normal reaction to 
invasion by disease or by foreign tissues. Inu-nunosuppressives are used to treat 
autolmmune diseases (in which the body's defenses work abnormally and attack its own 
tissues) and to help prevent rejection of organ transplants. 
Laxatives: Drugs that increase the frequency and ease of bowel movements, either by 
stimulating the bowel wall (stimulant laxative), by increasing the bulk of bowel 
contents (bulk laxative), or by lubricating them (stool-softeners, or bowel movement- 
softeners). Laxatives may be taken by mouth or directly into the lower bowel as 
suppositories or enemas. If laxatives are taken regularly, the bowels may ultimately 
become unable to work properly without them. 
Muscle Relaxants: Drugs that relieve muscle spasm in disorders such as backache. 
Antianxiety drugs (minor tranquilizers) that also have a muscle-relaxant action are used 
most commonly. 
Sedatives: Same as Antianxiety drugs. 
Sex Horniones ffetnale): There are two groups of these hormones (estrogens and 
progesterone), which are responsible for development of female secondary sexual 
characteristics. Small quantities are also produced in males. As drugs, female sex 
hormones are used to treat menstrual and menopausal disorders and are also used as oral 
contraceptives. Estrogens may be used to treat cancer of the breast or prostate, 
progestins (synthetic progesterone to treat endometiiossis). 
Se. x Hormones (Male): Androgenic hormones, of which the most powerful is 
testosterone, are responsible for development of inale secondary sexual characteristics. 
Small quantities are also produced in females. As drugs, male sex hon-nones are given 
to compensate for hormonal deficiency in hypopituitarism or disorders of the testes. 
They may be used to treat breast cancer in women, but either synthetic derivatives 
called anabolic steroids, which have less marked side- effects, or specific anti-estrogens 
are often preferred. Anabolic steroids also have a "body building" effect that has led to 
their (usually nonsanctioned) use in competitive sports, for both men and women. 
Sleeping Drugs: The two main groups of drugs that are used to induce sleep are 
benzodiazepines and barbiturates. All such drugs have a sedative effect in low doses 
and are effective sleeping medications in higher doses. Benzodiazepines drugs are used 
more widely than barbiturates because they are safer, the side-effects are less marked, 
and there is less risk of eventual physical dependence. 
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Tranquilizer: This is a term commonly used to describe any drug that has a calming or 
sedative effect. However, the drugs that are sometimes called minor tranquilizers should 
be called antianxiety drugs, and the drugs that are sometimes called major tranquilizers 
should be called antipsychotics. 
Vitamins: Chemicals essential in small quantities for good health. Some vitamins are 
not manufactured by the body, but adequate quantities are present in a normal diet. 
People whose diets are inadequate or who have digestive tract or liver disorders may 
need to take supplementary vitamins. 
http: //www. fda. gov/cder/handbook/category. htm 
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APPENDIX D 
Presentation of the Slides 
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- 
-- 
ltFii 
Figure DI: Plan of presentation of "new"slides - the order was of slide presentation 
was randomized for each trial and the order of presentation of 'old' and 'new' 
alternated 
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Figure D2: Plan of presentation of "Old"slides - the order was of slide presentation 
was randomized for each trial and the order of presentation of 'old' and 'new' 
alternated 
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Instructions to participants 
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Instructions to participants 
Thank you for agreeing to participate in this study. 
Your task will be to identify the names of drugs from a series of images 
displayed on the computer screen. Most drugs have two names -a 
brand name and generic name. You will be asked to give the generic 
name for each drug. A list of generic drug names is given on Sheets 1 
and 2. Please take a moment to read the sheets now. 
In each image a drug strength is also given and you will be required to 
state what that strength is. As soon as you are able to recognise the 
generic name and drug strength just say them out loud. Please state 
the generic drug name first followed by the strength. 
If you have any questions please ask them now. 
Thank you once again for your time and patience. 
Rhonda Latic 
PhD Researcher 
Bruncl University 
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Sheet 1 
GENERIC DRUG NAMES 
Warfarin 
Diazepam 
Co-Amoxiclav 
Furosemide 
Paracetamol 
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Sheet 2 
GENERIC DRUG NAMES 
Doxazosin 
Fenofibrate 
Rosiglitazone 
Zopiclone 
Venlafaxine 
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APPENDIX F 
The 3D test 
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Student participation in a class memorv test 
As part of a PhD study we would like you to take part in a short memory test. 
This involves a short explanation of the test procedure and familiarisation of 
three types of collars fitted to medicine bottles. This should take no more than 
ten minutes during one lesson. 
The second part of the memory test takes place during the lesson on the 
following day and will take each participant less than five minutes to identify 
the type of collar fitted to a bottle whilst doing a blind touch test. 
There will be rnýinirnal disruption of the two lessons and the student's learning 
will not be affected. 
If you are under 18 please ask a parent/guardian to give their consent to this 
test by signing below, and bring this with you to your next class. 
Thank you in anticipation, Rhonda Lane. 
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APPENDIX G 
Original workshop drawings 
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Figure G. I Rejected images for sedatives 
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Figure G. 2: Rejected drawings for expectorants 
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Figure G. 3 Rough drawings for expectorants 
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Figure G. 3 Rough drawings for anticoagulants 
D 
Appendices 
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Figure G4. Rough drawings for painkillers 
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Figure G. 5 Rough drawings for painkillers 
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Figure G6 : Rough drawings for immunosuppressants 
251 
Lane, R 
APPENDIX H 
Appropriateness ranking test sheet 
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The purpose of this questionnaire is to measure how suitable the images 
presented on the next page are to help identify medication. Please read the 
description above the line of pictures and write the number I in the box 
below the picture that matches the description best. Then write number 2 in 
the box below the next best picture and so on until you have given all the 
pictures in that section a number. Then move on to the next section. An 
example is given below. There is no right or wrong answer. 
Example 
Diuretic - used to rid the body of excess fluids 
3124 
Many thanks for your help. 
Rhonda Lane, PhD Student 
Room 305, Howell Building 
Department of Engineering and Design 
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1. Anti-Coagulants and thrombolytics - used to stop blood clotting or 
to dissolve blood clots. 
HHHHH 
2. Painkillers - used to reduce or relieve pain. 
4. Narcotics or sedatives - used to cause sleep. 
5. Immunosuppressant - used to reduce the body's normal reaction to attack 
by disease or by foreign tissues. Used in cancer treatments or after 
organ tra s lants to help prevent rejection of organ transplants. 
IIF,, 
II 
6. Muscle relaxant - used to relieve muscle spasm in conditions such as backache. 
(I 
Are you: Male Female? Please givc your age 
F] 
171 Fý 
Appendices 
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3. Expectorants - used to encourage the flow of saliva and promote coughing to ZZ, 
eliminate mucous from the airway. 
Lane, R Appendices 
APPENDIX I 
Results of appropriateness ranking 
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Table 11: The designers' rankings of their icons 
Arific(pagulants Item no 25 26** 27 28 29 30 31 
PI 0 
L61 Fil FEN E 
DI 1 6 -4 32 7 5 
D2 1 6 324 7 5 
D3 1 3 742 6 5 
D4 5 7 123 6 4 
D5* 2 6 451 7 3 
Totals 10 28 15 14 12 . 13 22 
Median 1.5 6 4 3.5 2.5 7 5 
Palnk, Wtrs Item no 32 33 34 35 36 37 38 
D1 7 
D2 4 
JO I 
D4 7 
D5* 5 
Totals 24 
Median 6 
Sedatives hem Ito 15.. 
DI 3 
D2 2 
D3 4 
D4 I 
D5* I 
-r, tws II 
McAlian 2.5 
563214 
637152 
472365 
315462 
632471 
24 20 19 14 25 14 
5.5 4.5 4 3.5 63 
17*' 18 20 21 22 23 
LIE 
647152 
574163 
563271 
374265 
674352 
25 31 22 9 29 13 
5.5 74262.5 
Expecturants Ile"I [IV 123678 
M-N-9 (ý') LI 
. '. 
PF-, 
mirk Dl 214367 
D2 4151672 
D3 3124675 
D4 5146273 
D5* 6172543 
Totals 20 5 22 is 25 32 is 
Median 4143671 
** These icons were not assessed by the experimental group 
*D5 did not take part in the D5 workshop but agreed to assess the icons 
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Table 12: Appropriateness ranking of anticoagulant icons by the exerpimental 
group 
Subjects 25 27 28 29 
Q69 3 5 6 2 
Q80 6 1 3 4 
Q68 2 6 1 4 
Q07 4 1 3 2 
Q08 1 5 3 4 
Q09 1 2 5 2 
QIO 5 1 3 4 
Qll 5 2 1 4 
Q12 5 2 1 3 
Q13 3 1 2 5 
Q14 1 6 3 2 
Q15 4 2 6 1 
Q16 4 2 5 1 
Q20 6 1 3 2 
Q21 4 1 5 2 
Q22 1 4 5 3 
Q26 4 1 2 3 
Q27 4 3 5 1 
Q28 3 6 1 2 
Q30 3 6 1 5 
Q31 3 4 1 2 
Q32 5 1 2 4 
Q33 1 3 4 2 
Q34 4 1 6 3 
Q35 5 3 4 2 
Q36 2 4 5 1 
Q37 5 6 4 2 
Q38 1 6 4 2 
Q39 1 3 4 2 
Q40 2 6 4 1 
Q41 5 2 6 4 
Q42 2 5 1 3 
Q43 4 5 1 2 
Q44 2 1 5 3 
Q45 3 4 5 6 
Q46 3 4 1 2 
Q47 1 4 5 3 
Q48 4 2 5 3 
Q49 1 3 5 2 
Q50 3 4 1 2 
Q53 3 2 5 4 
Q55 1 5 2 3 
Q57 3 5 1 2 
Q58 2 5 1 3 
Q59 1 4 5 2 
Q60 2 5 4 3 
061 2 4 5 1 
Q70 4 1 2 3 
144 160 162 128 
3.00 3.50 4.00 
30 31 
1 4 
5 2 
5 3 
3 5 
5 2 
5 4 
6 2 
3 6 
6 4 
6 4 
5 4 
5 3 
5 3 
5 4 
5 3 
5 2 
5 6 
6 2 
5 4 
4 2 
5 6 
6 3 
6 5 
5 2 
6 1 
3 6 
1 3 
5 3 
5 6 
3 5 
3 1 
4 6 
6 3 
6 4 
2 1 
5 6 
6 2 
6 1 
6 4 
6 5 
1 6 
6 4 
4 5 
6 4 
3 6 
1 6 
6 1 
6 4 
223 178 995Sum of ranks 
166Mean rank total 
2 5.00 4.00 Median rank 
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Table 13: Appropriateness ranking of painkiller icons by experimental group 
Subjects 32 33 34 35 36 37 38 
Q69 6 7 5 3 1 2 4 
Q80 4 6 5 7 2 1 3 
Q68 3 5 7 6 4 1 2 
Q07 3 5 7 4 2 1 5 
Q08 5 6 1 7 3 2 4 
Q09 7 5 3 1 2 4 6 
Q10 5 7 2 1 3 4 6 
Qll 7 5 4 3 2 2 6 
Q12 6 5 7 4 2 1 3 
Q13 2 5 3 4 7 1 6 
Q14 2 7 5 1 6 3 4 
Q15 5 2 6 7 3 1 4 
Q16 5 5 2 4 3 7 1 
Q20 4 5 7 2 1 3 6 
Q21 6 4 5 7 3 1 2 
Q22 7 3 6 4 1 2 5 
Q26 6 4 5 7 1 2 3 
Q27 5 6 2 7 3 1 4 
Q28 7 5 6 4 3 2 1 
Q30 5 7 3 1 4 6 2 
Q31 5 3 4 1 7 2 6 
Q32 7 3 6 5 2 1 4 
Q33 7 3 6 4 2 1 5 
Q34 5 6 3 4 1 2 7 
Q35 5 6 7 4 2 1 3 
Q36 5 3 4 6 6 1 2 
Q37 6 3 7 5 2 1 4 
Q38 5 6 7 1 3 2 4 
Q39 6 7 4 2 5 1 3 
Q40 7 5 6 4 1 2 3 
Q41 5 7 4 2 3 2 1 
042 2 4 5 7 3 1 6 
Q43 7 2 4 6 5 3 1 
Q44 6 3 5 7 4 2 1 
Q45 7 6 5 3 4 2 1 
Q46 5 6 7 2 1 4 3 
Q47 1 4 2 3 5 6 5 
Q48 7 5 3 5 2 1 4 
Q49 6 2 7 3 5 1 4 
Q50 7 6 3 4 2 1 4 
Q53 6 7 2 3 1 4 5 
Q55 7 4 1 6 2 5 3 
Q57 7 3 4 6 1 1 5 
Q58 6 7 1 3 5 4 2 
Q59 3 7 6 4 1 1 3 
Q60 3 7 3 6 1 1 5 
Q61 3 2 5 1 7 4 6 
Q70 6 7 1 3 4 5 2 
252 238 213 194 143 109 179 
5.5 5 5 4 3 2 4 
1328 Sum of ranks 
190 Mean rank total 
Median rank 
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Table 14: Appropriateness ranking of sedative icons by the experimental 
group 
Subjects 18 20 21 22 23 
Q69 3 5 2 3 1 
QBO 4 5 2 3 1 
Q68 2 5 4 3 1 
Q07 5 4 2 3 1 
Q08 3 4 2 5 1 
Q09 5 2 3 2 4 
Q10 3 5 2 4 1 
Q11 5 3 2 4 1 
Q12 4 5 2 3 1 
Q13 5 3 2 4 2 
Q14 4 5 2 3 1 
Q15 4 3 2 5 1 
Q16 3 4 2 5 1 
Q20 4 5 1 3 2 
Q21 4 5 1 3 2 
Q22 5 4 1 3 2 
Q26 3 5 2 4 1 
Q27 5 3 2 4 1 
Q28 5 4 2 3 1 
Q30 5 4 1 3 2 
Q31 3 5 2 4 1 
Q32 4 3 2 5 1 
Q33 4 3 2 5 1 
Q34 4 5 2 3 1 
Q35 5 3 2 4 1 
Q36 5 2 4 3 1 
Q37 4 3 2 5 1 
Q38 3 5 2 4 1 
Q39 3 3 2 4 1 
Q40 5 2 3 4 1 
Q41 5 4 2 3 1 
Q42 4 5 2 3 1 
Q43 5 3 2 4 1 
Q44 5 4 3 2 1 
Q45 5 3 2 4 1 
Q46 4 3 1 5 2 
Q47 5 4 2 3 1 
048 3 5 2 4 1 
Q49 3 4 2 5 1 
050 3 4 2 5 1 
Q53 3 5 2 4 1 
Q55 3 5 2 4 1 
Q57 4 5 1 3 2 
058 4 5 2 3 1 
Q59 2 4 5 1 3 
Q60 3 5 2 4 1 
061 4 3 2 5 1 
Q70 3 5 2 4 1 
189 193 100 177 60 719Sum or ranks 
143Mean rank total 
4 4 2 4 1 Median rank 
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Table 15: Appropriatcness ranking of expectorant icons by the 
experimental group 
1W 
M 
Appendices 
Subjects 1 2 3 5 6 7 8 
Q69 4 5 7 1 6 2 7 
Q80 5 6 4 1 3 6 2 
Q68 7 4 6 2 5 3 1 
Q07 6 3 7 1 5 7 2 
Q08 5 2 7 3 4 6 1 
Q09 5 1 7 2 6 7 4 
Q10 6 2 7 3 5 4 1 
Qll 1 2 7 5 6 3 4 
Q12 5 2 7 4 6 3 1 
Q13 7 5 6 3 1 2 4 
Q14 5 3 6 1 4 7 2 
Q15 7 1 6 3 5 4 2 
Q16 7 3 6 1 5 4 2 
Q20 4 7 6 2 5 3 1 
Q21 7 1 6 3 4 5 2 
Q22 6 1 7 3 4 5 2 
Q26 7 5 6 2 3 4 1 
Q27 7 1 6 5 2 3 4 
Q28 4 3 7 2 6 5 1 
Q30 6 4 7 1 5 3 2 
Q31 4 6 5 2 1 7 3 
Q32 3 4 7 1 6 5 2 
Q33 4 5 7 1 6 3 2 
Q34 4 1 7 3 6 7 2 
Q35 2 1 7 5 3 6 4 
Q36 5 7 4 2 3 1 6 
Q37 4 1 7 2 6 5 3 
Q38 6 5 7 3 4 2 1 
Q39 6 3 7 2 5 7 1 
Q40 6 1 7 1 4 5 2 
Q41 7 4 6 1 5 3 2 
Q42 6 4 6 2 7 3 1 
Q43 1 3 7 4 6 5 2 
Q44 4 2 5 6 7 1 1 
Q45 3 4 7 1 5 6 2 
Q46 7 1 6 4 3 2 5 
Q47 6 4 5 3 7 2 1 
Q48 7 6 5 1 4 3 2 
Q49 6 1 7 3 4 5 2 
Q50 7 5 6 3 4 1 2 
Q53 5 3 6 2 6 4 1 
Q55 5 3 7 2 7 4 1 
Q57 7 1 6 2 5 4 3 
Q58 4 7 5 2 6 3 1 
Q59 3 5 4 2 7 1 5 
Q60 4 1 7 6 2 5 3 
Q61 6 1 7 3 4 5 2 
Q70 4 1 6 2 5 7 3 
247 151 301 119 228 198 114 1358Sum of'ranks 
19, lMeam rmik total 
5 3 6.5 2 5 4 2 Median mik- 
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Experimental group rankings for immunosuppressants and muscle relaxants 
Subjects Gander Age 41 40 42 43 
Rank A8A8A8A8 
Q69 M 52 1111 
QBO F 37 1111 
Q68 F 45 1111 
Q07 M 23 1111 
008 M 22 1111 
Q09 M 19 1111 
Q10 M 19 1111 
Q11 M 19 1111 
012 M 20 1111 
Q13 F 20 1111 
Q14 M 19 1111 
Q15 M 2-2 1111 
Q16 M 23 1111 
020 M 33 1111 
021 M 22 1111 
Q22 M 22 1111 
026 F 20 1111 
Q27 M 19 1111 
Q28 M 23 1111 
Q30 F 23 1111 
Q31 F 20 1111 
Q32 F 21 1111 
033 F 22 1111 
034 M 22 1111 
Q35 M 18 1111 
036 M 21 11 .11 
Q37 M 19 1111 
Q38 M 21 1111 
Q39 F 21 1111 
Q40 M 21 1111 
041 M 20 1111 
042 M 19 1111 
Q43 M 23 1111 
Q44 F 30 1111 
045 M 22 1111 
046 M 22 1111 
Q47 M 21 1111 
Q48 M 20 1111 
Q49 M 32 1111 
050 M 22 1111 
Q53 F 45 1111 
Q55 F 51 1111 
057 F 47 1111 
Q58 F 36 1111 
Q59 M 34 1111 
060 F-1111 
061 M 46 1111 
Q70 F 45 1111 
Total 6 42 42 6 12 36 36 12 
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Rank 
Referent 1234567 
Expectorants 124.17 1 2.08 3 6.25 10 20.8 N 16.7 12 25 12 25 
2 15 31.3 5 10.4 8 16.7 7 14.6 7 14.6 3 6.25 .; 6.25 
30000036.25 5 10.4 16 33.3 24 50 
5 13 27.1 15 21.3 12 25 3 6.25 3 6.25 2 4.17 1) 0 
624.17 2 4.17 5 10.4 1 () 20.8 1.1 27.1 11 22.9 5 10.4 
748.33 5 10.4 11 22.9 7 16.7 1) 18.8 4 8.33 7 14.6 
8 13 27.1 20 41.7 5 10.4 6 12.5 2 4.17 1 2.08 1 2.08 
Painkillers 32 1 2.08 3 6.25 5 10.4 2 4.17 13 27.1 11 22.9 H 27.1 
33 0048.33 8 16.7 5 10.4 11 22.9 1) 18.8 11 22.9 
34 4 8.33 5 10.4 7 14.6 7 14.6 1) 18.8 7 14.6 1) 18.8 
35 7 14.6 4 8.33 8 16.7 11 22.9 3 6.25 o 12.5 1) 18.8 
36 11 22.9 12 25 10 20.6 5 10.4 5 10.4 2 4.17 3 6.25 
37 21 43.9 13 27.1 3 6.25 6 12.5 2 4.17 2 4.17 1 2.08 
38 6 12.5 6 12.5 1) 18.8 11 22.9 7 14.6 S 16.7 1 2.08 
Sedatives 18 024.17 15 31.3 15 31.3 15 31.3 
20 036.38 12 25 11 22.9 20 41.7 
21 6 12.5 36 75 2 4.17 2 4.17 1 2.08 
22 1 2.08 -" 4.17 1- 35.4 17 35.4 10 20.8 
23 39 81.3 - 14.6 1 2.08 1 2.08 001 
Anticoagulants 25 11 22.9 8 16.7 1) 18.8 11 22.9 6 12.8 2 4.17 
27 11 22.9 -, 14.6 6 12.5 1) 18.8 8 16.7 6 12.5 
28 11 22.9 5 10.4 6 12.5 7 14.6 14 29.2 4 8.33 
29 6 12.5 18 37.5 12 25 8 16.7 2 4.17 1 2.08 
30 4 8.33 1 2.08 6 12.5 3 6.25 16 33.3 17 35.4 
31 5 10.4 8 16.7 8 16.7 11 22.9 4 8.33 11 22.9 
Immuno 40 42 87.5 6 12.5 
41 6 12.5 42 87.5 
Relaxant 42 12 25.5 36 75 
43 36 75 12 25.5 
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Calculating Kendall's coefficient of concordance expecioraws 
R represents the rank surn of the jth individual. The surn of squares 1161. k 
individuals is given as: 
I ,ý 
ý2 
S=j Rj- - 
,(k 
The coefficient of concordance W defined as the ratio of S to the maxinIL1111 
possible value of S is: 
w 
12S 
The surn of the ranks for expectorants is 1358 
S= (249 - 
194)2 +(151-194 )2+ (301 - 194)2 + (118 _ 194)2 + (227 -- 
194)2 
+ (197 - 
194)2 +(115 ý 194) 
29438 
w 12 x 29438 
4iy( ---- 7 73 -ý=0.456 73-7 
Converting to Speannan's rho: 
- 
NW-1 
P= N-1 
(48 x 0.456) -1 i5 = 47-1 = 
0.454 
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Calculating Kendalls coefficient of concordancefor sedatives 
R represents the rank surn of thejth image. The surn of squares for k images is 
given as: 
YRJ 
S=J] Rj- 
k 
The coefficient of concordance W defined as tile ratio of S to the maxinwin 
possible value of S is: 
12S 
The surn of the ranks for sedatives is 719 
R represents the rank surn of thejth image. The surn of squarcs for k iniagcs is 
given as: 
ERj 
S=Z Rj -, k 
(46 - 143 
)2 +(50- 143 )2+ (43- 143)2 + (34- 143 )2 +(83 - 143 
)2 
+= 145 10 
12x 14510 w=-3=0.630 
4iý ý5- 5 
Converting to Spearman's rho 
NW-1 
N-1 
(48 x 0.63)-l 
= 0.635 47-1 
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Calculating Kendalls coefficient of concordancefor (ulticotigill(Illis 
R represents the rank sum of thejth image. The sum of squares for k iniagcs is C, 
given as: 
J]R, 
S=y Rj- , 
k 
The coefficient of concordance W defined as the ratio of S to the maximum 
possible value of S is: 
12S 
The sum of the ranks for anticoagulants is 994 
S= (143 - 
166)2 + (160-166)2 + (162-166)2 + (128 - 
166)2 (223- 166)2 
+(178 - 
166)2 5418 
W_ 12 x 5418 - 0.134 
converting to spearmans rho 
j5 = 
NW-1 
N-1 
(48 x 0,134) -1 
47-1 
0.118 
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Calculating Kendall's coefficient of concordancefor painkillers 
R represents the rank surn of thejtli image. The sum of squarcs for k images is 
given as: 
s=j- 
JR, 
R' 
k 
The coefficient of concordance W defined as the ratio of S to the maximum 
possible value of S is: 
12S 
The sum of the ranks for painkillers is 1328. 
S= (252 - 
190)2 +(238- 190)2 + (213 _ 190)2 + (194- 190)2 +(143 - 190)2 
+ (109 - 190) +(179- 190) = 15584 
w -- 
12 x 15584 
- 0.241 
Converting to Speamian's t-ho: 
MY -I 
N-1 
(48 x 0.24 l)-l 
47-1 -=0.23 
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The Comprehension test 
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The images presented here are symbols that might be used oil drug packaging ill tile 
future. The aim of this presentation is to match each s, vnibol with one of the column 
descriptions. Please put a tick in the column with the description you think most 
closely matches thesymbol. Please do this for each symbol in turn. If you cannot find 
a description to match the symbol, then please leave the column blank. 
S. ý nit) ol Muscle 
relaxant 
Expectorant Pain reliever A nti. 
coagulant 
Immuno. 
suppressant 
se(Intive 
Oki, 
I I 
Figure K I: Comprehension test sheet 
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Appendices 
The attached sheet is an assessment for icons that might be used on drug 
packaging. It forms part of my PhD rcsearch,. vWch is looking at ways of 
reducing medication adrniiýsLrafion errors in hospitals. 
Although there are many factors involved in medication administration errors, one 
major source of confiision is die design of packaging and labelling. Using simple 
pictures or icons might have a major impact in reducing flie-se errors.. 
Please look at the icons and follow the instructions on the sheet. I would be 
grateful if you would . vrite on the sheet the nLunbcr of ycars you have been 
practising. 
Thank your valuable contribution to my research. 
RJionda Lane 
PILD Student 
Brunei University 
Figure K2: Letter accompanying the comprehension test 
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Images 
Subjects 2 8 21 23 25 27 36 37 40 42 
si 1 1 1 1 - - 1 
S2 - - 1 1 - - 
S3 1 1 1 1 1 
S4 I - 1 1 - 
S5 I - 1 1 - 
S6 - - 1 1 1 
S7 - - 1 1 - 
S8 - - 1 1 - 
S9 - - 1 1 - 
Slo - - 1 1 - 
Sil - - 1 1 - 
S12 - - 1 1 - 
S13 - 
S14 - 
S15 - 
S16 - 
S17 - 
S18 - 
S19 - - 1 
S20 1 1 
S21 1 1 
S22 - 1 
S23 1 1 
S24 1 1 
S25 - 1 
S26 1 1 
S27 1 1 
S28 1 1 
S29 1 1 
S30 - 1 
S31 1 1 
S32 1 1 
S33 - I 
11 8 29 33 3 2 12 8 15 16 
33% 24% 68% #### 9% 6% 36% 24% 45% 48% 
I= correct identification of symbol 
-= no response or error 
#### - 100% 
Figure KI Results of comprehension test 
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Appendix L 
Schematic of intelligent hospital identity bracelet 
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Responses for test I 
Tem I kc-mills 
ýJlrj, clrf 
! Sýonlls Our, I ',, r- rcci 
! 
Qur.. -4i4, ms 3 COI MCI. QuOilitil-S 3 Owivo 
I \h, wh hom 
Fit . .1., di. -il - 
' kulmo, 1 11 m; It I -In 1-11 :,, 'JillItC 
Fil ýi 2 
- ; ol:, h h. oljl I 
i, ow 
k 
Til 2 1;: 111, 1 1.11) 
N ! ---111 
' 
'4t II 11.11,1. - 
2 diý; (, Filstmi lie Ye; l I b(m I ) I 11,111w 
boto 
"! 1 2 Qatc bot it oin Molilli 
1ý jlýios( 2 digils 0 I.; i. %t 2 diFi Ile 
mouth boril . I Lam 2 1-1[, S"111: 111le I jDale 1)(1111 1)(4111 
Hfý I liallic IS it] I )a I ble hot it : HI:; I 2 divi s 2 klllýI(s 
Legelid: 1. Incorret f 1) 
AnI401111( of time I-c%, cr. wd 
tracdel SvcmII1, O, Ir, fioII, 6 Corivo Quco ion, 7 9 Qt. c, t; Col-sco Cm I rý 
%, )i1c ý; Il iNi"I. 111 bw 11 ! 1-: 1-: [ 1 1ým I 
: Iil,. mI 11 1 1: 11c : 'o-II kw 
Vr; l; 
--- -------- ----- 
I A'I 'I I11: Yc. o ! -I it ); I Ic II : 
'411 
I Monti. bom Mond, I'm it kl. ýl Mollill hom 1 "'ttloom'. 
I I: iIA i:, tl: IV I Fil ýl I Yt: ll hol I) il. I, dwo. o 
I; il:, i lijilw. );, I, - bom 1 1: 111 wom. I hl A qllw I ý Yc -III 
Bit; 
I 
Filsl liatlic 
- - 
I 
-- 
slilliallic 
. 
I Date N. wll I Fit I i;,. 11,; 0 1 0 
B Im m 31 onth 1wl [I XI 0 1 asl 2 sIIIIIIIc ate yeAl hoill 
Bullon 
- - 
2 
. 
Ome bom 1, I 
I. Mollill bt, T 2 thils - 
I Fi I I .; 1 2 0I sill 1111111C I -- 131111.011 ... ... 1_j __- Fitsl_2 -... _1 . - .- Ycal 1)(1111 1 Finýl Imilic j rlow 1, -1 ...... I 
Legend: correci 1. Incorrea 1) 
(Source: Dunne, 2005) 
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Summary results 
Subject Write- Insert RFID iButton 
on 
2 3 3 2 
2 2 3 0 3 
3 0 2 4 2 
4 3 2 1 3 
5 2 1 2 3 
6 3 1) 4 3 
7 2 2 1? 3 
8 2 3 3 4 
9 1 1 3 2 
10 2 1) 2 3 
Total 19 21 24 27 
Percentage 47.50% 52.50% 60% 67.50% 
Total items or infonnation recalled from 4 hospital identity bracelets 
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